Fibrotic pathways in the dystrophin deficient heart by Wakefield, Amanda
  
 
 
UNIVERSITY OF SOUTHERN QUEENSLAND 
 
 
 
 
 
 
 
 
 
Fibrotic pathways in the dystrophin deficient heart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Dissertation submitted by  
Amanda Wakefield, BSc, Grad Dip Ed.  
 
For the award of 
Master of Science 
 
2009
  
I 
 
ABSTRACT 
 
Duchenne muscular dystrophy is the most prevalent and severe of the muscular dystrophies. 
A hallmark of dystrophic muscle is fibrosis which is a result of chronic cycles of degeneration 
and regeneration. Cardiac fibrosis interferes with contractility and rhythm of the heart and 
cardiomyopathy is a leading cause of mortality in DMD. While gene therapy may offer a cure 
in the future, there exists an immediate need to ameliorate the symptoms of DMD.  
 
The mdx mouse is the most widely used animal model in DMD research. The initial study of 
this dissertation examined cardiac parameters of the mdx mouse at different ages (3, 6 and 12 
months) and found a progressive cardiac involvement. Compromised systolic and diastolic 
function was evident from 6 months of age. An underlying morphological link between 
diastolic dysfunction is cardiac fibrosis and this was significantly increased in all ages 
examined.The role of proinflammatory cytokine TGF-β in fibrosis was investigated and 
mRNA levels were found to be significantly elevated at 3 months of age, which did not 
continue with the other two age groups examined. This suggests that TGF-β may be involved 
in the initiation of fibrotic pathways, but not in the progression of fibrosis. These results were 
supported by mRNA levels of procollagen and fibronectin which significantly decreased at 12 
months of age. This implies a shift away from the initial active collagen synthesis toward a 
decreased collagen degradation maintaining the high levels of fibrosis. 
 
Study 2 aimed to determine if insulin-like growth factor-1 could ameliorate the symptoms of 
the dystrophic heart by generating a novel transgenic mouse that overexpressed IGF-1                    
exclusively in the mdx heart. This study found IGF-1 overexpression to be beneficial to the 
dystrophic heart at 12 months of age. It mediated cardiac hypertrophy at 6 and 12 months of 
age which appeared to be a physiological adaptation as evidenced by the significantly 
improved cardiac function and rate of contractility at 12 months of age. IGF-1 mediated a 
dramatic reduction in ventricular fibrosis by 12 months of age to levels not significantly 
different than control mice. Thus IGF-1 appears to be capable of resolving the inflammatory 
response and thereby reducing fibrosis. This study supported the previous findings that at 6 
and 12 months of age TGF-β mRNA levels do not correlate with the degree of ventricular 
fibrosis.  
 
The final study of this dissertation further characterised the mdx:MyoD(-/-) mouse as a model 
of the cardiomyopathy associated with DMD. MyoD is required for efficient muscle 
regeneration and its removal from the germline of the mdx mouse resulted in significantly 
higher levels of ventricular fibrosis. This implies that the milder phenotype of the mdx mouse 
may be due in part to increased regeneration. As MyoD is only expressed in skeletal muscle, 
this also suggests that skeletal muscle pathology plays a role in dystrophin deficient 
cardiomyopathy.  
 
One surprising finding from this study was an improvement in cardiac function in the face of 
increased ventricular fibrosis. This may be a compensatory mechanism due to the increased 
skeletal pathology placing an extra work load on the heart. Cardiac mRNA levels of TGF-β 
did not correlate with the increased levels of ventricular fibrosis observed in the  
mdx:MyoD(-/-) supporting the findings of the previous two studies. While procollagen gene 
expression also did not correlate with fibrosis, fibronectin mRNA levels did suggesting that 
fibronectin may be a better marker for active collagen synthesis than procollagen. 
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The experiments in this dissertation revealed for the first time the beneficial effects of IGF-1 
on the dystrophic heart which was characterised by cardiac hypertrophy, improved function 
and decreased fibrosis. The detrimental effects of increased skeletal muscle pathology on the 
dystrophic heart were evidenced by increased ventricular fibrosis in mdx mice also lacking 
MyoD.  All three studies of this dissertation highlighted the complex nature of the 
multifactorial molecular pathways involved in cardiac fibrosis. 
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CHAPTER 1   LITERATURE REVIEW AND SCOPE OF STUDY 
 
1.1 DUCHENNE MUSCULAR DYSTROPHY 
1.1.1 Brief description of Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD), an X-linked myopathy, is the most prevalent   
and severe of the muscular dystrophies, with an incidence of one in every 3500 live 
male births (Scott et al. 1988). The disease is due to the absence of the sub-sarcolemmal  
protein dystrophin. Lack of dystrophin disrupts the dystrophin-glycoprotein complex  
that spans the sarcolemma and severs the link between the extracellular matrix and the  
cytoplasm (Campbell & Kahl 1989). The ability to sustain eccentric contractions is greatly  
reduced in dystrophic muscle  and leads to abortive cycles of regeneration and degeneration  
(Deconinck & Dan 2007). Regeneration fails to be maintained, with necrosis resulting in 
muscle loss and replacement with fibrous tissue. Boys with DMD exhibit muscle weakness 
and wasting and usually die before their third decade of life due to respiratory or cardiac 
complications (Eagle et al. 2002). 
 
1.1.2 History of the disease 
The most complete early description of DMD was presented in 1851 by Edward Meryon, and 
included case reports of eight affected boys from three different families (Emery, 1993). He 
noted that the disease appeared to be hereditary with a male predilection and was associated 
with muscle damage, while sparing the nervous system. Upon histological analysis, Meryon 
found that the sarcolemma in these patients was destroyed and was subsequently 
acknowledged that this is where the protein deficit occurs. The early history of DMD has 
been reviewed by Emery (Emery, 2003). 
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In 1861 the French neurologist, Guillaume Duchenne, described a further forty cases 
including a more detailed histological analysis of muscle biopsies and the disease was 
consequently named after him (Emery, 2003).  
 
Sir William Gowers presented a detailed description of the clinical manifestations of DMD in 
a series of papers published in 1879 in the Lancet (Gowers 1879). In particular he described a 
common clinical manifestation of the disease, now termed the Gowers manoeuvre, upon 
where the patient pushes on his legs or thighs while attempting to rise from the floor.  
 
In 1955 an allelic form of DMD with a milder phenotype was classified by Becker and 
termed Becker Muscular Dystrophy (BMD) (Becker & Kiener 1955). The clinical 
manifestations of BMD are variable ranging from some patients losing the ability to walk by  
their late teens, to others only experiencing cramps during exercise or mild proximal muscle  
weakness (Emery, 2003). Cardiac failure is the leading cause of death for BMD patients, with 
50% of BMD deaths due to cardiomyopathy, compared to 20% for DMD patients (Finsterer 
& Stollberger 2003). 
 
In 1987 the cDNA of the protein deficient in DMD was cloned and sequenced (Koenig et al. 
1987). The protein termed dystrophin was identified (Hoffman, Brown & Kunkel 1987) and 
was found to be localised to the cytoplasmic surface of the sarcolemma (Watkins et al. 1988).  
 
Studies on the function of dystrophin have been facilitated by the muscular dystrophy mouse  
(mdx), a murine model of DMD discovered in a colony of C57Bl/10ScSn (Bulfield et al. 
1984). A dystrophin-like protein, utrophin, was identified in 1992 which is expressed in 
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foetal and regenerating muscle and has been suggested to play a similar role to dystrophin 
(Tinsley, et al. 1992).  
 
1.1.3 Clinical signs of DMD 
Early delayed gross motor development 
DMD boys are normal at birth with the initial notable signs being a delay in the average age 
of walking and an abnormal gait. Clinical signs that usually present between ages 3-5 years 
include an awkward gait, inability to run, hypertrophy of the calf muscles, difficulty climbing 
stairs and difficulty rising from the floor resulting in the Gowers manoeuvre (Emery, 1993). 
An excess of muscular constituents, in particular creatine kinase (CK) are found in the serum 
of DMD patients indicating muscle degeneration (Moser 1984). Elevated CK levels occur 
early in DMD and later in BMD (Zatz et al. 1991). The rate of decline of the enzymes activity 
is significantly elevated in DMD, which correlates with the greater loss of muscle mass 
observed in DMD (Zatz et al. 1991). 
 
The mean age for diagnosis of DMD using creatine kinase levels is 4.9 years, which has 
remained unchanged over the last 20 years (Ciafaloni et al. 2009). This delay in diagnosis 
impacts on genetic counselling for families and delays initiation of steroid treatment, the 
mainstay of therapy for DMD, which has been shown to be more beneficial the earlier it is 
commenced (Merlini et al. 2003). 
 
Muscle hypertrophy 
A common manifestation of DMD is hypertrophy of skeletal muscles. Calf hypertrophy is 
commonly observed (Kanamori 1988) (see Figure 1.1) as is hypertrophy of the infraspinatus 
muscle (Pradhan & Mittal 1995). The hypertrophied muscles display muscle weakness due to 
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the dystrophin deficiency rendering the sarcolemma fragile and more susceptible to 
inflammation and cell death (Yiu & Kornberg 2008). 
 
 
 
Figure 1.1 Calf hypertrophy in DMD patient (Yiu & Kornberg 2008) 
 
Joint contractures  
During late childhood joint contractures occur due to shortening of muscle fibres and tendon  
contractures which may result in toe walking. Painful joint contractures combined with  
muscle weakness leads to ambulatory difficulties  with most boys being confined to a  
wheelchair  by the age of 11years (Emery, 2003). 
 
Progression of kyphoscoliosis 
As the disease progresses the proximal pelvic muscles weaken and a compensatory 
kyphoscoliosis becomes evident. Adequate wheelchair support is required in an attempt to  
minimise the effects. However, if the curvature of the spine progresses beyond 20-30 degrees  
there will be a concomitant deterioration of cardiac and pulmonary function. A study of 51  
Duchenne patients found that all exhibited scoliosis and once the curve was greater than 35  
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degrees, vital capacity was less than 40% of the predicted normal value (Smith, Koreska & 
Moseley 1989). Spinal fusion is often indicated to counteract scoliosis and retain vital 
capacity. 
 
Intellectual impairment  
Different isoforms of dystrophin are expressed in the brain and retina. In particular the 
carboxy-terminal truncated isoform of dystrophin contributes to normal brain function. One 
third of DMD patients exhibit mild to moderate intellectual impairment with a wide range of  
phenotypes in those affected (Muntoni, Torelli & Ferlini 2003). 
 
DMD patients usually show normal visual acuity, however electroretinography has shown 
defects in several patients (Muntoni, Torelli & Ferlini 2003). 
 
Respiratory dysfunction 
Pulmonary function decreases progressively with age, resulting in hypercapnic respiratory  
failure. A predictor of mortality is often when the vital capacity falls below 1L, with a high 
likelihood of mortality occurring within the subsequent three years (Phillips et al. 2001). 
Nocturnal ventilation has reduced the number of deaths due to respiratory failure and has 
increased life expectancy from 14.4 years in the 1960’s to 25.3 years for those ventilated 
since the 1990’s (Eagle et al. 2002). 
 
Cardiomyopathy 
Although advances in respiratory care have improved life expectancy for DMD boys,  
cardiomyopathy significantly shortens their life expectancy  (Eagle et al. 2002) with 20% of  
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DMD patients and 50 % of BMD patients dying due to cardiac complications (Finsterer & 
Stollberger 2003).  
 
The clinical symptoms of cardiomyopathy are first evident at age 10, and are present in all 
patients over 18 years of age (Nigro et al. 1990). While most DMD patients remain 
asymptomatic until their early teens despite the progression of cardiac dysfunction, this may 
be due to either limited energy expenditure, muscle weakness or being wheelchair bound 
(Ogata, Ishikawa & Minami 2009).  
 
 Early detection of cardiac dysfunction is important to enable effective management and early 
treatment may prolong life expectancy (Ogata, Ishikawa & Minami 2009). Ultrasonic tissue 
characterisation may enable this as it has the capability to detect abnormalities in myocardial 
features prior to the onset of changes of systolic function and overt cardiomyopathy (Giglio et 
al. 2003). Electrocardiography (ECG) can also detect abnormalities from an early age. 
Typical changes include short PR interval, right ventricular hypertrophy and deep Q waves 
(Thrush et al. 2009). Further diagnostic techniques capable of detecting cardiac changes prior 
to clinical manifestations include the use of magnetic resonance imaging (MRI). MRI 
analysis of the T2 relaxation time in the myocardium of a group of DMD patients without 
symptoms of cardiac dysfunction were found to be decreased, indicating altered tissue 
composition (Mavrogeni et al. 2005). The progressive decrease of the T2 relaxation time with 
age furthers the notion that cardiac involvement occurs early in DMD and increases with age 
(Mavrogeni et al. 2005). In support of this, another MRI study found the ratio between 
cardiac phosphocreatine to adenosine in carriers with DMD and BMD patients to be reduced 
in the absence of left ventricular dysfunction, suggesting that cardiac metabolic dysfunction 
precedes clinical symptoms (Crilley et al. 2000).  
  
7 
 
As the disease progresses there is an increase in cardiac fibrosis, left ventricular dysfunction 
and the incidence of arrhythmias (de Kermadec et al. 1994; Melacini et al. 1996). Post 
mortem examination of hearts from DMD boys reveals severe fibrosis of the epimyocardial 
portion of the free wall of the left ventricle (Frankel & Rosser 1976). The progressive cardiac 
fibrosis impacts diastolic function more than systolic function. Echocardiographic 
measurements of DMD patients under 12 demonstrate normal systolic function, while 
diastolic myocardial velocities are reduced (Mertens et al. 2008). In the last phase of DMD 
systolic function also becomes impaired and may lead to heart failure and death (Finsterer & 
Stollberger 2003).  
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1.2 DYSTROPHIN 
1.2.1 The Dystrophin gene 
The dystrophin gene, located at Xp21, is the largest mammalian gene comprising 2300 kb of  
genomic DNA of which only 14 kb are transcribed into mRNA (Koenig et al. 1987).The 
enormous size of the dystrophin gene has been implicated in its high mutation rate of 1 in 
10,000 (Koenig et al. 1987; Koenig, Monaco & Kunkel 1988).  
 
1.2.2 Dystrophin isoforms 
There are three full length isoforms, derived from three independent promoters which are  
expressed in brain, muscle and purkinje fibres which conduct an electrical stimulus enabling 
the heart to contract. Shorter transcripts are expressed in the retina, brain, and schwann cells. 
These are shown in Figure 1.2 (Muntoni, Torelli & Ferlini 2003).  
 
1.2.3 Dystrophin gene mutations 
Intragenic deletions represent the most common mutation, which account for 65 -72% of 
mutations (Aartsma-Rus et al. 2006; Emery, 2002). There are two deletion “hot spots”; Exons 
45-55 and Exons 2-19 (Koenig & Kunkel 1990). The clusters of these two hot spots allow for 
multiplex polymerase chain reaction (qPCR) screening of only 19 of the 79 exons to enable 
identification of 90% of these deletions (Beggs & Kunkel 1990). Although this is a very 
effective technique it cannot identify the less common event of duplications or genotype 
female carriers which would require quantitative polymerase chain reaction (qPCR) (Abbs & 
Bobrow 1992). 
 
The remaining mutations (approximately 30%) arise from duplications (5-15% of cases), 
point mutations resulting in nonsense, frame shift mutations, intronic deletions, or exonic  
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insertions of repetitive sequences (Muntoni, Torelli & Ferlini 2003).  
 
 
 
 
 
 
 
Figure 1.2 Genomic organisation of the dystrophin gene (Muntoni, Torelli & Ferlini 2003)  
A. The X chromosome highlighting Xp21, the dystrophin region which is enlarged  
below. The black lines on the gene represent the 79 exons and arrows indicate  
promoters in the brain (B), muscle (M), and purkinje fibres (P), retina (R), brain 3 (B3),  
schwann cells (S) and general (G). General promoters stimulate expression of protein 
detected in most non-muscle tissues including brain, retina, kidney, liver, and lung and are 
present in cardiac but not skeletal muscle. Dp represents the dystrophin protein. 
B. The domains of the different dystrophin proteins. The amino terminal is in green and is 
followed by the spectrin like domain in blue, the cysteine rich region in red and the carboxy- 
terminal in grey.  
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The reading frame hypothesis and genotype/phenotype correlation 
The size of the deletion of the dystrophin gene does not correlate with the severity of the  
phenotype. Small deletions of exon 44 have been shown to result in DMD pathology,  
whereas large deletions involving 50% of the dystrophin gene have resulted in the milder  
phenotype of BMD (England et al. 1990; Koenig, Monaco & Kunkel 1988).  
 
The severity of the DMD phenotype, however is dependent on whether the mutation disrupts  
the reading frame of the dystrophin gene as shown in figure 1.3. Mutations that maintain the  
reading frame result in abnormal but partly functional dystrophin and are associated with 
BMD. Mutations that disrupt the reading frame (frame shift) result in unstable mRNA  
that leads to the production of nearly undetectable concentrations of truncated dystrophin,  
resulting in DMD (Monaco et al. 1988). Over 4700 mutations have been reported in the  
Leiden DMD mutation database of which 91% are in agreement with this reading frame  
hypothesis (Aartsma-Rus et al. 2006). 
 
Patients with identical exonic deletions may display different phenotypes. These patients may 
have different deletion breakpoints within introns as intronic sequences may contain motifs 
that affect gene splicing, and these different deletion breakpoints may affect exon skipping 
events (Gualandi et al. 2003).  
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Figure 1.3 Diagrammatic representation of dystrophin protein and common exon deletions  
in DMD. Adapted from (Aartsma-Rus et al. 2006).  
(A) Dystrophin protein showing domains. The N-terminal actin-binding domain (ABD  
yellow), central rod domain which contains 24 spectrin like repeats (1-24 blue) interrupted by 
four hinge regions (H1-4 orange), a cysteine rich domain (light orange) and the C-terminal 
domain (dark orange) containing syntrophin and dystrobrevin binding domains (ASD and 
DBD). An additional actin binding domain is present between repeat units 11 and 17. 
The location of exons is shown beneath the protein structure. 
(B) Location of in-frame deletions and corresponding phenotypes. In-frame deletions 
involving only the central rod domain are usually associated with a mild phenotype unless the 
deletion is excessively large. A deletion of the N-terminal domain causes severe BMD, but a 
deletion of both the N-terminal and part of the central rod domain results in DMD.Mutations 
involving the cysteine rich domain usually results in DMD, whereas deletions of the 
syntrophin binding domains Exons 71-74 have been reported for some BMD patients. 
Mutations in Exon 74 or higher are found in both DMD and BMD patients.  
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1.2.4 Revertant fibres 
The mdx mouse has a nonsense mutation of the dystrophin gene at Exon 23 and as such there  
should be no functional dystrophin expressed by muscle cells (Sicinski et al. 1989). However, 
although mdx muscle is negative for dystrophin detected by immunoblotting, a very small 
percentage of myofibres are dystrophin positive as observed by immunofluorescence 
microscopy (Hoffman et al. 1990). This is also observed in DMD patients (Fanin et al. 1995; 
Klein et al. 1992). It has been suggested that this is due to a naturally occurring spontaneous 
exon skipping, and these dystrophin expressing fibres are termed revertant fibres (Wilton et 
al. 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
13 
 
1.3 THE DYSTROPHIN PROTEIN 
1.3.1 Dystrophin structure 
The dystrophin gene was cloned in 1985 (Kunkel et al. 1985) which was followed by  
the identification  of the protein product, dystrophin (Hoffman, Brown & Kunkel 1987). 
Dystrophin is approximately 400kb in size and is localised to the sarcolemma of skeletal, 
smooth and cardiac muscle cells (Zubrzycka-Gaarn et al. 1988). It is not present in the 
muscle cells of DMD boys or in various dystrophic animal models including the mdx mouse, 
the golden retriever muscular dystrophy dog (GRMD) and the dystrophic cat.  
 
As illustrated in figure 1.4, dystrophin is an integral component of the membrane associated  
proteins known collectively as the dystrophin-glycoprotein complex (DGC) 
(Campbell & Kahl 1989). The DGC is compromised of sarcoplasmic proteins α- 
dystrobrevin, syntrophins and neuronal nitric oxide synthase (nNOS)), transmembrane  
proteins (β-dystroglycan, the sarcoglycans, caveolin-3 and sarcospan) and extracellular  
proteins (α-dystroglycan and laminin) (Davies & Nowak 2006). Dystrophin binds to the DGC 
through its C terminus while the N terminus binds it to the cytoskeleton through filamentous 
(F) actin. The DGC therefore facilitates a mechanical link between the intracellular 
cytoskeleton and the extracellular matrix (ECM) (Davies & Nowak 2006). This mechanical 
link is imperative for membrane integrity (Campbell & Kahl 1989; Rybakova, Patel & 
Ervasti 2000).  
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Figure 1.4 The structure of the human dystrophin-glycoprotein complex (DGC) 
(Davies & Nowak 2006). Dystrophin binds to the DGC through its C terminus. The  
DGC is comprised of sarcoplasmic proteins α-dystrobrevin, syntrophins and neuronal nitric 
oxide synthase (nNOS)), transmembrane proteins (β-dystroglycan, the sarcoglycans, 
caveolin-3 and sarcospan) and extracellular proteins (α-dystroglycan and laminin). The N 
terminus of dystrophin binds to the cytoskeleton through filamentous (F)-actin. 
Dystrophin has four structural domains. The amino terminus binds to F-actin (Way et al. 
1992) and is followed by a large rod domain with 24 spectrin-like repeats and four hinge 
sections that confer flexibility and membrane resilience (Koenig & Kunkel 1990). Next is the 
WW domain which interacts with β-dystroglycan and is a motif found in proteins involved in 
signalling and regulatory functions (Chung & Campanelli 1999). The cysteine rich domain 
which follows is involved in calcium and calmodulin binding.  Finally the c-terminal region 
which binds the c-terminus region of dystrobrevin and the alternatively  
spliced region binds syntrophin (Sadoulet-Puccio, Rajala & Kunkel 1997).  
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N terminal domain of dystrophin 
The N terminal domain appears to be required for normal dystrophin function (Norwood et 
al. 2000).  Transgenic mdx mice that expressed an isoform of dystrophin that contained the 
cysteine-rich and C-terminal domains of dystrophin, but lacked the N-terminal actin-binding 
and central spectrin-like repeat domains resulted in a severe pathology (Cox et al. 1994).  
Generally a deletion in the N-terminal results in severe BMD, whereas a deletion of  
the N-terminal and the part of the central rod domain results in DMD (Aartsma-Rus et al. 
2006). 
 
Cysteine-rich region of dystrophin 
Transgenic mice that expressed an isoform of dystrophin that had deletions in the cysteine – 
rich region resulted in a disruption of the interaction between dystrophin and the DGC,  
leading to a severe dystrophic pathology (Rafael et al. 1996). Deletions in this region 
obliterate the β-dystroglycan binding site, which leads to a loss of β-dystroglycan and the 
sarcoglycan complex. This suggests that the cysteine rich region is imperative for a functional 
dystrophin and assembly of the DGC at the sarcolemma. Likewise mutations in the cysteine-
rich area of the dystrophin gene results in a DMD phenotype (Aartsma-Rus et al. 2006). 
 
Central rod domain of dystrophin 
Transgenic mice with a truncated central rod domain displayed normal DGC formation and  
therefore no dystrophic pathology (Chamberlain et al. 1997).This suggests that the large 
central rod domain does not appear to be critical for a functional dystrophin.  
 
Many BMD patients with mild pathologies have large in-frame deletions of this region and  
produce a shorter, but still functional dystrophin  (England et al. 1990). Generally boys with 
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deletions in this region that are greater than 36 exons in size result in DMD, whereas  
deletions less than 36 exons display a milder BMD phenotype (Aartsma-Rus et al. 2006). 
 
C-terminal end of dystrophin 
Deletion of the C-terminal end of dystrophin in transgenic mdx mice appears to have no  
effect on the function of the protein suggesting that this region is not required for the 
assembly of the DGC (Rafael et al. 1996).  
 
Inter- and intra-phenotypic variability is observed in BMD and DMD. For example deletions 
at the C-terminus of the dystrophin gene in boys generally results in the milder BMD 
phenotype, however one patient missing the C-terminus produced a truncated Becker-like 
dystrophin but displayed severe DMD phenotype (Hoffman et al. 1991).  
 
Figure 1.3 illustrates the domains of the dystrophin protein, common exon deletions and the  
phenotype they most often result in. 
 
 
1.3.2 Roles of dystrophin 
Evidence of a mechanical role for dystrophin 
Loss of dystrophin results in a loss of the DGC and the structural link between ECM and  
cytoskeleton. 
Dystrophin anchors the DGC of the sarcolemma to the underlying cytoskeleton (Campbell & 
Kahl 1989) and is required for an intact DGC with a dramatic reduction in all of the DGC 
proteins at the sarcolemma observed in DMD patients and mdx mice (Matsumura et al. 1994). 
When dystrophin is expressed in revertant fibres the DGC is restored (Matsumura et al. 
1994).  
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The DGC and other proteins form rib-like lattices known as costameres (Minetti et al. 1992). 
Costameres anchor the myofibrils to the sarcolemma and act as mechanical couplers between 
the contractile apparatus and the ECM. Loss of the DGC disrupts the costameric lattice which 
may lead to membrane fragility (Rybakova, Patel & Ervasti 2000). 
 
The dystrophic membrane shows increased susceptibility to eccentric contraction  
induced damage. 
Studies have shown that when mechanical stress is placed upon the sarcolemma during  
contraction it ruptures (Head, Williams & Stephenson 1994; Moens, Baatsen & Marechal 
1993; Petrof et al. 1993). Loss of the DGC appears to render the sarcolemma susceptible to 
damage from muscle contraction thus supporting the hypothesis that the primary role of 
dystrophin is as a structural support.  
 
The dystrophic membrane displays increased permeability.  
The lack of this structural link renders the membrane fragile and increases its permeability.  
The increased permeability of the membrane leads to elevation of the cytoplasmic  
concentration of albumin and immunoglobins as reviewed by Deconinck and Dan  
(Deconinck, & Dan 2007).  
 
Increased membrane permeability can be visualised by incorporation of the membrane  
impermeant dye Evans Blue (Hamer et al. 2002). Muscle enzymes such as pyruvate  
kinase and creatine kinase leak into the serum in DMD patients (Zatz et al. 1991) and mdx  
mice indicating muscle degeneration.    
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Calcium hypothesis 
Dystrophin deficiency leads to an increase in intracellular calcium in myocytes of muscle  
biopsies from DMD patients (Imbert et al. 1995) and mdx mice (Allen 2004; Woolf et al. 
2006). The process of calcium entry may occur via ionic channels or via membrane tears. 
Increased membrane permeability enables large proteins such as albumin and creatine kinase 
to enter and leave the cell and may also enable increased calcium influx (McNeil & Khakee 
1992).  
 
It has also been proposed that it is the calcium accumulation that brings about the observed 
increase in membrane permeability (Allen, Whitehead & Yeung 2005; Whitehead et al. 
2006). Further studies suggest that the increased calcium levels are due to calcium entry via  
ionic channels. Calcium influx was found to be almost totally inhibited by Ni
2+
, a non- 
specific cation channel inhibitor, suggesting that calcium entry is dependent upon permeable  
channels as opposed to membrane damage (Fraysse et al. 2004). Furthermore mdx mice are  
more likely to have open stretch-activated channels (SACS) and these channels seem to be  
more sensitive to the effects of contractions  (Allen 2004). These channels are further opened  
by stretch which exacerbates ionic influx and results in a decrease in the force of contraction. 
Gadolinum and streptomyocin block SACs in muscle fibres and are capable of blocking  
increase in [Na
+
] in mdx mouse muscle (Allen 2004), improving force and decreasing 
membrane permeability in isolated muscle and in the whole mouse (Whitehead et al. 2006). 
 
A recent study implicates transient receptor potential canonical 1 (TRPC1) as the calcium  
channel involved in the pathogenesis of DMD (Gervasio et al. 2008). TRPC1 are widely 
expressed calcium permeable channels in skeletal muscle (Venkatachalam & Montell 2007) 
and cardiac muscle (Williams & Allen 2007). It has been suggested that TRPC1 is a store 
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activated channels (SOC) or stretch activated channels (SAC) (Ducret et al. 2006). TRCP1 
has been shown to form SACs in vertebrate cells (Maroto et al. 2005). Another contradictory 
study on TRPC1 knockout mouse displayed no apparent pathology, suggesting that TRPC1 is 
not an obligatory component of SAC or SOC ion channels in vascular smooth muscles 
(Dietrich et al. 2007). The function of TRPC in cardiomyocytes and their possible 
involvement in cardiomyopathy has been reviewed by Dietrich (Dietrich et al. 2007).  
 
TRPC1 have been associated with DMD. SAC inhibitors stretomyocin and GsMTx4 reduced  
the resting calcium in isolated ventricular myocytes of old mdx, suggesting SACs are  
involved in the abnormal calcium handling seen in mdx mice. Furthermore an increased 
expression of TRPC1 was seen in old mdx mice (Williams & Allen 2007). In support of these 
results, suppression of TRPC1 decreases SOC and SAC occurrence and activity in mdx mice 
(Vandebrouck et al. 2002).  
 
Regulatory proteins, caveolins, have been implicated in the regulation of TRPC1 (Gervasio et 
al. 2008) and higher levels of muscle specific caveolin-3 have been observed in mdx muscle 
(Vaghy et al. 1998). TRPC1 binds to caveolin-3 and is regulated by src kinase (Gervasio et 
al. 2008). Hydrogen peroxide, a reactive oxygen species (ROS), increased src kinase activity 
and enhanced calcium influx, but only in myoblasts expressing both TRPC1 and caveolin-3. 
In mdx muscle a ROS scavenger, tiron and a src inhibitor, PP2, decreased calcium entry and 
mediated force recovery (Gervasio et al. 2008). As ROS production is increased in mdx and 
DMD (Whitehead, Yeung & Allen 2006), these findings implicate a ROS-Src-
TRPC1/caveolin-3 pathway in the pathogenesis of the disease (Gervasio et al. 2008). 
Chronic calcium overload results in activation of calcium dependant proteases, particularly 
calpains (MacLennan, McArdle & Edwards 1991). Proteases are a downstream calcium 
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activated target involved in protein degradation as evidenced in dystrophic skeletal muscle 
(Allen, Whitehead & Yeung 2005). 
 
1.3.3 Dystrophin in the cardiomyocyte 
In human and rat cardiac muscle, dystrophin is continuous with the cytoplasmic surface of  
the plasma membrane at costameric and non-costameric regions (Kaprielian et al. 2000; 
Kostin et al. 1998). It is absent at intercalated discs but, unlike skeletal muscle, is also present 
at transverse tubules. T-tubules are important in excitation contraction coupling and do not 
serve in the transmission of contractile force (Kaprielian et al. 2000). The presence of 
dystrophin in cardiomyocyte T-tubules suggests a diverse role for dystrophin in 
cardiomyocytes. 
 
1.3.4 Utrophin 
The dystrophin gene demonstrates over 80% homology with the autosomal gene utrophin  
which is located on chromosome 6 (Tinsley et al. 1992). Utrophin is found in all tissues and 
is expressed in high levels in DMD muscle. 
 
Utrophin is present in developing skeletal muscle and is localised around the sarcolemma 
(Khurana et al. 1991), whereas in adult muscle it becomes restricted to myotendinous and 
neuromuscular junctions (Ohlendieck et al. 1991). This pattern of localisation suggests that 
utrophin may perform the function of dystrophin in foetal and developing muscle fibres. 
Furthermore utrophin appears to be able to functionally substitute for dystrophin 
(Perkins & Davies 2002). 
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1.4 PATHOPHYSIOLOGY OF DYSTROPHIN DEFICIENT MUSCLE 
1.4.1 Initiation of necrosis 
Loss of dystrophin at the sarcolemma severs the link between the contractile protein actin and  
the cell membrane resulting in a marked reduction of all the other dystrophin associated 
proteins (Matsumura et al. 1994). This loss of integrity of the cell membrane disrupts normal 
calcium homeostasis and allows an influx of calcium into the cytoplasm, activating calcium 
dependent proteases (MacLennan, McArdle & Edwards 1991). Affected myofibres are more 
susceptible to inflammation and cell death (Matsumura & Campbell 1993).  
 
Although many of the processes that occur early in dystrophic muscle are stereotypical of  
necrosis, histological analysis points towards apoptosis preceding necrosis and characterising  
the onset of dystrophic pathology. This is followed by necrosis in the later stages of the  
disease (Tidball et al. 1995). 
 
1.4.2 Myocyte regeneration and fibrosis 
Inflammatory cytokines initiate the inflammatory process and cell death which leads to  
scarring and fibrosis. Tumor necrosis factor alpha (TNF-α), an early pro-inflammatory  
cytokine is upregulated in DMD patients (Porreca et al. 1999). However the exact role of this  
cytokine is contentious, with some studies finding TNF-α plays a role in the progressive  
deterioration of the mdx diaphragm (Gosselin & Martinez 2004), whereas others have  
found TNF-α to be associated with promoting muscle development, postnatal growth and  
regeneration (Li, & Schwartz 2001). The differences in the role TNF-α plays may be due to 
the cytokine influencing different types of muscles in different ways, and the stage of the 
disease. 
 
Pleiotropic cytokine transforming growth factor-β (TGF-β) has also been suggested as a  
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mediator of fibrosis in DMD (Bernasconi et al. 1999), mdx mice (Andreetta et al. 2006) and  
the canine model of DMD (Passerini et al. 2002). Differences in the amount or localisation 
of this cytokine may influence the balance between muscle regeneration and the development 
of fibrosis (Murakami et al. 1999).  
 
T lymphocytes have also been shown to play a role in fibrosis particularly in the diaphragm 
(Morrison et al. 2000). Furthermore, the expression of two myogenic regulatory factors, 
MyoD and myogenin have been shown to decrease as fibrosis progresses in mdx mice (Jin et 
al. 2000).  
 
1.4.3 Oxidative stress 
The abnormal membrane structure which leads to altered calcium homeostasis also results in  
excessive generation of reactive oxygen free radical species (ROS) (Whitehead, Yeung & 
Allen 2006). Dystrophin deficient muscle shows an increased production of ROS and 
decreased DGC signalling resulting in decreased expression of the enzyme neuronal nitric 
oxide synthase (nNOS). nNOS is responsible for the production of nitric oxide (NO) which 
mediates vasodilation and protects against ischemia (Rando 2001). Muscle biopsies from 
BMD patients show a correlation between disease severity and decreased nNOS at the 
sarcolemma (Chao et al. 1996). Mdx mice also have decreased nNOS (Bia et al. 1999). 
However, loss of nNOS alone does not explain subsequent cell death and degeneration as 
evidenced by an absence of muscular dystrophy in nNOS deficient mice (Chao, Silvagno & 
Bredt 1998). Rather it has been suggested that decreased nNOS at the sarcolemma results in a 
reduction in NO-mediated protection against ischemia, which combines with the increased 
susceptibility of dystrophic muscle to metabolic stress resulting in muscle degeneration 
(Rando 2001). 
  
23 
 
 
Oxidative stress is elevated in the failing myocardium and may be a regulator of the ECM 
through effects on matrix metalloproteinases (MMPs) and collagen synthesis (Siwik & 
Colucci 2004). 
 
1.4.4 Muscle regeneration 
Muscle satellite cells allow regeneration of new muscle fibres, but these are also dystrophin  
deficient and subsequently degenerate as shown in Figure 1.5. Furthermore DMD muscle  
precursor cells have been shown to replicate less than controls, which may be due to  
shortened telomere length resulting from previous replications (Decary et al. 2000). A 
decreased expression of myogenic regulator, MyoD (which is necessary in the regenerative  
process for the proliferation of satellite cells) is observed in mdx mice (Jin et al. 2000). 
 
The continuous nature of cycles of regeneration and degeneration cycle results in increased  
fibrosis within the muscle with chronic accumulation of fibrosis being indicative of  
DMD and mdx muscle (Chamberlain et al. 2007).  
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Figure 1.5 Pathophysiological processes occurring in dystrophin deficient muscle. 
A lack of dystrophin results in a loss of the DGC at the sarcolemma, rendering the  
membrane fragile. Decreased nNOS and NO production results in increased ROS. Increased 
calcium influx into the sub-sarcolemmal area activates calcium dependant proteases. 
Subsequent initiation of the inflammatory response and cell death result in scarring and 
fibrosis. The cycle of degeneration and regeneration is ongoing as replaced muscle is also 
dystrophin deficient, and the extent of fibrosis is increased with every cycle. 
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1.5 ANIMAL MODELS OF DMD 
1.5.1 Range of animal models used in DMD research 
There is a wide range of naturally occurring and genetically manipulated animals used to  
study DMD. The most commonly used dystrophin deficient animal is the mdx mouse, which  
arose from a  spontaneous mutation in a colony of C57B1/10ScSn mice (Bulfield et al. 1984). 
Other dystrophin deficient animals include the golden retriever muscular dystrophy dog 
(GRMD) (Kornegay et al. 1988), the dystrophic cat (Carpenter et al. 1989), the dystrophic 
chicken (Dawson 1966), cow (Poukka 1966) sheep  (Paulson, Pope & Baumann 1966), 
zebrafish (Chambers et al. 2001) and the nematode Caenorrhabditis elegans  (Mariol & 
Segalat 2001).  
 
1.5.2 Hypertrophic feline muscular dystrophy cat 
The feline muscular dystrophy cat (FXMD) lacks dystrophin and displays a true muscle  
hypertrophy, unlike the psuedohypertrophy seen in DMD and BMD. It exhibits a progressive  
histology characterised by necrosis and regeneration, but not fibrosis  (Carpenter et al. 1989).  
For this reason it is seldom used as a model for DMD research. 
 
1.5.3 Golden retriever muscular dystrophy dog 
The golden retriever muscular dystrophy (GRMD) dog is the best representation of DMD.  
Like DMD, the GRMD displays muscle weakness, necrosis and regeneration, elevated serum  
creatine kinase levels, and endomysial and perimysial fibrosis resulting in a severe myopathy  
(Valentine et al. 1990). GRMD dogs present clinical symptoms within the first weeks of life  
involving limb and masticatory muscles. Impairment of the diaphragm and the intercostal  
muscle leads to respiratory failure (Ambrosio et al. 2008). Like DMD and BMD, GRMD 
dogs also develop dilated cardiomyopathy (Chetboul et al. 2004) with death occurring early  
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at 2 years of age due to respiratory or cardiac failure (Ambrosio et al. 2008).  
 
The phenotype of the GRMD model is variable, which makes functional analysis difficult to 
interpret and compare (Banks & Chamberlain 2008). One recent case reported a GRMD dog 
lacking dystrophin, with high serum CK levels, but a very mild phenotype. The dog’s two 
brothers carried the same dystrophin mutation, but displayed severe phenotypes, with one 
dying at just two weeks of age (Ambrosio et al. 2008). Clinical observations of  
musculoskeletal, morphological, gastrointestinal, respiratory, cardiovascular, and renal  
features have been used to identify three distinguishable phenotypes which may go some way  
to explain this issue. They range from mild (grade I), moderate (grade II) to severe (grade  
III) and perhaps reflect the inter- and intra- phenotypic variability observed in DMD and 
BMD patients (Ambrosio et al. 2009). Qualitative and quantitative measurements in the 
GRMD dog model have recently been reviewed (Willmann et al. 2009). 
 
A limitation of the GRMD model is the high cost of maintenance and ethical issues 
involved in canine research. Although the GRMD has its limitations as an animal model for 
DMD, it is more useful for clinical trials than the mdx mouse which displays a much milder 
phenotype. Recent reports involving the GRMD dog include prednisone studies (Liu, J. M. et 
al. 2004), gene delivery using an adeno-associated virus (Yue et al. 2008), human adult stem 
cells transplantation (Kerkis et al. 2008), haematopoietic stem cell studies (Parker et al. 2008) 
and diaphragmatic transplantation (Krupnick et al. 2008). 
 
1.5.4 mdx mouse 
Genetic mutation in the mdx 
The mdx mouse has a point mutation in Exon 23, which introduces a premature stop codon  
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leading to an absence of full length dystrophin (Sicinski et al. 1989) and attenuation of the  
DGC (Ohlendieck et al. 1991). 
 
Life span 
Compared to wild type mice, mdx have a shorter life span, which is reduced in females by  
17% and in males by 19% (Chamberlain et al. 2007; Pastoret & Sebille 1995). They exhibit a 
progressive dystrophic muscle histopathology with old males being prone to spontaneous 
rhabdomyosarcomas (Chamberlain et al. 2007).  
 
Mdx skeletal muscles undergo chronic cycles of degeneration and regeneration 
Degeneration and regeneration of muscle fibres is observed at 2-4 weeks of age as evidenced 
by an increased number of differentiating myofibres with centralised nuclei and increased 
heterogeneity of myofibre size (McGeachie et al. 1993). Necrosis has also been observed at 
this age (Grounds & Torrisi 2004). The muscle breakdown peaks at 28 days, then decreases 
and stabilises at around 12 weeks of age to a relatively low level of damage (McGeachie et al. 
1993). In older mdx mice regeneration declines while the necrotic process continues (Pastoret 
& Sebille 1995). Further evidence for the chronic cycles of degeneration is a continual leak of 
cytosolic enzymes such creatine kinase and pyruvate kinase into the serum throughout the 
mdx lifespan (Bulfield et al. 1984).  
 
Mdx skeletal muscles exhibit
 
a heterogeneous response to dystrophin deficiency. Extraocular
 
muscles do not exhibit the dystrophic phenotype (Porter et al. 1998), whereas hindlimb 
muscles undergo a progressive
 
dystrophic process and the diaphragm displays a more severe 
pathology at all stages of the disease (Dupont-Versteegden & McCarter 1992). A gene 
expression profiling study suggested that inflammation-mediated repair may be lower in the 
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more severely
 
affected muscles, and this may compromise regeneration resulting in a more 
severe pathology (Porter et al. 2004). 
 
Body weight 
Body weight increases at 8 weeks old (Connolly et al. 2001) with body and muscle weights  
declining dramatically after 52 weeks (Pastoret & Sebille 1995). 
 
Hypertrophy 
Generalised hypertrophy of the trunk and upper and lower limb muscles is evident in  
mdx at 6 months of age with the extensor digitorum longus (EDL) and soleus muscle  
displaying a dramatic increase in muscle mass of 28% and 42% respectively  
(Lynch & Hinkel 2001) and the tibialis anterior increasing by 58% (Pastoret et al. 1995).  
 
Contradictory results regarding hypertrophy in old mdx mice exist, with the muscle mass of  
EDL and soleus muscles from mdx mice displaying a sustained hypertrophy at 28 months  
17% and 22% respectively greater than controls (Lynch et al. 2001). Whereas another study 
found that the tibialis anterior muscle mass of mdx mice was reduced to 50% of control  
values by 24 months (Pastoret et al. 1995), suggesting not all skeletal muscles exhibit 
hypertrophy . 
 
Force of contraction  
Although mdx muscles are larger, they are weaker than control mice when the force they 
produce is normalised to muscle weight or cross sectional area. Throughout their lifespan, 
normalised power output of mdx muscles is on average 20 % lower than control mice (Lynch 
et al. 2001). A contradictory study suggested mdx muscles are bigger and stronger, however 
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force values were not normalised to weight or cross sectional area (Bobet, Mooney & Gordon 
1998). 
 
 
Calcium homeostasis in mdx skeletal muscle  
Calcium homeostasis is altered in both mdx and DMD muscle. Studies report an increase in  
basal cytosolic calcium levels and sarcolemmal permeability in mdx muscle fibres (Fraysse et 
al. 2004). Abnormal calcium handling is exhibited in skeletal and cardiac myocytes  
(Lucas-Heron et al. 1987).  
 
The increased resting cytosolic calcium and sarcolemmal permeability in mdx myofibres is 
exacerbated by exercise, leading to excessive calcium signalling which intensifies cellular 
damage (Fraysse et al. 2004). Exercise also reduces strength (Burdi et al. 2006; Pierno et al. 
2007) and increases serum levels of creatine kinase (Rolland et al. 2006).  
 
 
Respiratory Muscle Involvement 
The diaphragm of the mdx mouse is the skeletal muscle that best reflects the progressive  
degeneration, fibrosis and functional deficit observed in limb muscles of DMD patients  
(Stedman et al. 1991). Fibrosis is up to seven times more than that of control diaphragm, and  
ten times that of the mdx hind-limb muscle (Stedman et al. 1991).  However, this is not  
initially reflected in the respiratory response, with mdx mice at 5 months of age exhibiting  
no difference in ventilation during air breathing and in response to hypercapnia when  
compared to controls (Gayraud et al. 2007).   By 15 months of age the accessory muscles of  
respiration exhibit similar but less severe histological changes (Stedman et al. 1991) and this  
is accompanied by an altered  response to hypercapnia at 16 months of age (Gayraud et al. 
2007).  
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Cardiac Involvement 
An early indicator of cardiac involvement in mdx mice is cardiomyocyte membrane damage.  
Using Evans blue dye infiltration, membrane leakage has been observed in mdx heart at 3  
months of age which persists up to 18 months (Van Erp et. al. submitted). Membrane leakage 
does not appear to affect cardiac function as this does not decrease until 15 months of age 
(Van Erp, Irwin & Hoey 2006). 
 
Cardiac calcium homeostasis 
Mdx cardiomyocytes have elevated levels of intracellular calcium, leading to decreased  
cardiomyocyte function and necrosis resulting from calcium dependant proteases 
(Alloatti et al. 1995). Mdx cardiomyocytes exhibit abnormal calcium signalling response to 
mechanical stress and this is accompanied with an increased production of ROS (Jung et al. 
2008). The two mechanisms combine synergistically to modify calcium signalling (Jung et al. 
2008).  
 
Cardiac Fibrosis 
Chronic cycles of degeneration in cardiomyocytes of mdx leads to cardiac fibrosis  
(Quinlan et al. 2004; Van Erp, Irwin & Hoey 2006). High levels of fibrosis have been 
observed in mdx hearts at 6 months of age (Van erp et. al. submitted) and 9 -10 months of age 
(Spurney et al. 2008). By 12 months of age fibrosis has been reported at 8% collagen which 
increased to 12% collagen by 24 months of age (Cohn et al. 2007).  
 
It is difficult to compare results on the quantitative analysis of fibrosis between studies as 
results vary substantially. One study reported 17 month old mdx hearts displaying 7-9% 
collagen (Quinlan et al. 2004) whereas another study found younger 15 month old mdx hearts 
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exhibiting 13% collagen (Van erp et. al. submitted). Differences may be attributed to 
inconsistencies in methodology or inherent variations in different mdx mouse colonies 
worldwide.  
 
Fibrosis in mdx hearts have been reported to affect all the regions of the left and right 
ventricle approximately equally (Quinlan et al. 2004). This differs from the hearts of DMD  
patients where fibrosis is most severe in the posterobasal portions of the left ventricle with a 
sparing of the right ventricle (Frankel & Rosser 1976). Differences in the distribution of  
cardiac fibrosis between DMD patients and the mdx mouse are also reflected in  
echocardiographic differences (Quinlan et al. 2004). High levels of fibrosis can eventually 
lead to decreased cardiac systolic and diastolic function (Van Erp, Irwin & Hoey 2006).  
 
Transforming Growth Factor (TGF- β) 
TGF-β is a profibrotic cytokine known to play an important role in inflammation and wound  
repair with its expression related to fibrosis (Passerini et al. 2002). TGF-β increases  
collagen synthesis primarily by increased transcription (Mauviel 2005). It also increases  
collagen by stabilising  procollagen mRNA and  by decreasing matrix metalloproteinase 
(MMP) activity which leads to a decreased breakdown of collagen (Eghbali et al. 1991; Li, 
McTiernan & Feldman 2000).   
 
Although levels of TGF-β expression have been shown to be increased early in life in the  
mdx diaphragm (at age 6 weeks) and early in the life of the GRMD (up to 60 days) its levels  
do not continue to increase with age and fibrosis (Gosselin et al. 2004). Data concerning 
TGF-β expression in the mdx heart is limited. One study reported no increase in TGF-β 
mRNA expression in mdx hearts at 15 months old even though there is a significant increase 
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in fibrosis at that age and while long term pirfenidone treatment lowered TGF-β expression, it 
did not reduce fibrosis (Van Erp, Irwin & Hoey 2006). 
 
Unpublished data from our laboratory also confirms that although there is ongoing fibrosis in  
young mdx hearts it does not correlate with TGF-β mRNA expression (Van Erp et. al. 2009  
submitted). These findings suggest that there is a lack of direct correlation between TGF-β 
expression and ventricular fibrosis. This inconsistency may be partly explained by a shift 
toward reduced degradation of collagen rather than active collagen deposition maintaining 
ventricular fibrosis in older mdx hearts (Van Erp, Irwin & Hoey 2006).  
 
Procollagen 
The cardiac collagen network consists of collagen type I and III, with type I being 
predominant (ratio of approx. 70:30) (Weber et al. 1989).  Collagen type I is synthesised in 
fibroblasts as procollagen I. When procollagen I is secreted into the ECM proteinases remove 
the N-terminal and C-terminal propeptides to form collagen type I (Lopez et al. 2001). Serum 
levels of the carboxy terminal propeptide of procollagen type I have been used as a marker of 
extracellular collagen type I synthesis in hypertensive heart disease (Querejeta et al. 2000). 
To the authors knowledge cardiac mRNA levels of procollagen type I have not be determined 
in mdx mice. This research project examined for the first time, procollagen mRNA levels as a 
marker of collagen type I synthesis in mdx mice and two transgenic strains.  
 
 
Fibronectin 
Fibronectin plays a pivotal role in the ECM as it provides the structural network for the 
formation of the fibrotic network as it binds to integrin receptors and links cardiac myocytes 
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to the basal lamina (Chen, H. et al. 2004). In the adult heart fibronectin is expressed within 
fibroblasts and around the microvasculature (Farhadian et al. 1995). Fibronectin 
polymerisation into the ECM has been shown to be required for the deposition of collagen 
type I (Sottile & Hocking 2002).  Fibronectin expression is increased during myocardial 
injury and inflammation (Farhadian et al. 1995). It acts as a chemoattractant for fibroblasts 
(Jane-Lise et al. 2000) and plays a role in wound repair and remodelling (Ulrich et al. 1997). 
Fibronectin has also been shown to stimulate several pathways involved in cardiomyocyte 
hypertrophy (Chen et al. 2004).  
 
To date there is a lack of studies involving cardiac gene expression of fibronectin in the mdx 
mouse. As this gene plays an integral role in cardiac fibrosis this research project determined 
cardiac mRNA levels of fibronectin in the mdx mouse and two transgenic mouse models to 
further elucidate fibrotic pathways.  
 
Cardiac function 
Contractile properties are markedly altered in atria of mdx hearts. In particular half-relaxation 
time at 12 – 14 weeks of age is significantly prolonged in the mdx heart (Sapp, Bobet & 
Howlett 1996).   Normal ventricular function has been observed in mdx mice hearts at 8 
weeks with decreased function occurring at 9-10 months of age which was characterised by 
decreased fractional shortening and left ventricular end diastolic dimension increase, 
suggesting dilated cardiomyopathy (Quinlan et al. 2004).  
 
Ex vivo experiments have highlighted the abnormal vulnerability of dystrophin deficient 
cardiomyocytes to mechanical stress which results in sarcolemmal damage and impaired 
contractile function (Danialou et al. 2001). Even in young mdx mice, the heart is unusually 
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susceptible to mechanical stress with 8 week old mdx mouse hearts displaying abnormal 
function under ex-vivo perfused conditions with both short term (isoproterenol induced heart 
failure) and chronic afterload increases (aortic constriction) (Danialou et al. 2001). These 
results suggest that dystrophin may protect cardiomyocytes from mechanical stress and 
workload-induced damage (Danialou et al. 2001).  
 
It has been shown in young mdx mice that β1-adrenoreceptor function is normal (Lu & Hoey 
2000a). In old mdx β1-adrenoreceptor function deteriorates with disease progression as 
evidenced by reduced potency of (-)-isoprenaline, and decreased cardiac contractility (Lu & 
Hoey 2000b). The aged mdx mouse exhibits cardiac dysfunction similar to DMD patients 
with mdx hearts at 15 months of age exhibiting a 26% decrease in left ventricular developed 
pressure, 29% decrease in contractility and 21% decrease in rate of relaxation compared to 
age matched controls (Van Erp, Irwin & Hoey 2006).  
 
Electrocardiographic and heart rate variability changes 
Electrocardiography (ECG) of mdx hearts also supports a progression from normal cardiac 
function in young mdx mice to a dilated cardiomyopathy in adult mdx mice (Quinlan et al. 
2004). By 12-24 months of age mdx mice display autonomic dysfunction, impaired 
conduction, arrhythmias, deteriorated left ventricular function and dilated cardiomyopathy  
(Wehling-Henricks et al. 2005).  
 
Mdx hearts display a significant tachycardia and decreased heart rate variability with a heart 
rate 15% faster than control mice (Chu et al. 2002). Heart rate variability is an indicator of  
autonomic function with depressed heart rate variability indicative of cardiac autonomic  
dysfunction (Gehrmann et al. 2000). It is suggested that the decreased heart rate variability  
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observed in mdx hearts reflects an imbalance in the autonomic nervous system modulation of 
heart rate, with decreased parasympathetic activity and increased sympathetic activity  
(Chu et al. 2002). 
 
Evidence from different studies supports old mdx mice as a better model for DMD cardiac  
disorders than young mdx mice with the progression of cardiomyopathy observed in mdx  
mice at 42 weeks of age being comparable to the cardiac involvement of DMD patients  
(Quinlan et al. 2004).  
 
Limitations of the mdx mouse model 
The use of the mdx mouse as an animal model for DMD has been questioned due to its  
milder phenotype  and lack of widespread fibrosis and fatty infiltration (Megeney et al. 
1999). This mild phenotype may be a result of upregulation of utrophin  (BostickYueLong et 
al. 2008) and utrophin/dystrophin double knockout mice have been suggested to resemble 
DMD pathology more closely than mdx mice (Deconinck et al. 1997). It has also been 
proposed that the reduced dystrophic features of the mdx mouse may be due to increased 
skeletal muscle regeneration. Removal of the myogenic regulator MyoD from the germline of 
mdx mice resulted in a more severe skeletal muscle pathology suggesting that increased 
regeneration does play a role in the milder phenotype of mdx mice (Megeney et al. 1999).  
 
The mdx mouse displays distinct stages throughout its life span and different degrees of  
pathology depending on age and muscle type. For example evidence supports old mdx mice  
as a better model for DMD cardiac disorders and skeletal muscle pathology than young mdx 
mice (Chamberlain et al. 2007; Quinlan et al. 2004). 
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Experimental data on the mdx mouse is difficult to compare due to differences in 
methodologies and animal strains and housing. A recent review of quantitative and  
qualitative measurements of the mdx mouse including life span, body weights, force of  
contraction, biochemistry, histology and respiratory and cardiac physiology highlighted the 
need for standardised experimental protocols (Willmann et al. 2009). 
 
Studies on cardiac involvement in the mdx mouse are limited and there exists a need for 
further characterisation of the model to enable targeting and comparison of potential 
therapies. Fibrosis is a predominant feature of the dystrophic heart, however the molecular 
pathways involved in cardiac fibrosis are unclear. Temporal gene expression profiling studies 
have been reported in mdx skeletal muscles, but not cardiac muscle (Porter et al. 2004; Porter 
et al. 2003). Research is required to evaluate genes involved in cardiac fibrosis over the life 
span of the mdx mouse to assess which genes are associated with the initiation of fibrosis and 
remodelling of the ECM. 
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1.6 THERAPEUTIC STRATEGIES 
Currently there is no cure for DMD. While gene or cell therapy is promising, at present 
palliative care is aimed at ameliorating the symptoms of DMD. The only drug treatment 
proven to be able to preserve or maintain skeletal muscle function in DMD boys are steroids 
and they have been termed the “gold standard” to which other potential treatments are 
compared to. Steroids have been shown to improve muscle strength and function, prolong 
walking, improve respiratory and heart function and lower the risk of scoliosis (Bushby et al. 
2004). 
 
1.6.1 Steroids 
Two randomised double-blind control trials on DMD boys found the steroid prednisone 
improved and stabilised muscle strength for up to three years, with the main side effect being 
excessive weight gain (Fenichel et al. 1991). Steroid use has been shown to be more 
beneficial to DMD patients than not being treated, with treated boys walking longer and 
having a decreased risk of scoliosis, however there is an increased risk of vertebral 
compression fractures and long bone fractures (King et al. 2007). The benefits of prednisone 
treatment may be optimised by commencing treatment before muscle function begins to 
decline as prednisone is effective in prolonging not recovering function (Merlini et al. 2003).  
 
A comparative study of prednisone and deflazacort (an oxazolone derivative of prednisone) 
found deflazacort to be as efficient as prednisone in slowing down the decline of muscle 
strength in DMD boys (Reitter 1995). Deflazacort treatment prolongs mobility by 3-5 years, 
and both respiratory and cardiac function is improved (Biggar et al. 2006).While deflazacort 
treatment may have the advantage of resulting in less weight gain than prednisone, it leads to 
growth limitations and assymptomatic cataracts (Biggar et al. 2006).  
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Although prednisone is the most widely used drug to treat DMD, the exact mechanism by  
which it confers muscle improvement is unclear. The beneficial effects of steroids in DMD 
are thought to be associated with increased circulating insulin-like growth factor (IGF-1) 
levels (Rifai et al. 1995).  Prednisone has been shown to reduce the number of anti-
inflammatory cells in mdx suggesting an immunosuppressive role (Wehling-Henricks, Lee & 
Tidball 2004). It has also been reported that prednisone can reduce calcium influx and the 
size of calcium pools in mdx (Metzinger et al. 1995) and satelite cell myogenisis is enhanced 
by prednisone (Passaquin et al. 1993).  
 
1.6.2 Exon skipping strategies 
The concept of revertant fibres suggested that exon-skipping could be manipulated to produce  
shorter, but functional dystrophin (Wilton et al. 1999). If a deletion, duplication or point  
mutation of the dystrophin gene disrupts the reading frame resulting in DMD, the reading 
frame can potentially be restored by exon skipping with antisense oligonucleotides (AOs). If 
the region skipped is part of a non-essential region, like the rod domain, the result is a shorter 
but functional dystrophin protein.  
 
Two kinds of chemically protected AOs are being used in animal and clinical trials, 2’O- 
methy-phosphorothioates (2’O-methyls) and morpholinos (www.treat-nmd.eu/soc/eng/dmd). 
Comparative studies of the two chemistries found that some exons are skipped more 
efficiently by 2’O methyls, others by morpholinos, whereas for some both chemistries 
appeared to be equally efficient (Heemskerk et al. 2009). 
 
2’O-Methyl Antisense Oligonucleotides 
Preclinical experiments in cell cultures, mice and dogs have shown successful exon-skipping  
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with 2’O methyl AOs (Gebski et al. 2003; McClorey et al. 2006). A small clinical trial of 4 
DMD boys who were already confined to wheelchairs, with deletions of the dystrophin gene 
at exons 50, 52, 48-50 and 19-50 involved injections of 2’O methyl AO against Exon 51 
(PRO051) into the tibialis anterior muscle (van Deutekom et al. 2007). After four weeks of 
treatment dystrophin expression was observed at the sarcolemma at 17-35% that of normal 
expression in 64-97% of muscle fibres (van Deutekom et al. 2007). While the study proved 
the principle of exon skipping in DMD boys, the expression of dystrophin was low and it 
highlighted the need to commence treatment while the muscles are still intact. 
 
Morpholino Antisense Oligonucleotides 
Preclinical experiments conducted on eight different morpholino AOs and tested in cell  
cultures of normal and dystrophic human muscle and non-dystrophic mice containing the 
human DMD gene found the morpholino AO H51A to be the most successful in exon  
skipping in mdx mice (Arechavala-Gomeza et al. 2007). One limitation of morpholinos is 
their inability to enter the heart. This has been addressed by a peptide-conjugated morpholino 
AO with systemic injections of this AO into mdx mice resulting in dystrophin expression in 
skeletal and cardiac muscle (Yin et al. 2008). 
 
Another type of AOs, peptide nucleic acids (PNAs) are showing promising results at  
improving cell delivery. They have a peptide backbone, are water soluble and intramuscular 
injections into the tibialis anterior of 8 week old mdx mice restored dystrophin expression 
(Ivanova et al. 2008). 
 
Another approach combines exon skipping with gene therapy, thus genetically instructing 
muscles to produce the AOs themselves (Goyenvalle et al. 2004). This technique would 
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negate the need for repeated injections. Modified U7-snRNAs (small nuclear RNA), 
containing the information for the construction of AOs, were placed into the DNA of type-2 
adeno-associated viruses (AAV) and injected locally and systemically into mdx mice which 
resulted in a shorter, but functional dystrophin in 80% of fibres which persisted for more than 
one year (Goyenvalle et al. 2004).  
 
Following on from that study, a “universal” U7snRNA vector has been developed that brings 
about exon skipping by universal proteins, heterogeneous nuclear ribonucleoproteins A1/A2 
(hnRNP) (Goyenvalle et al. 2009). Advantages of this approach include shorter approval time 
compared to the many different AOs required for different exon skipping and the ability to 
perform multi-exon skipping by using two or more U7snRNAs (Goyenvalle et al. 2009).  
 
75% of DMD patients could potentially benefit from exon skipping (Aartsma-Rus et al. 
2004). It is important to recognise, however that this treatment is not a cure and results in the 
less severe BMD phenotype. Although BMD patients lead active lives into middle age and 
older, 50% of patients die due to cardiac failure (Finsterer & Stollberger 2003). Exon-
skipping treatment needs to be repeated and it cannot repair lost muscle, therefore limiting its 
benefits for older patients. Careful genotyping is required for this type of treatment to enable 
targeting of deletions, and large or multiple deletions may not be amenable to this technique.  
 
 
PTC124 
 
High-throughput screens of about 800,000 low molecular weight compounds to identify 
compounds that promoted read through of premature stop codons, but not normal stop codons 
resulted in the development of the drug PTC124 (Welch et al. 2007). PTC124 has been 
shown to promote dystrophin production in muscle cells from humans, and in mdx mice 
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which expressed dystrophin nonsense alleles (Welch et al. 2007). Phase I clinical trials of 
PTC124 on 61 healthy adults showed no serious side effects which has been followed by the 
commencement of “proof of principle” studies on the extensor digitorum brevis muscle of 38 
DMD boys (www.treat-nmd.eu/soc/eng/dmd). It is important to note that while PTC124 
offers a promising therapeutic option, it will only be for the 13-15% of DMD boys with 
nonsense mutations. 
 
1.6.3 Vectors for gene delivery 
There are three main classes of vectors used for gene therapy in DMD, adenoviruses (Ad-v),  
adeno-associated viruses (AAV), and plasmids. 
  
Adenoviruses 
Ad-v are capable of delivering the mini-dystrophin gene to mdx mice, however they  
illicit a high immune response and have a limited capacity (Chamberlain 2002). In an attempt 
to overcome the size limitation, gutted Ad-v vectors have been developed that have the 
advantage of carrying full length dystrophin (Clemens et al. 1996).  
 
Adeno-associated virus vector 
AAV vectors are capable of transporting mini- or micro-dystrophin genes into skeletal and  
cardiac muscle, resulting in the expression of a shorter, but functional dystrophin  
(Chakkalakal et al. 2005). Preclinical experiments transferring a modified dystrophin gene  
using AAV serotype 6 into mdx mice utilising a vasculature permeabilising agent  
showed wide spread muscle specific expression of a functional mini dystrophin 
(Gregorevic et al. 2004) and an amelioration of cardiomyopathy in mdx was observed with  
injection of an AAV serotype 9 (Bostick Yue Lai et al. 2008).  
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Although AAV vectors exhibit a lower immune response than Ad-v vectors, studies on dogs  
treated with AAV serotype 2 have shown an immune response against the transgene  
product resulting in a loss of the transduced myofibres (Yuasa et al. 2007). These results 
highlight the difference between the immune response of murine models and larger animals, 
with dogs being more susceptible to immunogens than mice emphasising the need to 
characterise the immune response in larger animals before using AAV vectors for human 
trials. It has been demonstrated that a brief course of immunosuppressants can overcome the 
immune response in dogs and enable long-term expression of canine micro-dystrophin in the 
skeletal muscles of the canine x-linked dystrophic dog (Wang et al. 2007). Regional vascular 
delivery has been successfully demonstrated in mdx mice and non-dystrophic macaque 
monkeys at doses suitable for clinical trials (Rodino-Klapac et al. 2007). 
 
Like AOs, AAV vector delivery of a mini-dystrophin gene will not cure DMD, rather change 
it to a milder BMD. However one advantage of AAV vector delivery over AOs is that it has 
the potential to benefit all DMD patients as it is not mutation specific.  
 
Plasmids 
Naked plasmid DNA can transfer genes to muscle cells with minimal immunogenicity and  
toxicity, however when administered by intramuscular injection they exhibit low transfection  
efficiency. Although electroporation may overcome this hurdle and has been shown to result  
in higher levels of transfection of full length dystrophin in skeletal muscles of mdx mice, it is  
also associated with muscle damage (Murakami et al. 2003). Pre-treatment of muscles with 
bovine hyaluronidase prior to electroporation further enhances transfection without 
increasing the muscle damage related to the electroporation process (McMahon et al. 2001). 
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The first clinical trial with plasmid DNA gene delivery commenced in 2005 with 9 DMD and  
BMD patients aged over 15 (Fardeau et al. 2005).  The plasmid, which contained full length 
dystrophin was injected into a single muscle. Although the level of expression of dystrophin 
was low, no local or general adverse effects were seen (Fardeau et al. 2005). While this 
technology could potentially represent a treatment for all DMD patients the transfection 
efficiency is low and retention may be limited requiring repeated administration (Fardeau et 
al. 2005). 
 
1.6.4 Myoblast transplantation 
Myoblast transplantation aims to introduce muscle precursor cells containing the full length  
dystrophin gene into dystrophic muscle. One advantage of this technique would be that the  
dystrophin would be under the control of its normal control sequences. However, a limitation 
to the technique is the low amount of normal dystrophin expressed after transplantation  
(Skuk et al. 2006). Injections of normal myogenic cells (derived from relatives) into the 
tibialis anterior of 9 DMD patients, resulted in 8 patients having full length dystrophin in only 
3.5 to 26% of muscle fibres that was restricted to the sites of injection (Skuk et al. 2006). 
Although the patients were immunosuppressed with tacrolimus, acute rejection may not have 
been efficiently controlled in all cases thus reducing the amount of new dystrophin observed 
(Skuk et al. 2006). 
 
Myoblast transplantation has the potential to be combined with other treatments. For example  
blocking myostatin with the antagonist follistatin in combination with myoblast cell transfer  
improved myoblast transfer and muscle function in mdx mice (Benabdallah et al. 2008). A 
promising source for myoblasts involves using the myogenic regulator (MyoD). MyoD has  
  
44 
 
been shown to convert fibroblasts (non-muscle cells) into muscle cells (Weintraub et al. 
1989). 
 
1.6.5 Stem cells 
Stem cells offer a possible therapy for DMD as they are a source of healthy muscle  
precursor cells that could repopulate dystrophic muscles cells, replacing defective dystrophin  
with a functional protein.  
 
Embryonic stem cells 
Embryonic stem cells have the potential of developing into muscle cells. A recent study  
found that differentiating embryonic stem cells need transcription factor Pax3 to form 
myogenic (muscle forming) cells, necessitating  the introduction of this gene into the X- 
chromosome of the stem cells (Darabi et al. 2008). Injection of these embryonic stem cells 
locally and systemically into the mdx mouse resulted in improved muscle function, however 
new dystrophin was observed in only 11% to 16% of muscle fibres (Darabi et al. 2008).  
 
Muscle stem cells 
Two types of adult stem cells have been identified, mesioangioblasts which are associated  
with the walls of large blood vessels within muscle tissue, and pericytes which are associated  
with small blood vessels. Pericytes have the advantage of being able to cross the vasculature  
and fuse and form myotubes which enables them to be injected arterially  (Dellavalle et al. 
2007). 
 
Mesioangioblasts delivered systemically to the GRMD dog restored dystrophin to the  
muscles and improved function and mobility (Sampaolesi et al. 2006). Six GRMD dogs  
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received mesioangioblasts from the skeletal muscle of healthy unrelated dogs (heterologous 
cells), while four dogs received mesioangioblasts from their own tissue (autologous cells)  
that had been transduced with a lentiviral vector expressing human dystrophin. The dogs  
receiving the heterologous treatment showed the most improvement, with expression  
of dystrophin in up to 70% of the muscle fibres. While dystrophin expression was high  
there was a lack of correlation between the amount of dystrophin detected and improvement 
in muscle function. Furthermore the study has been recently criticized for not taking into  
account the benefits that may have arisen from the immunosuppressive drug cyclosporin A  
(CSA) that was used (Grounds & Davies 2007). CSA has been shown to have both  
beneficial and detrimental effects on muscular dystrophy (De Luca et al. 2005; Stupka et al. 
2004).    
 
A double-blind phase I clinical trial on 8 DMD boys tested the safety of autologous  
transplantation of muscle derived CD133+ cells (Torrente et al. 2007). CD133 cells contain 
the marker protein CD133 in their membrane and have been shown to be able to repair 
muscle cells and form new ones in damaged muscle tissue (Torrente et al. 2004).  The trial 
found that there were no local or systemic side effects associated with the transplantation in 
all treated patients (Torrente et al. 2007). This preliminary outcome leads the way for further 
clinical trials to test the efficacy of the treatment. 
 
Exon-skipped stem cells 
Isolated CD133+ stem cells obtained from the muscles of DMD boys, have been subjected to  
exon-skipping to repair the dystrophin gene and then transferred into mdx mice with a  
lentivirus (Benchaouir et al. 2007). This resulted in muscle regeneration, with dystrophin in 
regenerating fibres and restored muscle function (Benchaouir et al. 2007). However future 
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research needs to examine the effect of integration of the lentivirus on the control of 
housekeeping genes or tumor suppressing genes. 
 
1.6.6 Alternative drug therapies for dystrophic muscle    
Utrophin upregulation 
Utrophin has been suggested as a possible pharmacological intervention for the absence of  
dystrophin. Old mdx mice have been shown to upregulate utrophin in cardiac myocytes, 
perhaps as a compensatory mechanism (Bostick et al. 2008). Although it is insufficient to 
prevent the dilated cardiomyopathy observed in old mdx mice, it may in part explain the 
milder phenotype of the mdx mouse.  
 
Using gene therapy, expression of full length utrophin in transgenic mdx mice have resulted  
in improvements in function and prevention of dystrophic manifestations (Tinsley et al. 1998) 
and likewise overexpression of  utrophin in the GRMD dog ameliorated it’s dystrophic  
pathology (Cerletti et al. 2003).  
 
While in utero overexpression of utrophin in mdx mice has been shown to prevent the 
increase of mechano-sensitive calcium channel activity, this did not prevent increased CK 
levels, centronucleation of muscle fibres and susceptibility to mechanical stress with the 
effects of utrophin being dose dependant (Squire et al. 2002). 
 
Utrophin based drug therapy has the advantage that it could be administered systemically as 
utrophin expression in tissue other than muscle does not appear to be toxic (Fisher et al. 
2001). Utrophin levels can be stimulated by treatment with heregulin (Krag et al. 2004), 
activation of calcineurin signalling and increased nitric oxide levels. However these potential 
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drug-based therapies may induce significant side-effects as highlighted in a review by Miura 
(Miura & Jasmin 2006).  
 
Inhibition of myostatin 
Myostatin is a negative regulator of skeletal muscle growth and inactivation of the myostatin 
gene results in increased musculature which may reverse muscle wasting in DMD 
(Bogdanovich et al. 2005). Myostatin inhibitors include myostatin antibodies, myostatin 
propeptide, follistatin and follistatin-related protein. A myostatin-specific inhibitor derived 
from follistatin has been developed and transgenic mice expressing this have shown increased 
skeletal muscle mass and strength (Tsuchida 2008). Mdx mice crossed with these transgenic 
mice also resulted in increased muscle mass and function (Tsuchida 2008). Follistatin 
delivered with AAV-type-1 vectors into single muscles has been tested on mdx mice at three 
weeks old and seven months old and resulted in increased muscle strength and reduced 
inflammation and fibrosis (Haidet et al. 2008). Therefore, while inhibiting myostatin does not 
address the protein deficiency in DMD, this treatment may have the potential to limit the 
symptoms. 
 
Inhibition of transforming growth factor (TGF-β)  
TGF-β is a pleiotropic cytokine which plays a role in inflammation, embryonic development,  
cell growth and wound repair. GRMD dogs and mdx mice have increased amounts of TGF-β  
(Passerini et al. 2002). Further to this TGF-β levels are high in the skeletal muscles of DMD 
boys, with expression peaking at 2-6 years of age (Bernasconi et al. 1995). 
 
The correlation between ventricular fibrosis and TGF-β is unclear as highlighted by anti-
fibrotic drug, pirfenidone reducing levels of TGF-β in old mdx hearts, but not reducing 
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fibrosis (Van Erp, Irwin & Hoey 2006). Experiments administering pirfenidone to younger 
mice during the acute inflammatory stage would be valuable to determine if early 
administration could inhibit upregulation of inflammatory or profibrotic cytokines, like TGF-
β, to prevent fibrosis forming. 
 
L-arginine and neuronal nitric oxide synthase (nNOS) 
A lack of dystrophin results in a decrease in the concentration of neuronal nitric oxide 
(nNOS) (a component of the DGC) and its mislocalisation from the sarcolemma to the 
cytosol (Crosbie 2001). As nNOS produces nitric oxide (NO) from L-arginine, lower levels 
of nNOS results in decreased levels of NO. NO plays important roles in fibrosis and can 
reduce muscle inflammation and membrane lysis (Wehling, Spencer & Tidball 2001). 
Administration of NO precursor, L-arginine showed a reduction of cardiac fibrosis and 
improved coronary blood flow and heart function (Van erp submitted for publication). 
 
Upregulation of Insulin-like growth factor -1 
Insulin-like growth factor-1 (IGF-1) is of interest as possible therapy for DMD as it has been 
shown to increase muscle mass and strength in skeletal muscles of mdx mice while limiting 
fibrosis (Barton et al. 2002). IGF-1 will be discussed further in section 1.7. 
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1.6.7 Therapies to alleviate symptoms of cardiomyopathy 
Current treatment for DMD cardiomyopathy involves angiotensin-converting enzyme (ACE) 
inhibitors and beta-blockers. ACE inhibitors and β-blockers have been shown to reverse 
symptoms of cardiomyopathy in DMD and BMD and prolong survival (Ishikawa, Bach & 
Minami 1999). A combinatorial treatment has been demonstrated to have a beneficial effect 
on long term survival and to be more effective when commenced on asymptomatic patients 
with left ventricular dysfunction as opposed to symptomatic patients (Ogata, Ishikawa & 
Minami 2009).  
 
Angiotensin II is thought to play a role in cardiac fibrosis in various cardiomyopathies by 
influencing both collagen synthesis and degradation (Gonzalez et al. 2002). ACE inhibitors 
impart an antihypertensive effect and may inhibit angiotensin II effects on fibroblast 
proliferation and their ability to synthesise collagen I and III resulting in an amelioration of 
fibrosis. Spontaneous hypertensive rats treated with ACE inhibitor quinapril displayed a 
marked reduction in left ventricular fibrosis as a result of decreased procollagen type I C-
terminal peptide (as a marker of collagen synthesis) and increased collagen type I 
pyrindinoline cross-linked C-terminal telopeptide (as a marker of collagen type I degradation) 
(Lopez et al. 2001). This reduction in ventricular fibrosis was also observed in a human trial 
of patients with hypertensive
 
heart disease who were treated with ACE inhibitor lisinopril 
which was accompanied by improved left ventricular diastolic function (Brilla, Funck & 
Rupp 2000). While angiotensin II may mediate the synthesis of collagen type I, and thus 
ACE inhibitors reduce collagen type I, another study involving hypertensive rats treated with 
ACE inhibitors found myocardial fibrosis still present suggesting other profibrotic factors 
(such as aldosterone) are involved (Querejeta et al. 2004). 
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1.6.8 Gene therapy for DMD cardiomyopathy 
While there has been extensive research into skeletal muscle gene therapy for DMD, studies 
on the heart are limited. Issues that need to be clarified include which gene to use as full-
length dystrophin exceeds the packaging of most viral vectors. AAV mediated expression of 
microdystrophin (lacking the C-terminal domain and a deletion from repeat 4 to 23 in the rod 
domain) in the heart was found to restore the DGC and protect the heart after mechanical 
challenge by β- isoproterenol (Yue et al. 2003). One limitation to the use of this microgene is 
the unknown consequence of C-terminal deletion (Duan 2006). 
 
To determine the level of transduction of dystrophin required to protect the heart one study 
challenged the hearts of heterozygous female mdx mice with β-isoproterenol (Yue et al. 
2004). As a result of random X-chromosome inactivation these mice express dystrophin in 
approximately 50% of heart cells. The study found that 50% dystrophin expression was 
sufficient to attenuate stress-induced cardiomyopathy (Yue et al. 2004). 
 
The pathogenesis of cardiomyopathy associated with DMD has not been clearly defined. It 
has been suggested that skeletal muscle pathology may play a role in cardiac pathology 
(Megeney et al. 1999). Further research needs to clarify this as treating the heart alone may 
not be sufficient to ameliorate DMD cardiomyopathy. 
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1.7 INSULIN-LIKE GROWTH FACTOR-1 
1.7.1 Introduction  
DMD muscle is characterised by chronic cycles of regeneration and degeneration associated  
with the activation of satellite cells to replace muscle cells. As the disease progresses the  
regenerative capacity of dystrophic muscle is exhausted leading to fibrosis and necrosis. 
Upregulation of IGF-1 warrants investigation as a potential treatment for DMD as it exhibits 
proliferative and differentiating effects on muscle growth, increasing muscle mass and 
strength. Studies on skeletal muscles of mdx mice have also shown that IGF-1 overexpression 
reduces fibrosis, a hallmark of dystrophic muscle (Barton et al. 2002).  
 
While gene therapy, stem cells or myoblast treatment are many years away from  
providing a cure for DMD, there is a potential for IGF-1 treatment alone or as an adjunct  
therapy to ameliorate dystrophic symptoms in the interim.  
 
Insulin-like growth factor-1   
IGF-1 is a 70 amino acid single chain polypeptide with three stabilising bridges, thus it has a 
similar shape to insulin and their genes shows a high degree of sequence homolgy. The gene 
for human IGF-1was first isolated in 1985 and mapped to q22-q24 chromosome 12 (Bell et 
al. 1985). The gene consists of 6 exons and 5 introns and spans more than 80kb of cDNA 
(Bell et al. 1985). 
 
IGF-1 is an endogenous hormone with 75% being synthesised in the liver under the control of  
circulating growth hormone (GH) (Schwander et al. 1983). The remaining 25% of IGF-1 is  
produced by a number of different cell types, including muscle and acts locally in an  
autocrine or paracrine manner.  
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1.7.2 IGF-1 Isoforms 
The IGF-1 gene encodes at least four different IGF-1 isoforms. Differential promoter use, 
alternative splicing and post translational modification of the IGF-1 gene gives rise to six  
human isoforms and four rat isoforms (Barton 2006a). The isoforms differ in structure and 
function.  
 
The rodent gene has 6 exons which give rise to classes 1 and 2, derived from Exon 1 or 2 
respectively. Transcripts which exclude Exon 5 are termed transcripts A and those which 
exclude Exon 6 are termed transcript B.  
 
The human gene also has 6 exons, and its alternative splicing is classified the same as the 
rodent gene except for an additional C transcript which is produced by an internal splice site 
within Exon 5 resulting in a frameshift and premature termination in Exon 6 (Barton 2006a). 
 
The isoforms that initiate at Exon 1 (class 1) are widespread in all tissue and act in an  
autocrine or paracrine manner (Shavlakadze et al. 2005). Enhanced autocrine/paracrine  
action of IGF-1 has been shown to mediate muscle growth (Eppler et al. 2007). 
  
Isoforms initiating at Exon 2 (class 2) are more abundant in the liver, are highly responsive to  
GH and work in an endocrine manner (Shavlakadze et al. 2005). High levels of circulating 
IGF-1 has been implicated in an increased risk for several common cancers (Pollak 2004). 
 
Alternative splicing does not affect the mature IGF-1 protein, but does produce different E  
peptide extensions and it has been suggested that the isoform from which IGF-1 is produced  
can affect its potency as a mediator of the hypertrophic response (Barton 2006a).  
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Isoforms with the E peptide extension IGF-1a and IGF-1b promote muscle hypertrophy, with  
conjecture as to the duration and efficiency of the isoforms. It has been suggested that  
rat IGF1-b (also termed mechano growth factor) is more efficient than IGF-1a at producing 
hypertrophy (Goldspink 2005). Other studies have found both isoforms to be equally efficient 
in producing hypertrophy in young mice with only IGF-1a being effective in older mice and 
rat IGF-1b potency diminishing with age (Barton 2006b). These studies implicate rat IGF-1b 
in activating proliferation and IGF-1a appears to preferentially enhance differentiation. In 
support of this, exercise induces mRNA expression of rat IGF-1b prior to IGF-1a mRNA in 
rat muscles, which is consistent with IGF-1b activating proliferation (Haddad & Adams 
2002). Another study found that rat tibialis anterior muscle post injury displayed an early 
increase in IGF-1b which activated satellite cells and this was followed by IGF-1a expression 
which sustained protein synthesis in order to finish the repair process (Hill, Wernig & 
Goldspink 2003). 
 
1.7.3 The IGF-1/GH axis 
The IGF-1/GH axis consists of:                   
 two ligands (IGF-1 and IGF-2)                    
 two cell surface receptors (IGF-1R and IGF-2R)                   
 seven binding proteins (IGF-1BP 1 to 7) and associated degrading enzymes.                                                                                                                                                                                                                       
 
IGF-1 receptor 
IGF-1 acts exclusively by binding to the tyrosine kinase IGF-1 receptor, which is a  
transmembrane protein. It consists of two extracellular alpha subunits with IGF-1 binding  
sites and two beta subunits with three tyrosine residues which undergo phosphorylation and  
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therefore activation upon binding to IGF-1 (Dupont & LeRoith 2001).  IGF-1 and its receptor 
are imperative for normal growth with knockout mice lacking IGF-1 showing severe growth 
retardation and mice lacking IGF-1 receptors dying at birth (Liu et al. 1993). 
 
Binding proteins 
IGF-1 is bound to IGF-BPs in the circulation and throughout the extracellular matrix (Sitar et 
al. 2006). The binding proteins release IGF-1 slowly from the blood to the tissues, which 
increases IGF-1 half life to approximately 20 hours and greatly prolongs the growth effects of 
GH secretion, which has a half life of less than 20 minutes. The binding proteins directly 
control the interaction between IGF-1 and its receptor, transporting IGF-1 in the plasma and 
providing tissue and cell localisation (Jones & Clemmons 1995). IGF-BP3 may play an 
important role in cardiac hypertrophy (Ito et al. 1993). 
 
1.7.4 IGF-1 signalling pathways  
IGF-1 stimulates both proliferation and differentiation of myoblasts (Coolican et al. 1997). 
Once IGF-1 is released from its binding protein it binds to the IGF-1 receptor located at the  
cell surface. This can involve activation of three pathways - the mitogen-activated protein 
kinase pathway (MAPK), the phosphatidylinositol 3-kinase pathway (PI3K) and the calcium-
calmodulin dependant protein kinase pathway as illustrated in Fig 1.6 (Mourkioti & 
Rosenthal 2005).  
 
The MAPK pathway mediates cellular proliferation (Engert, Berglund & Rosenthal 1996). It 
induces DNA synthesis and mitogenesis, activating cell cycle progression markers such as 
cyclin D, cdk4, c-fos and c-jun (Mourkioti & Rosenthal 2005). (See Figure 1.6) 
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The PI3K pathway, which is activated during differentiation, initiates protein synthesis and  
increases intracellular calcium. It prevents cell death by inhibiting pro-apoptotic proteins  
and inducing expression of anti-apoptotic proteins. Activation of the PI3K pathway also 
suppresses protein breakdown and expression of atrophy genes (Sacheck et al. 2004). (See 
Figure 1.6). 
 
IGF-1 signalling of the calcium-calmodulin dependant protein kinase pathway induces 
histone deacetylases (HDACs) and myocyte enhancer factor (MEF2) and also expression of 
GATA-binding protein 2 (GATA-2) and nuclear factor of activated T-cells c1 (NFATc1) 
implicated in the regulation of skeletal muscle hypertrophy as illustrated in Fig 1.6 (Musaro 
et al. 1999).  
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Figure 1.6 IGF-1 signaling pathways in skeletal muscle adapted from Mourkioti (Mourkioti 
& Rosenthal 2005). The binding of IGF-1 to the IGF-1 receptor located at the cell surface 
induces phosphorylation of the receptor which can activate three pathways. 
1. MAP kinase pathway – activating cell cycle progression markers. 2. PI3K pathway – 
activating expression of markers for terminal muscle differentiation, cell survival, protein 
synthesis and protein degradation. 3. Calcium-calmodulin dependant protein kinase pathway 
which is implicated in the regulation of skeletal muscle hypertrophy. 
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1.7.5 IGF-1 and skeletal muscle 
Comparison of studies on the effects of IGF-1 on skeletal muscle is complicated by the many  
different modes of delivery and the IGF-1 isoform or receptor that is used. Methods of 
delivery include transgenic overexpression, viral mediated delivery, plasmid injection, 
systemic administration and bioengineered tissue as summarised in Tables 1.1 and 1.2. 
 
 
Table  1.1  Summary of studies involving transgenic overexpression of IGF-1 gene in  
skeletal muscle of mice. 
 
Citation Comments on study 
 
Coleman et al., 1995 Avian skeletal alpha actin promoter, hIGF-1. 
Uniform hypertrophy observed. 
Criswell et al., 1998 Hypertrophy in fast and slow muscle. 
Chakravarthy et al., 2000 IGF-1 overexpression extends satellite cell 
regenerative capacity. 
Musaro et al., 2001, Musaro et al., 2004 IGF-1 overexpression mediated hypertrophy and 
increased force generation particularily in fast 
fibres. 
Barton et al., 2002 IGF-1 overexpression in mdx showed hypertrophy 
and hyperplasia and reduction of fibrosis of 
diaphragm. 
Fiorotto et al. 2003 IGF-1 overexpression induced muscle 
hypertrophy 
Shavlakadze et al. 2004 IGF-1 overexpression reduced necrosis in mdx 
mouse.  
Shavlakadze et al. 2005 IGF-1 overexpression reduced skeletal muscle 
atrophy resulting from denervation 
Song et al. 2005 IGF-1 overexpression blocks angiotensin II-
induced skeletal muscle wasting. 
Pelosi et al., 2007 IGF-1 overexpression accelerated the regenerative 
process of injured skeletal muscle, modulating the 
inflammatory response and limiting fibrosis. 
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Table 1.2   Summary of different modes of IGF-1 delivery to skeletal muscle of mice 
 
 
MODE OF DELIVERY                                                  
 
EXAMPLES OF STUDIES 
Viral mediated delivery  IGF-1 stimulated muscle cell differentiation 
and myofiber hypertrophy                 
(Coleman et al. 1995). 
 
 IGF-1 stimulated muscle regeneration via the 
activation of satellite cells, blocking the age-
related loss of skeletal muscle function 
       (Barton-Davis et al. 1998). 
 
 IGF-1 induced local skeletal muscle 
hypertrophy and attenuated age-related 
skeletal muscle atrophy, restoring and 
improving muscle mass and strength 
      (Musaro et al. 1999). 
 
 Improvement of dystrophic muscle by 
rAAV/microdystrophin vector is augmented 
by IGF-1 co-delivery (Abmayr et al. 2005). 
 
 Comparison of IGF-1A and IGF-1B found 
both equally effective in increasing muscle 
mass with IGF-IB t only effective in growing 
animals (Barton 2006b). 
 
 
Systemic administration  IGF-I treatment ameliorates muscle wasting 
and improves the functional properties of 
skeletal muscles of dystrophic mice 
      (Lynch et al. 2001). 
 
 Administration of IGF-1 improves fatigue 
resistance of skeletal muscles from dystrophic 
mdx mice (Gregorevic et al. 2004). 
 
 IGF-I enhanced oxidative status and reduced 
contraction-induced damage in skeletal 
muscles of mdx dystrophic mice 
      (Schertzer et al. 2006). 
 
Bioengineered tissue  Paracrine release of IGF-1 from a 
bioengineered tissue stimulates skeletal 
muscle growth in vitro (Shansky et al. 2006) 
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1.7.6 Transgenic overexpression of IGF-1  
 
Two main mouse strains have been developed using different transgenic constructs that 
overexpress IGF-1 specifically in skeletal muscle and they each exhibit a different phenotype 
(Shavlakadze et al. 2005). 
 
The two different promoters used in the transgenic constructs are:  
1. skeletal α-actin which is the major actin isoform in adult skeletal muscle and is only 
active in differentiated skeletal and cardiac muscle. Although there is a greater expression of  
the transgene with this promoter in skeletal muscle, it is also expressed in the heart and  
circulation (Delaughter et al., 1999, Shavlakadze et al., 2005). 
 
2. myosin light chain 1/3 which is activated by differentiated muscle cells. It has the  
advantage of not being expressed in cardiac muscle so that IGF-1 overexpression effects can  
be observed in skeletal muscle alone. 
 
It is also important to take in to consideration the isoform expressed, with most studies using  
either rat or human IGF-1Ea, as this isoform is expressed in skeletal and cardiac muscle and  
does not enter the circulation, but remains in the muscle bed (Musaro et al. 2001). 
 
1.7.7 Effects of IGF-1 on skeletal muscle 
It has been well documented that overexpression of IGF-1 in the skeletal muscles of  
transgenic mice induces hypertrophy (Barton-Davis et al. 1998; Barton-Davis, Shoturma & 
Sweeney 1999; Barton 2006b; Barton et al. 2002; Coleman et al. 1995; Criswell et al. 1998; 
Fiorotto, Schwartz & Delaughter 2003; Musaro et al. 2001; Sacheck et al. 2004; Shavlakadze 
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et al. 2004). The hypertrophy is accompanied with increased muscle strength and extended 
muscle mass and strength in aging mice (Musaro et al. 2001).  
 
IGF-1 transgenic overexpression in skeletal muscles of normal mice has been shown to 
modulate the inflammatory response and limit fibrosis after cardiotoxin induced muscle 
injury as illustrated in Fig 1.7 (Pelosi et al. 2007). IGF-1 is a powerful enhancer of the 
regeneration response inducing proliferation and differentiation of satellite cells and 
extending their replicative life span (Chakravarthy et al. 2000). IGF-1 has also been shown to 
increase recruitment and production of proliferating bone marrow cells (Musaro et al. 2004). 
 
These attributes of IGF-1 overexpression suggest it could be beneficial for dystrophic muscle. 
Treatment of skeletal muscles of mdx mice with recombinant human IGF-1 reduced fibrosis,  
necrosis and improved fatigue resistance (Gregorevic, Plant & Lynch 2004). Transgenic mice 
overexpressing IGF-1 in skeletal muscles have been crossed with mdx mice (Barton et al. 
2002). These IGF-1+/mdx mice showed an amelioration of the histopathological changes 
normally seen in the mdx mouse. In particular IGF-1+/mdx mice displayed hypertrophy 
which was accompanied with increased strength and a reduction of fibrosis and necrosis 
(Barton et al. 2002). In 21 day old IGF-1/mdx mice (the age of acute onset of necrosis) 
myofibre damage was reduced without hypertrophy, thus suggesting a protective role for 
IGF-1 (Shavlakadze et al. 2004).  Further evidence of this protective role, is the potential of 
overexpression of IGF-1 in mdx mice to reduce the susceptibility of dystrophic muscle to 
exercise induced damage (Ridgley et al. 2009). 
 
IGF-1 may reduce muscle damage by attenuating excitation-contraction coupling (E-C) 
coupling failure. Dystrophic skeletal muscles display abnormal E-C (De Luca et al. 2001) and 
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overexpression of IGF-1 in the dystrophic EDL muscle attenuates this failure (Schertzer et al. 
2008).       
                    
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Diagrammatic representation of the role of IGF-1 in the coordination between 
inflammation and regeneration in skeletal muscle. Adpated from (Mourkioti & Rosenthal 
2005). Muscle injury breaks capillaries and initiates the inflammation process. Regeneration 
of skeletal muscle activates TGF-β initiating fibrosis which replaces the space within 
myofibres with connective tissue. Fibrotic tissue initially aids muscle repair, however 
continued accumulation of fibrotic tissue fills the space new muscle cells would normally 
occupy. This results in the muscle not being able to regain normal contractile properties 
which leads to decreased strength. Effective muscle regeneration depends on an exact balance  
between pro- and anti- inflammatory factors. IGF-1 reduces the chronic inflammatory  
response and moves the balance toward muscle regeneration. 
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1.7.8 IGF-1 and the heart 
IGF-1 has been shown to promote cardiac growth, improve cardiac contractility, cardiac  
output, stroke volume and ejection fraction as reviewed by Ren et al.(1999). IGF-1 is an 
endogenous regulator of myocardial function and associated with its general anabolic effects, 
it improves cardiac function through a direct inotropic effect on normal and various disease 
models  hearts (Ren, Samson & Sowers 1999).  
 
Physiological hypertrophy as evidenced by improved cardiac function 
An increased level of IGF-1 has been shown to result in cardiac hypertrophy. Several studies 
have found this to be due to increased cardiomyocyte size (Duerr et al. 1995; Ito et al. 1993; 
Santini et al. 2007). While other studies have reported increased number of cardiomyocytes 
with IGF-1 overexpression, a different isoform of IGF-1(IGF-1B) was used (Reiss et al. 
1996; Welch et al. 2002). 
 
The cardiac hypertrophy mediated by IGF-1 appears to be a physiological adaptation as 
evidenced by an improvement in function (Cittadini et al. 1998; Duerr et al. 1995; Santini et 
al. 2007; Serose et al. 2005). One study found the cardiac hypertrophy to be initially a 
physiological adaptation which progressed to a pathological condition (Delaughter et al. 
1999). This may be due to the cDNA for the IGF-1 being driven by a skeletal α-actin 
promoter which resulted in high levels of systemic IGF-1. 
 
The inotropic effect of IGF-1 overexpression may be due to IGF-1 mediating an increase in 
the sensitivity of cardiomyocytes to calcium (Ren 2002). Rat hearts immersed in a bathing 
solution of IGF-1 resulted in cardiomyocytes being more sensitive to calcium through a 
wortmannin-sensitive pathway (Cittadini et al. 1998).  
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Evidence suggests that IGF-1 plays a protective role against myocardial injury. It has been  
shown to inhibit cardiac necrosis and apoptosis (Buerke et al. 1995; Davani et al. 2003; Li, Q. 
et al. 1997; Santini et al. 2007). Further supporting this cardioprotective role, IGF-1 has been 
shown to stimulate the gene expression of detoxifying proteins and antioxidant enzymes 
produced in pathological conditions (Santini et al. 2007). In the diabetic rat IGF-1 
overexpression protects the heart against diabetic cardiomyoapthy by reducing angiotensin 
synthesis (Kajstura et al. 2001). Further to this, angiotensin is thought to play a role in cardiac 
fibrosis (Gonzalez et al. 2002) and attenuation of the renin-angiotensin system by ACE 
inhibitors has been shown to be beneficial to the dystrophic heart (Ishikawa, Bach & Minami 
1999).  
 
IGF-1 plays an important role in the repair of injured hearts, restoring function and limiting  
fibrosis. Transgenic mice, overexpressing IGF-1 driven by the α-myosin heavy chain 
promoter were subjected to two different modes of injury, ligation of the coronary artery and 
direct cardio toxin injection. As α-myosin heavy chain is only expressed in cardiac muscle, 
the use of this promoter restricts the overexpression of IGF-1 to the heart excluding effects on 
other tissues. IGF-1 mediated a restoration of cardiac function in these transgenic mice by 
blocking scar formation and enabling myocardial reconstruction (Santini et al. 2007). In 
support of these findings, administration of IGF-1 (systemically and by direct myocardial 
injection) to the hearts of δ-sarcoglycan deficient hamsters conferred improved cardiac 
function accompanied by a reduction in interstitial fibrosis (Serose et al. 2005).  
 
IGF-1 is thought to restore stucture and function to damaged cardiac tissue by resolving  
inflammation at the site of injury, preventing scar formation and enabling tissue replacement  
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as illustrated in Figure 1.8. A study highlighting this observed anti-inflammatory cytokines 
interleukin-4 (IL-4) and interleukin-10 (IL-10) to be significantly upregulated in transgenic 
IGF-1 overexpression mouse hearts after cardio toxin injection (Santini et al. 2007). 
Furthermore, proinflammatory cytokine interleukin-6 (IL-6) was down regulated (Santini et 
al. 2007). Other pro-inflammatory cytokines (in particular TGF-β) were not affected (Santini 
et al. 2007). 
 
1.7.9 Cardiac signalling pathways initiated by IGF-1 
There is evidence for differing signalling pathways initiated by IGF-1 in skeletal and  
cardiac muscle (Rommel et al. 2001; Santini et al. 2007). In skeletal muscle IGF-1 is  
thought to mediate cellular growth by initiating the P13K phosphorylation  pathway via Akt  
and  mTOR intermediates (Rommel et al. 2001). In cardiomyocytes, PI3K signalling is  
thought to be through PDK1/SGK1signalling intermediates, independent of Akt  
(Santini et al. 2007). This pathway is illustrated in Figure 1.8. 
 
With regard to muscle hypertrophy, skeletal and cardiac muscle appear to share a similar 
signalling system which is regulated by calcineurin controlling associations between NFAT 
and GATA transcription factors (Molkentin et al. 1998; Mourkioti & Rosenthal 2005). 
Hypertrophic stimuli acting on the cell membrane leads to an elevation of intracellular Ca
2+
 
which in turn activates calcineurin. Calcineurin dephosphorylates NF-AT3, resulting in its 
translocation to the nucleus, where it interacts with GATA4 to synergistically activate 
transcription of hypertrophic genes (Molkentin et al. 1998). 
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Figure 1.8 Mechanisms of IGF-1 to induce cardiac repair. Adapted from Santini (Santini et 
al. 2007)                                                                                                                                  
A. IGF-1 overexpressed exclusively in the hearts of transgenic mice induces protein synthesis 
and cell survival pathways in the myocardium through a PDK1/SGK1 phosphorylation 
cascade.                                                                                                                                      
B. Following myocardial infarction (MI), pathways mediated by IGF-1 result in a rapid 
decrease in proinflammatory cytokine IL6 that promotes fibrosis and cardiac dysfunction, 
while activating cytokines such as IL4 and IL10 that resolve inflammation.                           
C. This compliant tissue environment is amenable to cardiac wall replacement, as 
demonstrated by increased proliferation of cells at 4 weeks post injury (Beltrami et al.2003).  
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Data regarding transgenic mice that overexpress IGF-1 exclusively in the heart enable the 
evaluation of the effects of IGF-1 on the myocardium. Researchers have used this to observe 
the effects of IGF-1 on various cardiac disease states and after cardiac injury. IGF-1 has been 
shown to have a cardioprotective effect, and to mediate repair of the injured heart restoring 
function, while limiting fibrosis by resolving inflammation (Santini et al. 2007). It is 
important to assess whether the beneficial actions of IGF-1 seen in conditions such as 
myocardial infarction could be translated to the severe dystrophic changes observed in DMD. 
Rather than an acute necrotic episode and inflammatory response of myocardial infarction, 
dystrophic muscle is characterised by relentless cycles of degeneration and fibrosis. 
Transgenic mdx mice that overexpress IGF-1 in skeletal muscle have shown that IGF-1 plays 
a protective role (Shavlakadze et al. 2004), increases muscle mass and strength with a 
reduction of fibrosis and necrosis (Barton et al. 2002). Clearly there exists a need to 
investigate the effects of IGF-1 overexpression on the dystrophic heart.  
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1.8 MYOGENIC REGULATOR MyoD 
 
1.8.1 Introduction 
 
The myogenic regulator, MyoD is vital for muscle differentiation and is expressed in skeletal  
muscle but not in the heart. It is a member of the basic helix-loop-helix family (bHLH).The  
mouse MyoD1 gene was isolated in 1991 (Zingg, Alva & Jost 1991). The MyoD gene family 
includes MyoD, Myf-5, myogenin, and MRF4 (Chen & Goldhamer 1999). 
 
1.8.2 MyoD and satellite cell function 
Satellite cells in adult skeletal muscle are situated underneath the basement membrane and 
are mitotically quiescent (Yablonka-Reuveni & Rivera 1994) and do not express any of the 
myogenic regulatory family (Cornelison & Wold 1997). Once activated, satellite cells 
isolated from skeletal muscles of mice expressed either MyoD or myf5 first among the MRFs 
which was followed by expression of proliferating cell nuclear antigen (a marker for cell 
proliferation) (Cornelison & Wold 1997). Following proliferation, myogenin and MRF-4 
expression marks the entry of myoblasts into differentiation, which is rapidly followed by 
terminal withdrawal from the cell cycle and expression of muscle specific structural proteins 
as illustrated by Fig 1.9 (Yablonka-Reuveni & Anderson 2006).  
  
In the mdx mouse, satellite cells are thought to be active, participating in the ongoing 
regeneration that is characteristic of dystrophic muscle (Anderson et al. 1998). Cell cultures 
from mdx mice showed an earlier decline in MyoD expression than controls and an earlier 
increase in myogenin expression (Yablonka-Reuveni & Anderson 2006). This suggests that 
dystrophic muscle exhibits a more rapid differentiation than normal muscle (Yablonka-
Reuveni & Anderson 2006). 
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Figure 1.9 Role for MyoD in satellite cell function adapted from Megeney and Seale 
(Megeney et al. 1996; Seale & Rudnicki 2000). 
Upregulation of MyoD appears to be required for entry into myogenic precursor cells 
proliferative phase before terminal differentiation. MyoD is upregulated with entry into cell 
cycle, Myf-5 and MRF4 are expressed intermediate, and myogenin is expressed last 
(Yablonka-Reuveni & Rivera 1994). Lack of MyoD leads to increased numbers of myogenic 
cells due to stem cell self renewal, as opposed to progression through the development 
program (Megeney et al. 1996). IGF-1 and other growth factors promote proliferation of 
myogenic precursor cells (mpcs). Following proliferation mpcs undergo terminal 
differentiation in the formation of myocytes, which requires the expression of myogenin and 
MRF4 before fusing with exisiting or new fibres. 
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1.8.3 MyoD null mice 
To elucidate the role of MyoD in myogenesis, mice with a null mutation of the MyoD gene 
were generated (Rudnicki et al. 1992).  Unexpectedly these mice were viable and fertile 
however mRNA levels of Myf-5 were increased (Rudnicki et al. 1992). Myf-5 is normally 
reduced during gestation when MyoD mRNA first appears. This suggests that Myf5 
expression can be repressed by MyoD and that Myf5 may be capable of functionally 
replacing MyoD (Rudnicki et al. 1992). However either MyoD or Myf5 is required for the 
formation of skeletal muscle with mice deficient for both MyoD and Myf5 displaying a 
complete lack of skeletal myoblasts and muscle (Rudnicki et al. 1993). 
1.8.4 MyoD and dystrophin double knockout mice 
To further examine the role of MyoD in muscle regeneration, mice lacking MyoD were then 
interbred with mdx mice which are characterised by ongoing cycles of muscle degeneration 
and regeneration (Megeney et al. 1996). The milder phenotype of the mdx mouse compared 
to DMD patients is thought to be due, in part, to increased muscle regeneration (Anderson, 
Bressler & Ovalle 1988). Transgenic null MyoD dystrophic mice displayed more severe 
dystrophic changes in skeletal muscle than mdx mice, highlighting the importance of MyoD 
in muscle regeneration as highlighted in Figure 1.10 (Megeney et al. 1996). These changes 
include curvature of the spine, an abnormal waddling gait characterised by weight bearing on 
the tarsal joints, and reduced muscle mass (Megeney et al. 1996). While DMD patients do not 
have a defiency in MyoD, the phenotype of the mdx/MyoD(-/-) model correlates to that 
observed in DMD patients.  
 
Mdx mice are characterised by skeletal muscle hypertrophy (Anderson, Ovalle & Bressler 
1987), and this was reduced or absent in mdx/MyoD(-/-) mice (Megeney et al. 1996). The 
increased skeletal myopathy suggests a dramatic decrease in their regenerative capacity, 
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however several centrally located nuclei were observed, indicating that some regenerative 
potential did still did exist in these mice (Megeney et al. 1996). This study also highlighted a 
unique role for MyoD in proliferation during regeneration, which Myf5 cannot substitute for 
as shown in figure 1.9 (Megeney et al. 1996).  
 
Apart from the diaphragm, the mdx mouse does not exhibit the muscle fibre loss and 
widespread fibrosis observed in DMD boys (Stedman et al. 1991). Further to this, unlike mdx 
skeletal muscle, DMD muscle has reduced satellite cell populations and proliferative 
potential of myogenic precursor cells (Webster & Blau 1990). Therefore the  
mdx/MyoD(-/-) mouse with its reduced proliferative potential of myogenic cell and increased 
skeletal myopathic phenotype, offers a transgenic model that more closely resembles DMD. 
 
As MyoD is not expressed in cardiac muscle, mdx/MyoD(-/-) double knockout mice also 
provide an insight into the effect of skeletal muscle damage on cardiomyopathy. It has been 
suggested that the cardiomyopathy in boys with DMD may not be wholly due to the lack of 
dystrophin in the cardiomyocytes, but may also be due to dystrophic changes in skeletal 
muscle leading to postural changes which place extra work load on the heart (Megeney et al. 
1999). In support of this, BMD patients have greater mobility and exhibit a more severe  
cardiomyopathy than DMD, suggesting that increased mobility places a heavier work  
load on the dystrophic heart resulting in a more severe cardiomyopathy (Finsterer & 
Stollberger 2003). 
 
The mdx mouse exhibits a progressive cardiomyopathy (Quinlan et al. 2004) that appears to 
be exacerbated by removal of the MyoD gene (Megeney et al. 1999). At 5 months of age the 
Mdx/MyoD(-/-) double knockout mice demonstrates a more severe cardiomyopathy 
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highlighted by increased levels of fibrosis compared to mdx mouse, suggesting this model 
may represent DMD cardiomyopathy more closely than the mdx mouse (Megeney et al. 
1999).  
 
To date the only study regarding cardiac involvement in these transgenic mice, examined 
heart weight, fibrosis and activation of stress-activated protein kinases (Megeney et al. 1999).  
This transgenic model warrants further characterisation to validate its use as a model for 
dystrophin deficient cardiomyopathy which may resemble DMD more closely than the mdx 
mouse.  
 
 
 
 
Figure 1.10 Photos of mdx:MyoD(-/-) (left) and mdx mice (right) at 5 months of age. 
Adapted from Duan (Duan 2006). 
The increased skeletal muscle pathology of the mdx:MyoD(-/-) mouse is characterised by a 
decreased muscle mass and increased kyphosis as indicated by the arrow. 
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1.9 AIMS AND SCOPE OF STUDY 
1.9.1 Age study 
The aim of the initial study in this research project was to further characterise the mdx mouse 
as a model of cardiomyopathy associated with DMD. Functional studies on the mdx heart are 
few and this study aimed to provide baseline measurements of cardiac function. Mdx mice 
appear to display a progressive cardiomyopathy, so it is imperative to examine changes in 
cardiac function of the animal with age. This study used three age groups, 3, 6, 12 months in 
an attempt to observe early changes in cardiac function.  
 
Cardiac fibrosis is a predominant feature of cardiac muscle in DMD and mdx mice. Despite 
this it has been poorly reported and the complex molecular pathways involved have not been 
fully elucidated. Any future therapies aimed at alleviating fibrosis would need clarification of 
the mechanisms involved. To this end, the study examined the degree of cardiac fibrosis at 
different age groups and  mRNA levels of  genes involved in the inflammatory process (TGF-
β) and genes involved in the remodelling of the ECM (procollagen and fibronectin). Using 
three age groups enabled aspects of the molecular pathway involved in the early stages of 
fibrosis to be compared to those later in the life of the animal. Therefore this study aimed to 
test the hypothesis that the mdx mouse is a valid model of dystrophin deficient 
cardiomyopathy, and Figure 1.11 provides an overview of this. 
 
1.9.2 IGF-1 study 
The second study addressed the effects of overexpression of IGF-1 on the dystrophic heart. 
The growth enhancing effects of IGF-1 have been well documented, and it has been reported 
to reduce fibrosis in dystrophic skeletal muscle and improve cardiac function in other animal 
models of cardiac dysfunction. This study aimed to assess the effect of IGF-1 on the 
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dystrophic heart by generating a novel mouse model that overexpressed IGF-1 exclusively in 
the mdx mouse heart. Morphological and in vivo cardiac functional analyses were performed 
at two ages, 6 and 12 months, to enable a comparison of the effects of IGF-1 on a younger 
and older animal.  
 
This study also aimed to examine cardiac fibrosis and the pathways involved. In particular 
the gene expression levels of TGF-β, procollagen and fibronectin were evaluated. Once again 
the two age groups provided an opportunity to determine any differences in the fibrotic 
pathways of the younger animal compared to the older one.  
 
This study tested the hypothesis that overexpression of IGF-1 exclusively in the dystrophic 
heart, has the ability to ameliorate the symptoms of ventricular fibrosis and improve cardiac 
function. Figure 1.11 provides an overview of this IGF-1 study. 
 
1.9.3 MyoD study 
The main aim of the third study was to further characterise the mdx:MyoD(-/-) mouse as a 
model that may resemble the cardiomyopathy associated with DMD more closely than  the 
mdx mouse. Further to this, as the MyoD gene is only present in skeletal muscle, its removal 
provides a model that enables assessment of the impact of exacerbated skeletal muscle 
pathology on the myocardium.  
 
The study involved histological analysis to determine the level of cardiac fibrosis and in vivo 
functional experiments were performed on this mouse model for the first time. Young, 3 
month old mice were used in an attempt to assess early cardiac changes. Cardiac gene 
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expression of TGF-β, procollagen and fibronectin provided further valuable data on the 
molecular events involved in fibrosis.  
 
This final study tested the hypothesis that the mdx:MyoD mouse is a better model for the 
cardiomyopathy associated with DMD than the mdx mouse. Figure 1.11 provides an 
overview of the MyoD study. 
 
The experimental design for all three studies aimed to examine cardiac involvement at  
 the organ level with the Langendorff technique utilising the ex vivo isolated heart,  
 the tissue level with histological analysis of ventricular fibrosis and 
 the molecular level by qRT-PCR analysis of cardiac genes involved in fibrosis. 
 
 
 
 
 
 
 
 
  
75 
 
 
 
 
Figure 1.11 Overview of research project. Three studies involved are 1. Age study,  2. IGF-1 
study and  3. MyoD study. 
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1 ANIMALS 
Mdx mice (C57BL/10scsn mdx) and C57 (C57BL/10ScSn) control mice were bred and  
housed at the University of Southern Queensland animal house in accordance with the  
National Health and Medical Research council code of practice. Mice were subjected to a 12  
hour light/dark cycle at 20-25
0
C with free access to food and water. All experiments were 
approved by the University of Southern Queensland animal ethics committee. 
 
2.1.1  mdx and C57 mice 
 Mdx and C57 mice used in the age study were sourced from and bred at the University of  
Southern Queensland animal house. Experimental mice were genotyped and used at 3, 6 and  
12 months of age. Only males were used in experiments to reduce variability due to sex. 
 
2.1.2  IGF-1 mice 
This project utilised foundation mice that overexpressed muscle specific IGF-1 (mIGF-1) 
under a myosin heavy chain (MHC) promoter which restricted overexpression to the heart. 
These mice were provided generously by Professor Miranda Grounds from the University of 
Western Australia. 
 
The experimental mice were generated by crossing the MHC/mIGF-1 mice, which were on 
an FVB background, with mdx females. The resultant F1 generation were genotyped using a 
PCR (described in 2.2.3) for IGF-1 using interleukin used as a control gene. Male mice that 
were positive for the IGF-1 transgene were backcrossed with mdx females. The resultant F2 
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generation were genotyped and consisted of mdx positive for the mIGF-1 transgene (IGF-
1+/mdx) and mdx negative for the IGF-1 transgene (IGF-1-/mdx).  
 
Likewise the control strain, C57 were generated in the same way and the F2 generation 
resulted in C57 positive for mIGF-1 (IGF-1+/C57) and C57 negative for the mIGF-1 (IGF-1-
/C57).  
 
These F2 generation mice were allowed to grow out to either 6 months or 12 months of age. 
Only males were used for experiments to reduce variability due to sex. 
 
2.1.3 MyoD mice 
This project utilised transgenic MyoD mice that had a disruption of the MyoD gene, caused  
by insertion of a vector which resulted in MyoD not being expressed in skeletal muscles.  
These transgenic mice were provided generously by Professor Miranda Grounds from the 
University of Western Australia. 
 
The experimental mice were generated by crossing MyoD deficient mice with mdx females. 
The resultant F1 generation were genotyped for absence of the MyoD gene using PCR 
(described in 2.2.4). The male mice lacking MyoD were backcrossed with mdx females. The 
resultant F2 generation were genotyped and consisted of mdx positive for MyoD and mdx 
negative for the MyoD gene.  
 
Likewise, C57 mice were crossed with MyoD deficient mice which resulted in C57 positive 
for MyoD and C57 negative for the MyoD. Male mice without the MyoD gene were 
backcrossed with C57 females. The resultant F2 generation provided C57 mice lacking the 
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MyoD gene and they were allowed to grow out to 3 months. Only males were used for 
experiments to reduce variability due to sex. 
 
2.2 GENOTYPING 
2.2.1 DNA extraction 
DNA for genotyping was obtained by removing approximately 2mm of the tip of the mouse 
tail which was digested in 50mM of Tris-Cl (pH 8), 20mM of EDTA (pH 8), 2% SDS and 
10mg/ml of Proteinase K (Merck) and incubated at 55
°
C for at least 6 hours. The digest was 
then chilled on ice for 10 minutes and 250µL of a saturated salt solution added. After 5 
minutes centrifugation at 13,000rpm, isopropanol was then added to the supernatant to 
precipitate the DNA. The DNA pellet was washed with 70% ethanol and resuspended in 
50µL of 10mM Tris-Cl 1mM EDTA. 
 
2.2.2 mdx PCR 
All mdx and C57 mice were genotyped using a high resolution melt assay to ensure integrity 
of the strains (Trebbin & Hoey 2009). 
 
2.2.3 IGF-1 PCR  
In order to test for the presence of the IGF-1 transgene the following PCR reaction was  
performed. IGF-1 primers (Invitrogen) at a concentration of 10 μL were used in the reaction 
with the following oligo sequences (5’ to 3’):  
IGF-1 upstream TTC CTG ACA GTG TCT GTG 
IGF-1 downstream GAG CTG ACT TTG TAG GCT TCA  
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Interleukin primers (Invitrogen) at a concentration of 10µM were used as a control gene to 
ensure that a false negative result did not occur. The oligo sequences for these primers were 
as follows: 
IL-2A CTA GGC CAC AGA ATT GAA AGA TCT 
IL-2B GTA GCT GGA AAT TCT AGC ATC C 
 
The reagents used in the reaction were 10xThermopol buffer (NEB), 10mM dNTP, 25mM 
MgCl2, and Taq polymerase (NEB). The cycling conditions were 94
°
C for 2 minutes, 94
°
C 
for 1 minute, 55
° 
C for 2 minutes, 72
°
C for 3 minutes, then going back to the second step and 
repeating 31 times. The final step being 72
°
C for 10 minutes. 
 
2.2.4 MyoD PCR  
To detect the absence of the MyoD gene a PCR reaction was performed using 20µg/mL stock 
MyoD primers (Invitrogen) with the following oligo sequences (5’ to 3’): 
MyoDF1: 5’- CTT CTA TGA TGA TCC GTG TTT CGA C-3’ 
MyoDR1: 5’- CTG CAG ACC TTC GAT GTA GCG-3’ 
 
Neo and SJT primers (Invitrogen), with a stock concentration of 20μg/mL were used as a 
control gene to ensure that a false negative mouse did not occur. The oligo sequences for 
these primers were as follows: 
Neo 1F 5’- TCG TGC TTT ACG GTA TCG CCG CTC CCG ATT -3’ 
SJT 61 5’- CCC AAG CTC CGC CCT ACT ACA CTC CTA TTG GCT TGA GGC G-3’ 
 
The reagents used in the reaction were; 10x magic buffer (1x consisting of 16.6mM  
ammonium sulphate, 67 mM TRIS pH8.8, 6.7mM MgCl2 ,5mM beta-mercaptoethanol,  
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6.7μM EDTA), 10mM dNTP, 10mg/ml bovine serum albumin (BSA), dimethyl sulphoxide 
(DMSO) and Taq polymerase (NEB).  
 
The cycling conditions were 93
° 
C for 2 minutes, and then 30 times 93
°
C for 30 seconds, 57
°
C 
for 30 seconds, 65
° 
C for 2 minutes. The final step consisted of 65
°
C for 10 minutes.  
 
2.3 FUNCTIONAL EXPERIMENTS 
Functional experiments performed in all studies involved the Langendorff perfused  
heart system as described below. 
 
2.3.1 Mouse numbers for functional experiments age study 
Functional experiments were conducted on mdx and C57 mice at 3, 6 and 12 months of age 
and the numbers are shown in Table 2.1. 
 
 
Table 2.1 Mouse numbers for functional experiments age study 
 3 months of age 6 months of age 12 months of age 
mdx n=5 n=7 n=5 
C57 n=5 n=8 n=11 
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2.3.2 Mouse numbers and groups for functional experiments IGF-1 study 
Functional experiments were conducted 6 and 12 month old mice. The resultant groups and  
mouse numbers are shown in Table 2.2. 
 
Table 2.2 Mouse numbers and groups for functional experiments IGF-1 study 
 6 months of age 12 months of age 
IGF-1-/mdx n=7 n=5 
IGF-1+/mdx n=7 n=12 
IGF-1-/C57 n=8 n=11 
IGF-1+/C57 n=5 n=5 
 
 
2.3.3 Mouse numbers and groups for functional experiments MyoD study 
All experiments were conducted on 3 month old mice. The resultant groups and mouse  
numbers used for functional experiments are shown in table 2.3. 
 
 
Table 2.3 Mouse numbers and groups for Langendoff experiments MyoD 
mdx mdx:MyoD(-/-) C57:MyoD(-/-) 
n=5 n=5 n=6 
 
 
2.3.4  Langendorff Experiment 
Mice were weighed and then anaethetised by intraperitoneal injection of sodium 
pentobarbitone solution (Boehringer Ingelheim) at a concentration of 100mg/kg. A 
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thoracotomy was performed and the excised heart was rinsed in Krebs physiological solution 
containing (mM): NaCl, 119; NaHCO3, 22; KCl, 4.7; KH2PO4, 1.2; CaCl2.2H20, 2.5; 
MgCl2,1.2; glucose, 11; sodium pyruvate, 10; EDTA, 0.5 with 10mM of 2,3-butanedione 
monoxime (BDM). 
 
The aorta was isolated and immediately cannulated using dysilk veterinary suture on  
a 23 gauge needle attached to Langendorff apparatus. Lungs and the left atria were removed. 
An apical drain (made from polyethlylene tubing) was inserted into the left ventricle to 
prevent accumulation of fluid in the heart by thesbian veins. The heart was perfused 
retrogradely at a pressure of 80mmHg with Krebs at 37
o
C and bubbled with carbogen 
(95%O2, 5%CO2) to oxygenate and maintain a pH of 7.4. Data from hearts with a coronary 
flow greater than 5 mL/min were excluded from experimental analysis. 
 
A polyvinyl chloride balloon attached to a physiological pressure transducer (MLT844 AD 
instruments, Castle Hill NSW, Australia) was inserted into the left ventricle. The balloon was 
connected to a water filled microsyringe and the volume of water was adjusted to achieve an 
end diastolic pressure of 10mmHg.  
 
The heart was stimulated via a Grass SD9 stimulator set at 7Hz, 5ms pulse width, to achieve 
a heart paced at 424bpm.The heart was equilibrated at this pressure for 10 minutes and then 
function was recorded as mmHg, ensuring an end diastolic pressure of 10mmHg. 
 
At completion of the experiment the heart was removed and weighed and tibial length was 
measured. The superior section of the ventricles were snap frozen in liquid nitrogen cooled 
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isopentane and stored at -80
o
C until required for qRT-PCR experiments. The inferior sections 
of the ventricles were placed in Telly/Bouins for histological analysis. 
 
2.4 HISTOLOGY 
Histological analysis in all studies involved picrosirius red staining of ventricular sections of 
the heart. 
 
2.4.1 Mouse numbers for histology 
Histological analysis was performed on tissue from 5 mice per group for all studies. 
 
2.4.2 Histological analysis 
The inferior sections of Langendorff perfused hearts were placed in Tellys fixative (100mL 
5% ethanol, 5mL glacial acetic acid and 10mL of 37% formaldehyde) for three days and in a 
modified Bouins solution ( 85mL saturated picric acid, 5mL glacial acetic acid and 10mL 
37% formaldehyde) for one day. The heart sections were washed once a day in 70% ethanol 
for three days, and then stored in 70% ethanol.  
 
The heart sections were then embedded in paraffin wax and 7µm sections cut on a Reichert-
Jung Biocut 2035 microtome and floated onto microscope slides (Menzel-Glaser polysine 
coated slides). The slides were stained with the collagen selective stain, 0.1% w/v picrosirius 
red (Sirius red F3B, Chroma dyes, in saturated picric acid) and visualised with a Nikon 
eclipse E600 microscope. The images were captured with a cooled CCD digital camera 
(micropublisher 5.0, OImaging, Canada), with a magnification of x40.  
 
Percentage collagen was quantified using analySIS software (Soft imaging system,  
  
84 
 
GmbH Munster, Germany). Five regions of the section, involving left and right ventricles, 
were viewed and the average percentage collagen determined by colour separation density 
analysis. 
 
2.5 RNA ANALYSIS 
RNA analysis of TGF-β, procollagen and fibronectin gene expression were performed in  
each study.  
 
2.5.1 Mouse numbers and groups for RNA analysis  
RNA analyses were performed on tissue from 5 mice per group for all studies. 
 
2.5.2 RNA Extractions 
The superior ventricular sections, stored at -80 
o 
C after Langendorff experiments, were 
sectioned with a cryostat at 6µm thickness. The cryostat-sectioned tissue samples were lysed 
in 150μL of TRIzol reagent, homogenised and volume made up to 800μL with TRIzol. After 
passing the sample through a 26 gauge needle, 160μL of chloroform was added and the 
samples centrifuged at 12,000g for 10 minutes at 4°C. The aqueous layer containing the RNA 
was decanted and RNA was precipitated by adding 400 μL of isopropyl alcohol.  The RNA 
pellet was washed with RNase free ethanol, dried and then resuspended and treated with 
RNA aqueous kit (Ambion, Austin, Texas).  
 
The RNA was quantified using Pharmacia Biotech Gene Quant II and a 50ng/μL stock 
prepared. To ensure that the RNA was not contaminated with DNA, a genomic PCR was run. 
β-actin F561 and β-actin R688 primers (Invitrogen) were used at a concentration of 10μm 
each, 10x NEB buffer, 10mM dNTP, 25mM MgCl2, and Taq polymerase (NEB). The 
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following cycling conditions were used: 94
°
C for 2 mins x1; 94
°
C for 30 secs, 56
°
C for 1min 
and 72
°
C for 2 mins x 30; and finally held at 11
°
C. 
 
2.5.3 Preparation of cDNA 
cDNA was prepared from the extracted RNA using Super Script III First Strand Synthesis 
SuperMix and incubated at 25
°
C for 10 mins, 50
°
C for 30 mins and 85
°
C for 5 mins. 
 
2.5.4 mRNA RT-PCR Reaction 
The primers (Genebank) shown in Table 2.4 were used at a concentration of 200nM with β-
actin serving as a housekeeping gene. 
 
Table 2.4 Primers used in qRT-PCR  
Gene Forward Primer Reverse Primer 
TGF-β CCG CAA CAA CGC 
CAT CTA TG 
CTC GCA GGG ACA 
GCA AT 
TNF-α CCC TCA CAC TCA 
GAT CAT CTT CT 
GCT ACG ACG TGG 
GCT ACA G 
β-actin CCC AGA TCA TGT 
TTG AGA CCT 
CCA TCA CAA TGC 
CTG TGG TA 
Fn1 TGT GAC AAC TGC 
CGT AGA CC 
GAC CAA CTG TCA 
CCA TTG AGG 
Col α1 GCA AAG AGT CTA 
CAT GTC TAG 
CCT ACA TCT TCT 
GAG TTT GG 
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The reaction included SYBER GreenER
TM
qPCR SuperMix Universal mix, and a 1 in 5  
dilution of cDNA. The Rotor-Gene real time PCR thermocycler was used with the following  
cycling conditions: 50
°
C for 2 mins, 95
°
C for 10 mins, and 40 cycles of 95
°
C for 15 secs and  
60
°
C. Rotor-Gene software analysed results using the following formula: Pfaffl formula R=E  
target
 ∆CP target
/E reference
∆CP reference 
 
 
2.6 Statistical analysis 
All data is presented as mean ± SEM, comparisons made using the unpaired students t-test  
and ANOVA. P<0.05 was considered statistically significant. 
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CHAPTER 3:  EFFECT OF AGE ON CARDIAC FUNCTION IN mdx MICE 
 
 
3.1 INTRODUCTION 
 
DMD boys usually die before their third decade of life due to respiratory or cardiac  
complications (Eagle et al. 2002). Although improved respiratory care has increased the life 
expectancy of DMD patients, cardiomyopathy still results with 20% of DMD and 50% of 
BMD patients dying from cardiac complications (Finsterer & Stollberger 2003). DMD 
associated cardiomyopathy is progressive with clinical symptoms first evident in patients at 
10 years of age, and present in all patients over 18 years (Nigro et al. 1990). 
 
The mdx mouse is the best characterised mouse model for DMD. The effects of dystrophin 
deficiency on the skeletal muscles of the mdx mouse have been well characterised, however 
there are fewer studies documenting cardiac involvement.  
 
The mdx mouse has been shown to exhibit abnormal adrenoreceptor responses (Lu & Hoey 
2000b), calcium channel dysfunction (Williams & Allen 2007) and increased fibrosis (Cohn 
et al. 2007; Quinlan et al. 2004; Van Erp, Irwin & Hoey 2006). Electrocardiographic 
differences observed in the mdx mouse include tachycardia, decreased heart rate variability 
and increased heart rate at 10 -12 weeks of age (Chu et al. 2002), and older mdx mice (42 
weeks) exhibit dilated cardiomyopathy (Quinlan et al. 2004).  
 
Due to the prominent role cardiomyopathy plays in the morbidity and mortality of DMD 
patients, cardiac involvement in the mdx mouse needs to be further characterised. As 
cardiomyopathy in DMD patients is progressive, a temporal study on cardiac involvement in 
the mdx mouse is required to serve as a preliminary study for establishing a baseline for 
future studies utilising transgenic models. 
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In order to evaluate the progression of cardiac involvement in the mdx mouse and to optimise 
the targeting of potential DMD therapies, this initial study concentrated on the time frame of 
pathology. The study aimed to evaluate age related changes in cardiac morphology, function, 
fibrosis, and gene expression of TGF-β, procollagen and fibronectin in mdx compared to C57 
control mice. Age groups of 3, 6 and 12 months were chosen to enable observation of cardiac 
involvement and progression with age. These studies also provided quantitative data 
regarding mdx and C57 mice for later comparisons with novel transgenic strains such as  
IGF-1 cardiac overexpression dystrophic mice and MyoD deficient mdx mice  
(mdx:MyoD(-/-)). Quantitative data was established for the first time for mRNA levels of 
TGF-β, procollagen, fibronectin in the mdx heart. In addition these preliminary studies 
enabled expertise to be gained in ex vivo experiments measuring cardiac function, molecular 
techniques and histological assessment of fibrosis. 
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3.2 RESULTS 
3.2.1 Morphology 
At 3 and 12 months of age mdx mice exhibited a higher heart weight normalised to tibial 
length (mg/mm) than age matched C57 mice (P< 0.05). Normalised heart weight was highest 
at 3 months for mdx mice, compared to 6 and 12 months of age (P<0.05) (see Table 3.1 and 
Figure 3.1) Tibial length was not significantly different between mdx and C57 mice at 3 
months of age, however heart weights were significantly higher (Table 3.1) resulting in a 
higher heart weight/tibial length ratio in mdx mice. 
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Figure 3.1 Morphometry data from mdx and C57 mice at 3, 6 and 12 months of age. Heart 
weight (gm) normalized to tibial length (mm). Heart weight normalised to tibial length was 
significantly greater for mdx mice at 3 months compared to 6 and 12 month old mdx mice, 
and compared to age matched controls. In addition, normalised heart weight of mdx mice at 
12 months of age was significantly greater than age matched controls. (* P<0.05, **P<0.01, 
***P<0.001) 
 
 
 
 
  
91 
 
3.2.2 Cardiac function 
Ex vivo cardiac function, measured via Langendorff mounted hearts as left ventricular 
developed pressure in mmHg, was not significantly different between mdx mice hearts and 
C57 mice at 3, 6 and 12 months of age (see fig 3.2).  
 
Rate of contraction, measured as a positive change in pressure (+dp/dt in mmHg/second) 
decreased in mdx mice by 36% at 6 months of age compared to 3 month old mdx mice 
(P<0.001) (see fig 3.3A).  
 
Rate of relaxation, measured as a negative change in pressure (–dp/dt in mmHg/second) 
decreased in 6 month old mdx mice compared to 3 month old mdx mice (P<0.001). It also 
decreased in 12 month old mdx mice compared to 3 month old mdx mice (P<0.05). 
C57 mice also showed a decrease in rate of relaxation at 6 and 12 months of age compared to 
3 months (P<0.01). These results are shown in Figure 3.3B. 
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Figure 3.2 Cardiac function of mdx and C57 mice at 3, 6 and 12 months of age 
Left ventricular developed pressure is not significantly different between mdx and C57 mice 
at 3, 6 and 12 months of age.  
 
 
 
 
 
 
  
93 
 
 
Rate of pressure development
Mouse age (months)
+d
P
/d
t (
m
m
H
g/
se
c)
0
2000
4000
6000
8000
10000
12000
3 6 12
mdx
C57***
 
 
 
       
Rate of relaxation
-d
P
/d
t 
(m
m
H
g
)
-7000
-6000
-5000
-4000
-3000
-2000
-1000
0
3 6 12
Mouse age (months)
**
**
***
*  
 
 Figure 3.3 Rate of pressure development and rate of relaxation in mdx and C57 hearts at 3, 6 
and 12 months of age. Contraction measured as rate of pressure development (+dP/dt) 
mmHg/sec (A), and rate of relaxation (-dP/dt) mmHg/sec (B). The rate of contraction was 
significantly greater at 3 months of age for mdx mice than at 6 months. Rates of relaxation 
were also greater for 3 month old mdx and C57 mice compared to older mice. (* P<0.05, 
**P<0.01, ***P<0.001) 
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3.2.3 Ventricular fibrosis 
Mdx mouse hearts display 72-90% greater ventricular fibrosis at all ages compared to age 
matched C57 mice (P<0.01 and P<0.001 respectively) as shown by picrosirius red staining. 
There was no significant difference in the amount of cardiac fibrosis seen between mdx mice 
at 3, 6 and 12 months of age (see Figure 3.4 and representative photomicrographs Figure 3.5). 
 
 
 
 
 
Ventricular fibrosis
Mouse age (months)
%
 c
o
lla
g
e
n
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3 6 12
mdx
C57
** ** ***
 
 
Figure 3.4 Ventricular fibrosis (expressed as % collagen) of mdx and C57 mice at 3, 6 and 12 
months of age. At each of the ages, mdx mice exhibited significantly increased ventricular 
fibrosis compared to age matched controls, however mdx ventricular fibrosis did not increase 
significantly in the ages examined. (* P<0.05, **P<0.01, ***P<0.001) 
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Figure 3.5 Representative photomicrographs of ventricular sections of C57 and mdx hearts at 
3, 6 and 12 months of age (picrosirius red stained). Magnification x40. Mdx hearts exhibit 
significantly more fibrosis than C57 at all ages examined. 
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3.2.5 Gene expression of TGF-β, procollagen and fibronectin 
Cardiac gene expression of TGF-β, relative to β-actin, decreased in mdx mouse at 12 months 
of age compared to 3 months (P<0.001). TGF-β expression of mdx mouse hearts compared to 
age matched C57 mice was not significantly different at 3 and 6 months of age, but by 12 
months of age mdx mice showed less expression than 12 month old C57 mice (P<0.05) 
(Figure 3.6). 
 
Cardiac gene expression of procollagen, also relative to β-actin, significantly increased in 
mdx mouse hearts at 6 months of age compared to 3 months (P<0.001) and then decreased at 
12 months of age compared to 6 months (P<0.01). Procollagen gene expression was 
significantly increased in mdx mice at 6 months of age compared to C57 mice at that age 
(P<0.01), but at 12 months of age there was no significant difference between both strains 
(Figure 3.7A). 
 
Cardiac gene expression of fibronectin, also relative to β-actin, was greater in mdx mouse 
hearts at 6 months of age compared to mdx mice at both 3 months of age (P<0.001) and 12 
months of age (P<0.005). Mdx fibronectin mRNA at 6 months was significantly higher than 
age matched C57 mice, but at 12 months of age there was no significant difference in 
expression of fibronectin between mdx and C57 mice (Figure 3.7B). 
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Figure 3.6 Cardiac gene expression levels of TGF-β mRNA as determined by quantitative 
real time PCR relative to β-actin for mdx and C57 mice at 3, 6 and 12 months of age. mRNA 
levels of TGF-β were significantly higher for 3 month old mdx mice compared to 12 month 
old mdx mice. 12 month old mdx mice also displayed significantly less TGF-β than age 
matched control. (* P<0.05, **P<0.01, ***P<0.001) 
 
 
 
 
 
  
98 
 
 
 
Cardiac Procollagen mRNA levels
R
e
la
ti
v
e
 g
e
n
e
 e
x
p
re
s
s
io
n
0.0
0.5
1.0
1.5
2.0
2.5
3 6 12
Mouse age (months)
***
**
**
mdx
C57
 
 
 
Cardiac Fibronectin mRNA levels
R
e
la
tiv
e
 g
e
n
e
 e
xp
re
ss
io
n
0.0
0.1
0.2
0.3
0.4
3 6 12
Mouse age (months)
***
***
*
 
               
Figure 3.7 Cardiac gene expression of procollagen and fibronectin determined by 
quantitative real time PCR relative to β-actin of mdx at 3, 6 and 12 months of age and C57 at 
6 and 12 months. Data for procollagen and fibronectin was not available for control mice at 3 
months of age due to time constraints. mRNA levels of procollagen and fibronectin were 
significantly higher for 6 month old mdx hearts compared to 3 and 12 month old mdx, and age 
matched control. (* P<0.05, **P<0.01, ***P<0.001) 
 
B. 
A. 
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3.3 DISCUSSION 
Previous studies have demonstrated that the skeletal muscles of mdx mice exhibit an abrupt 
onset of necrosis at 21 days of age, peaking at 28 days (McGeachie et al. 1993). Sarcolemmal 
damage is evident at 22 days of age accompanied with high amounts of necrosis (Grounds & 
Torrisi 2004; McGeachie et al. 1993). In contrast, cardiac muscle has intact sarcolemma at 24 
and 28 day old, with data from our laboratory showing that membrane damage did not occur 
until 3 months of age (Cornford-Nairn et al 2009 submitted for publication). 
 
This early sarcolemmal damage appears to be crucial in the progression of the dystrophic 
pathology and is exacerbated by inflammatory cell and cytokine infiltration leading to 
necrosis and later fibrosis (Grounds & Torrisi 2004; Hodgetts et al. 2006). Indeed by 3 
months of age the present study found cardiac fibrosis to be significantly increased in mdx 
mice compared to controls, an effect that was maintained through all ages. The higher heart 
weight to tibial length ratio observed at 3 months of age is due to increased heart weight (see 
table 1) and may reflect a compensatory hypertrophy of the heart as the mdx mouse at this 
age has come out of a period of widespread skeletal muscle necrosis. In support of this 
study’s findings, an increase in left ventricular mass at 2 months of age in mdx mice has been 
reported by others (Quinlan et al. 2004).  
 
By 6 months of age normalised heart weights between mdx mice and age matched C57 were 
not significantly different and this has been observed by others (Danialou et al. 2001; Yue et 
al. 2004). This may reflect a stabilisation of growth after the peak phase of degeneration and 
regeneration (McGeachie et al. 1993). 
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At 12 months of age, mdx mice had a higher heart weight/tibial length ratio, due to an 
increased heart weight, compared to control mice. Indeed another study has shown an 
increased left ventricular mass of in mdx mice at 42 weeks (Quinlan et al. 2004). This cardiac 
hypertrophy does not appear to be a physiological adaptation but rather a pathological one, as 
functional data from this study showed no improvement in function or contraction, and a 
decrease in rate of relaxation. This pathological hypertrophy may possibly be either a 
compensatory mechanism due to the extra work load placed on the mdx mouse heart by the 
deterioration of skeletal muscles or due to the lack of dystrophin in the cardiomyocytes, or 
both.  
 
Cardiac function has been shown to be normal in young mdx mice, progressing to a dilated 
cardiomyopathy by 42 weeks of age, with decreases in fractional shortening and heart rate, 
increases in left ventricular end diastolic and systolic diameter and calculated left ventricular  
mass (Quinlan et al. 2004). Cardiac dysfunction is not evident in mdx mice until 15 months of 
age when left ventricular pressure was seen to decrease by 26% (Van Erp, Irwin & Hoey 
2006). The present study partly supports these findings with ex vivo measures of cardiac 
dysfunction in the mdx mouse heart not evident at the three age groups examined. At 6 month 
of age, however, mdx hearts displayed a decreased rate of relaxation and contractility, and at 
12 months of age a decreased rate of relaxation with a trend to decreased contractility was 
also observed. These results suggest that at 3 months of age fibrosis and hypertrophy of the 
heart doesn’t impact on cardiac function, however by 6 months of age the fibrosis is 
associated with diastolic dysfunction.  
 
The compromised diastolic function is thought to be due to cardiac fibrosis which impairs the 
re-lengthening of cardiomyocytes during the diastolic phase of the cardiac cycle (Vasan & 
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Benjamin 2001; Weber et al. 1989). In addition to this, diastolic dysfunction has been 
associated with an increased activity of matrix metalloproteinases (MMP-2 and MMP-9), 
which are involved in matrix remodelling (Li et al. 2000). MMPs have been found to be 
upregulated in DMD (Pescatori et al. 2007; von Moers et al. 2005) and mdx mice (Porter et 
al. 2003).  
 
Fibrosis was increased dramatically in mdx mouse hearts by between 72-90% at each age 
group compared to control mice. This finding is consistent with previous mdx mouse studies       
(Buyse et al. 2009; Quinlan et al. 2004; Van Erp, Irwin & Hoey 2006). A progression in 
cardiac fibrosis with age was not observed in this current study, with values between the age 
groups showing no significant difference. Although a progression in fibrosis has been shown 
to occur in other studies, it occurred after 12 months of age (Cohn et al. 2007). 
 
The correlation between cardiac fibrosis and dysfunction is unclear. Cardiac expression of a 
mini dystrophin gene was capable of restoring the histology of mdx mouse hearts but not the 
cardiac function (Bostick et al. 2009). 
 
Fibrosis may affect the electrical conduction between myocytes, and some ECG 
abnormalities found in mdx mice hearts (such as altered PR and QRS intervals and R waves) 
are thought to be due to increased fibrosis (Bostick Yue Long et al. 2008). In DMD patients 
ECG abnormalities have been attributed to fibrosis of the conduction system and/or 
autonomic nervous system (Finsterer & Stollberger 2003).  
 
The mechanism leading to cardiac fibrosis is thought to be partially mediated by the                   
inflammatory cytokine TGF-β (Khan & Sheppard 2006). TGF-β is a potent stimulator of 
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collagen-producing cardiac fibroblasts, and it was expected that its levels would increase in 
mdx hearts, reflecting increased fibrosis. While it is acknowledged that gene expression does 
not necessarily reflect protein transcription and translation, the increased fibrosis displayed in 
mdx mouse hearts compared to C57 control mice at all ages, was not reflected in TGF-β 
mRNA values. There was no significant difference in levels of this cytokine between mdx 
mice compared to age matched controls except at 12 months of age where C57 TGF- β 
mRNA levels were significantly higher than mdx. This lack of correlation in ventricular 
fibrosis and TGF- β mRNA levels is supported by previous work from our laboratory in 15 
month old mdx mouse hearts showing no difference in levels of TGF-β mRNA compared to 
control mice despite increased levels of ventricular fibrosis (Van Erp, Irwin & Hoey 2006).   
 
In this current study, however mdx hearts from younger ages (3 months) exhibited higher 
levels of TGF-β mRNA than 12 months old mdx mice with these 12 month old mdx mice also 
exhibiting a decreased expression compared to age matched controls. These results suggest 
that TGF-β may be involved in the initiation of profibrotic pathways, but it does not appear to 
be the main driver in the ongoing progression of fibrosis. In support of our findings, another 
study on the mdx diaphragm found that TGF-β mRNA levels peaked at 6 weeks of age, but 
not at 9 or 12 weeks of age (Gosselin et al. 2004). This study also suggested that TGF-β may 
be involved in initiation of the fibrotic pathway. The age of the mdx mouse where TGF-β 
mRNA peaked in the diaphragm was a considerably younger age than the 3 months used in 
this study, however previous studies from our laboratory have found no significant heart 
pathology at 21, 24 or 28 days (as measured by EBD leakage, macrophage infiltration or 
immunostaining), possibly indicating minimal involvement of cytokines in the heart at those 
ages. As sarcolemmal fragility and EBD leakage is first evident at 3 months of age in the mdx 
heart, this would be followed by the inflammatory response and therefore the increased TGF-
  
103 
 
β mRNA levels seen in this study at 3 months of age may reflect the early involvement of 
TGF-β in initiating cardiac profibrotic pathways. It appears from this current cardiac study 
and previous skeletal muscle studies that there is a temporal difference between skeletal and 
cardiac TGF-β mediated pathways. 
 
 TGF-β levels in DMD boys shows an early increase up to 6 years of age, then declining to 
very low levels despite fibrosis continuing to increase (Bernasconi et al. 1995). The link 
between TGF-β mRNA levels and increased fibrosis is contentious. Another study, involving 
the anti-fibrotic drug pirfenidone, found that although it reduced TGF-β levels in the mdx 
mouse heart, improving cardiac function, it did not reduce fibrosis (Van Erp, Irwin & Hoey 
2006). The mRNA expression of TGF-β also did not correlate with muscle fibrosis in mdx 
quadriceps and diaphragm (Zhou et al. 2006). Contradictory to these studies, TGF-β protein 
content has been shown to correlate with collagen deposition in the human myocardium (Li, 
McTiernan & Feldman 2000). This current study found that although fibrosis continued at 12 
months of age in mdx mouse hearts, TGF-β levels decreased (compared to age matched 
controls and 3 month old mdx mice). 
 
There are several possible explanations to account for the lack of correlation between TGF-β 
mRNA levels and fibrosis observed in this and other studies. It has been suggested that once 
profibrotic pathways have been established other mediators or autocrine processes take over 
(Bernasconi et al. 1995). As the sum balance of collagen deposition is a function of both 
synthesis and degradation, increased fibrosis observed in older mdx mice and DMD patients 
may not be due solely to TGF-β involvement in the synthesis of collagen, but rather a 
decreased rate of its degradation. TGF-β has been shown to inhibit matrix degrading 
proteases such as matrix metalloproteinases (MMPs) that are involved in the breakdown of 
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the ECM (von Moers et al. 2005). In particular MMP1 is involved in the breakdown of 
fibrillar proteins and MMP2 degrades type IV collagens. Increased levels of MMP2 and 
tissue inhibitors of matrix metalloproteinase 2 (TIMP2) leads to the formation of the large 
inhibitor of matrix metalloproteinases (LIMP) which in turn inhibits MMP1 (Kolkenbrock et 
al. 1991).  
 
Gene expression profiling in the early stages of DMD show an increase in MMP2, TIMP1 
and TIMP2 levels in DMD (Pescatori et al. 2007). DMD patients from 2 to 13 years of age 
also showed increased mRNA levels of MMP-2, TIMP-1 and TIMP-2 (von Moers et al. 
2005). In the skeletal muscles of mdx mice several MMPs, and TIMP 1 and 3 show increased 
gene expression (observed at a later stage from 23 – 112 days of age) (Porter et al. 2003).  
 
Two consequences of these increases are: (i). the metabolic effects of increased MMP-2 on 
collagen breakdown would be negated by increased transcription of its inhibitor, TIMP-2 and 
(ii). increased MMP-2 and TIMP-2 would result in increased generation of LIMP. The 
inhibition of MMP-1 by LIMP would be compounded with increased TIMP-1, resulting in 
reduced degradation of fibrillar collagens. In addition the inhibition and complex formation 
of MMP-2 would prevent it from degrading denatured collagens (von Moers et al. 2005).  
A  disturbance in the balance between MMPs and TIMPs has been shown to contribute to 
liver fibrosis (Iredale 1997) and myocardial fibrosis (Li, McTiernan & Feldman 2000). The 
activity of MMPs has been shown to be increased, and TIMPs decreased in the failing human 
heart (Li, McTiernan & Feldman 1999; Thomas et al. 1998). Increased MMP2 and MMP9 
activity has also been shown to result in cardiac dilation and diastolic dysfunction in mice 
with cardiac restricted overexpression of TNFα (Li, et al. 2000).  
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Signalling pathways responsible for regulating MMP expression  have not been clearly 
defined, however they are regulated at pre- and post-transcriptional levels by growth factors, 
cytokines (for example TNF-α, TGF-β) and matrikines (degraded products of matrix 
proteins) (Li, McTiernan & Feldman 2000). While TGF-β suppresses proteolytic activity 
through reduced proteinase synthesis and increased TIMP expression, it also increases MMP2 
expression (Wahl et al. 1993).  
 
Temporal gene expression analysis of skeletal muscle of the mdx mouse showed that the 
timing of induction of the molecular pathology differed from DMD (Porter et al. 2004). DMD 
patients exhibit altered expression of genes involved in the inflammatory response, ECM 
remodelling, muscle regeneration and energy metabolism conserved from presymptomatic 
patients (age <6 months) to older symptomatic patients (4-5 years of age) (Chen, et al. 2000; 
Pescatori et al. 2007). Disease progression does not appear to introduce changes in muscle 
gene expression profile. Mdx mice, however were characterised by minimal transcription 
alterations in the pre-necrotic phase (Porter et al. 2004). In the skeletal muscles of mdx mice 
it is not until the post necrotic phases that parallel changes in gene expression were observed, 
with approximately 67 % of the inflammatory genes induced in the mdx mouse displaying a 
similar pattern to DMD patients (Pescatori et al. 2007). 
 
There is also a difference in transcription levels of the muscle genes that are expressed in 
different mdx skeletal muscles. For example collagen transcription is increased in the 
diaphragm at 112 days of age, whereas in the hindlimb it is decreased at that age (Porter et al. 
2004). For this reason, gene profiling of a specific mdx skeletal muscle would not necessarily 
reflect cardiac muscle changes occurring at the same point. 
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In the hindlimb and diaphragm of mdx mice, levels of transcripts for the genes involved in the 
inflammatory response and ECM remodelling do not begin to increase until 23 days of age. 
Levels peaked at 50 days of age and then decreased again (Porter et al. 2004). Although 
observed changes in skeletal muscle do not necessarily reflect changes in cardiac muscle, the 
reported increased cardiac TGF-β levels at 3 months of age is occurring 40 days after the 
peak observed  in the previous skeletal muscle study (Porter et al. 2004) thus further 
highlighting the temporal difference between skeletal and cardiac muscle in TGF-β mediated 
pathways. This skeletal muscle gene profiling study also supports the hypothesis that TGF-β 
is involved in initiating fibrotic pathways as inflammatory gene expression increased at just 
23 days of age, peaking by 50 days and then decreasing (Porter et al. 2004).  
 
Further elucidation of the complex interplay between collagen deposition and breakdown 
may be found by examining expression of other genes such as procollagen and fibronectin. 
Procollagen plays an important role in fibrosis as the precursor to collagen and fibronectin 
provides structural support for the formation of the fibrotic network. By 6 months of age mdx 
mice exhibited increased procollagen and fibronectin, compared to age matched controls and 
compared to 3 and 12 months old mdx mice. This may reflect active collagen deposition at 6 
months compared to the other ages. The decreased levels at 12 months of age in the face of 
high fibrotic levels may reflect a shift in emphasis from active collagen synthesis to reduced 
collagen deposition to maintain the fibrosis. 
  
Gene expression of procollagen and fibronectin has been shown to be upregulated in 
presymptomatic and symptomatic DMD patients (Chen et al. 2000; Pescatori et al. 2007). In 
skeletal muscles of mdx mice procollagen and fibronectin begin to increase at 23 days, 
peaking at 50 days, and then declining (Porter et al. 2003). The results of this study showed a 
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peak much later in life, reflecting again the temporal difference in levels of gene expression 
of fibronectin and procollagen between cardiac and skeletal muscle in the mdx mouse and the 
lack of correlation in the expression of these genes and the level of fibrosis. 
 
Figure 3.8 summarises changes in skeletal and cardiac muscle of mdx mice across their 
lifespan, with particular emphasis on fibrosis, function and inflammatory gene response. 
 
3.4 SHORTCOMINGS OF THE STUDY 
One shortcoming of this study was the lack of procollagen and fibronectin data for C57 mice 
at 3 months of age. This deficit was due to time constraints placed on this research project 
and lack of available mice at that age.  
 
Future research into the dystrophic changes in cardiac muscle in the mdx mouse would 
benefit from utilising younger age groups than used in this study and further in vivo 
experiments such as echocardiography and millar catheter. Ages under 3 months would 
enable the evaluation of early changes in cardiomyocytes and initiation of fibrotic pathways.  
 
Due to the relentless nature of cardiac fibrosis associated with DMD it is imperative to 
further clarify the molecular pathways involved. In particular future research needs to address 
cardiac expression levels of MMPs and TIMPs as these proteases appear to be pivotal in 
collagen metabolism.  
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   mdx CARDIAC MUSCLE                BIRTH          mdx   SKELETAL MUSCLE 
                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 days Necrosis (McGeachie et al. 1993) 
22 days Sarcolemmal damage (Grounds & 
Torrisi 2004) 
23 days Increased level of gene expression 
involved in inflammatory response & ECM 
remodelling (Porter et al. 2003) 
 
28 days Peak in necrosis (McGeachie et al. 
1993) 
 
6 weeks TGF-β increased in diaphragms 
(Gosselin et al. 2004) 
 
7 weeks Peak of expression of genes involved 
in inflammatory response & ECM 
remodelling (Porter et al. 2003) 
 
9 weeks No difference in TGF-β levels  in 
diaphragm compared to control (Gosselin et 
al. 2004) 
 
 
 
 
 
 
 
 
 
 
 
6 to 17 months limb muscles of 6- to 17-
month-old mdx mice are larger but weaker, 
with lower normalised force and power 
(LynchHinkle et al. 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
24 months diaphragm reduction in strength to 
13.5% of control with 7 times more fibrosis 
(Stedman et al. 1991) 
Limb muscles smaller and weaker 
(LynchHinkle et al. 2001) 
 
No evidence of                     21 days 
sarcolemmal damage, inflammatory 
cell infiltration   
(submitted work from our laboratory)  
 
 
 
 
 
 
 
 
 
mdx cardiomyocytes                8weeks 
abnormally vulnerable to mechanical 
stress (Danialou et al. 2001)                                    
 
 
ECG changes                        10 weeks    
(Chu et al. 2002)                          
 
 
Membrane  leakage              12 weeks 
(unpublished data from our laboratory) 
Hypertrophy, increased fibrosis.  
Increased TGF-β (present study)  
 
 
Increased fibrosis                6 months  
Increased procollagen &  fibronectin 
Decreased contractility & relaxation 
(present study) 
 
 
Dilated                             10
.
5 months 
cardiomyopathy  (Quinlan et al. 2004) 
 
 
Fibrosis                              12 months 
Heart wt/tibial length maintained  
 (present study) 
Fibrosis increases (Cohn et al. 2007) 
 
 
Decreased cardiac             15 months 
function. 
TGF-β levels no different to control 
(Van Erp, Irwin & Hoey 2006) 
 
 
 
 
                         DEATH 
average age 26.5 months for male mdx 
mice, and 27.0 months for female from 
respiratory or cardiac failure or tumours  
(Chamberlain et al. 2007)  
Figure 3.8 Timeline of dystrophic changes in 
skeletal and cardiac muscle in the mdx mouse. 
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3.5 CONCLUSION 
This study determined the level of cardiac involvement of the mdx heart at 3, 6 and 12 
months of age. At 3 months of age cardiac hypertrophy was observed which may reflect a 
compensatory mechanism as skeletal muscle comes out of a period of widespread necrosis. 
By 12 months of age the increased heart weight was accompanied by decreased diastolic 
function, suggesting a pathological hypertrophy. 
 
Fibrosis was increased in the mdx heart at all the ages studied. While it did not affect LV 
developed pressure, by 6 months of age impaired rate of contraction and relaxation became 
evident. Decreased diastolic function was also observed at 12 months of age. As mdx mice at 
15 months of age have been previously shown to exhibit impaired cardiac function (Van Erp, 
Irwin & Hoey 2006), these present results suggest a progression toward cardiac dysfunction 
commencing at 6 months of age. 
 
Dystrophic fibrotic pathways are complex and have not been fully elucidated. This study 
highlights an involvement of TGF-β in the initiation of profibrotic pathways, a phenomenon 
which does not persist. This indicates that there may be a shift away from the initial increase 
in collagen synthesis, to a reduction in collagen degradation with age.  Literature supports a 
role for MMPs and their inhibitors TIMPs in the decreased breakdown of the ECM. 
 
There is a lack of cardiac data regarding genes involved in the remodelling of the ECM and 
this study provides novel data on fibronectin and procollagen mRNA levels in the mdx mouse 
heart. Both of these genes were found to be upregulated at 6 months of age in mdx hearts 
indicative of active collagen synthesis at this age. This increase correlates with high levels of 
ventricular fibrosis and the initial impairment in systolic and diastolic function observed. By 
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12 months of age the expression of these genes decreases even though levels of ventricular 
fibrosis are still significantly elevated. These results lend further support to the hypothesis of 
reduced rate of collagen degradation at older ages in the mdx mouse sustaining the high 
levels of fibrosis. 
 
This study provides a useful baseline for the following experiments using novel transgenic 
mouse models. It also provided essential development of expertise in ex vivo cardiac function 
techniques, histological analysis of fibrosis and molecular techniques. 
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CHAPTER 4   OVEREXPRESSION OF IGF-1 PARTIALLY RESTORES FUNCTION 
IN THE mdx HEART 
 
4.1 INTRODUCTION 
DMD is a characterised by repetitive cycles of muscle damage and repair resulting in muscle 
wasting as the degenerative process overwhelms the capability of the
 
muscle for regeneration  
(Moser 1984). After injury, muscle repair occurs in different phases: necrosis/degeneration 
and inflammation, regeneration and fibrosis. These appear to be interrelated (Huard, Li & Fu 
2002).  
 
Contraction induced damage results in necrosis, which is mediated by intrinsic proteases 
(Huard, Li & Fu 2002). Neutrophils invade the injured muscle and release free radicals and 
oxidants which cause lysing of the sarcolemma (Tidball 2005). The necrotic area is also 
infiltrated by small blood vessels, activated macrophages, mononuclear cells and T-
lymphocytes (Huard, Li & Fu 2002). Activated lymphocytes secrete cytokines and growth 
factors. Cytokines, macrophages and other cellular components activate and attract 
fibroblasts into the area of injury (Mourkioti & Rosenthal 2005). Fibroblasts overproduce 
TGF-β and are thought to produce the majority of collagen. Collagen remodels the ECM, 
reduces vascularity and eventually replaces connective tissue with scar tissue (fibrosis) as 
reviewed by Prisk (Prisk & Huard 2003). Although fibrotic tissue provides an early support 
network for broken myofibres to reconnect, if it continues to increase it restricts the 
regenerative potential of the new myofibres by filling up space where new muscle fibres 
would normally be (Mourkioti & Rosenthal 2005).  
 
IGF-1 has been shown to increase the regenerative capacity of dystrophic skeletal muscle by 
reducing the replacement of muscle fibres with fibrosis through modulation of the 
inflammatory response (Barton et al. 2002). Further, overexpression of IGF-1 in hepatic 
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stellate cells of cirrhotic rats showed attenuated fibrosis which was partly mediated by down 
regulation of TGF-β (Sanz et al. 2005). A recent study found IGF-1 gene transfer to cirrhotic 
livers improved liver function and reduced fibrosis which was associated with up regulation 
of MMPs and down regulation of TIMP-1 (Sobrevals et al. 2010). 
 
Muscle cell regeneration involves the activation of satellite cells. Following muscle injury 
satellite cells proliferate, fuse with damaged myotubes, then differentiate and mature. IGF-1 
is involved in the proliferation and differentiation of satellite cells and has been shown to 
extend their replicative life span (Chakravarthy et al. 2000). IGF-1 has also been shown to 
enhance bone marrow derived side population stem cells (Musaro et al. 2004). IGF-1 appears 
to be a crucial factor in mediating skeletal muscle growth (Florini, Ewton & Coolican 1996). 
It has an anabolic effect on skeletal muscle promoting muscle hypertrophy (Zdanowicz et al. 
1995), and blocking age related loss of muscle mass and function (Barton-Davis et al. 1998).  
 
Cardiac and skeletal muscles are markedly different in their postnatal capacity for cell 
replication during growth and regeneration (Grounds et al. 2002). Cardiac cells were 
previously thought to be incapable of replication after birth and there was thought to be no 
replacement with new cardiomyocytes after injury. Human studies, however, have shown that 
after myocardial infarction, there is a subpopulation
 
of myocytes that are not terminally 
differentiated and do proliferate (Beltrami et al. 2001). The level of cardiomyocyte 
proliferation is low in the normal heart and increases with heart disease (Kajstura et al. 1998). 
It is unclear whether these proliferating cells are derived
 
from resident cardiomyocytes or 
from circulating stem cells. One potential strategy for cardiomyocyte replacement after injury 
would therefore be to stimulate proliferation of these undifferentiated myocytes.  
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The subpopulation of undifferentiated myocytes in adult rat hearts exhibit all the properties 
expected for cardiac stem cells ie. self-renewing, clonogenic, and multipotent, and giving rise 
to a minimum of three differentiated cell types: myocytes, smooth muscle, and endothelial 
vascular cells (Beltrami et al. 2003). IGF-1 injected into a mouse heart after myocardial 
infarction promotes the survival and proliferation of cardiac stem cells (Beltrami et al. 2003). 
 
Evidence suggests that IGF-1 plays an important role in cardiac regeneration and IGF-1 has 
been shown to increase cardiomyocyte replication (Reiss et al. 1996; Welch, S. et al. 2002). 
IGF-1 has also been demonstrated to play a protective role in the heart by preventing 
cardiomyocyte death (Li et al. 1997). 
 
In the normal heart, hypertrophic growth (ie. enlargement of individual cardiomyocytes) is 
sufficient to maintain adequate cardiac function (Grounds et al. 2002). IGF-1 plays an 
important role in the hypertrophic response of the myocardium (Wang, P. H. et al. 1998). 
IGF-1 overexpressed or administered to the hearts of murine species induces cardiac 
hypertrophy (Duerr et al. 1995; Ito et al. 1993; Santini et al. 2007; Welch, S. et al. 2002). The 
hypertrophy mediated by IGF-1 appears to be a physiological adaptation as evidenced by an 
improved cardiac function as reviewed by Ren (Ren, Samson & Sowers 1999).  
 
IGF-1 has been demonstrated to play a protective role in the myocardium by attenuating the 
renin angiotensin system. Overexpression of IGF-1 in the heart of the streptozotocin-induced 
diabetic rat reduced angiotensin II and apoptosis (Kajstura et al. 2001). Angiotensin has been 
implicated in collagen synthesis and degradation in various cardiomyopathies (Gonzalez et al. 
2002).  
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While the inflammatory response is an integral component of muscle regeneration, it must be 
resolved to allow muscle repair (Pelosi et al. 2007). The ability of IGF-1 to resolve the 
inflammatory response and reduce fibrosis makes it a promising therapy for the dystrophic 
heart with its characteristic chronic inflammatory response and progressive fibrosis.  
 
The first studies on IGF-1 overexpression in the skeletal muscle of mdx mice demonstrated 
that IGF-1 increased muscle mass and strength, decreased myonecrosis, and
 
reduced fibrosis 
(Barton et al. 2002). The beneficial effects of IGF-1 on the heart has been assessed in normal 
rats (Cittadini et al. 1996), rats after myocardial infarction (Duerr et al. 1995), the δ-
sarcoglycan deficient hamster (Serose et al. 2005), the diabetic rat (Kajstura et al. 2001), the 
tropomodulin-overexpression mouse (Welch, S. et al. 2002), patients with chronic heart 
failure (Donath et al. 1998), and healthy people (Donath et al. 1996). To date, however the 
effects of IGF-1 on the dystrophic heart have not been determined. This current study 
addressed this by generating transgenic mice with cardiac restricted overexpression of IGF-1 
that have been crossed with mdx mice providing a novel animal model. These IGF-1/mdx 
mice offer a chronic model of injury, as opposed to the acute model of injury in the study by 
Santini and co-workers (Santini et al. 2007). 
 
The aims of this current study were to ascertain whether cardiac overexpression of IGF-1 
could improve function and ameliorate fibrosis in the dystrophic heart. Transgenic control 
mice that overexpressed cardiac restricted IGF-1 were also generated to compare any 
differences between the responses of normal cardiac muscle to dystrophic cardiac muscle. 
Levels of gene expression of TGF-β, procollagen and fibronectin were measured in an 
attempt to further elucidate profibrotic molecular pathways. Two age groups of 6 months and 
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12 months old were examined to determine the effect of IGF-1 overexpression with age of 
the animal. 
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4.2 RESULTS 
4.2.1 Method for the generation of transgenic mdx and C57 mice overexpressing IGF-1 
exclusively in the heart 
Male IGF-1 mice were used which overexpressed the mIGF-1 isoform, comprising a Class 1
 
signal peptide and a C-terminal Ea extension peptide using an α myosin heavy chain  
(α-MHC) promoter to restrict overexpression exclusively to the heart. These animals were 
generously provided by Professor Miranda Grounds University of Western Australia. Figure 
4.1 illustrates the rodent IGF-1 gene with the α-MHC promoter.  
 
These transgenic mice were crossed with mdx and C57 female mice from the University of 
Southern Queensland Animal house. This F1 generation was genotyped for the presence of 
the IGF-1 gene as outlined in Section 2.2.3. Male mice positive for IGF-1 were then back 
crossed with mdx or C57 female mice. These mice were genotyped for IGF-1 to determine 
the four experimental groups, IGF-1+/mdx, IGF-1-/mdx and IGF-1+/C57, IGF-1-/C57. 
Subsequent experiments in this study were conducted on male mice to reduce variability due 
to sex of the mouse. Tables 4.1 and 4.2 outline breeding numbers and resultant positive and 
negative genotyped offspring from these matings.     
    
                  
 
Figure 4.1 Schematic representation of the αMHC/mIGF-1 transgene construct. Adapted 
from Santini (Santini et al. 2007) 
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Table 4.1 Generation of IGF-1 + / mdx mice and IGF-1 -/ mdx mice 
 
 
 
      POSITIVE  
    IGF-1 genotype 
       NEGATIVE 
      IGF-1 genotype 
F1 ♂ IGF-1 x ♀ mdx 
        22 crosses 
 
   28 ♂ IGF-1 + /mdx 
 
     49 ♂ IGF-1 - / mdx 
F2 ♂ IGF-1 +/mdx x ♀ mdx 
       20 crosses 
 
   22 ♂ IGF-1+ / mdx 
 
     44 ♂ IGF-1 -/ mdx 
 
 
 
 
 
Table 4.2 Generation of IGF-1+/C57 mice and IGF-1-/C57 
 
 
 
          POSITIVE  
       IGF-1 genotype 
         NEGATIVE 
       IGF-1 genotype 
F1 ♂ IGF-1 x ♀ C57 
          17 crosses 
 
    9 ♂ IGF-1+/C57 
 
    14 ♂ IGF-1-/C57 
F2 ♂ IGF-1 / C57 x ♀ C57 
         18 crosses 
 
   15 ♂ IGF-1+/C57 
 
    39 ♂ IGF-1-/C57 
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4.2.2 Morphology 
Mdx mice that overexpressed IGF-1 in the heart (IGF-1+/mdx) displayed a significantly 
greater body weight at 12 months of age compared to IGF-1-/mdx mice at the same age 
(P<0.05). C57 mice that overexpressed IGF-1 in the heart (IGF-1+/C57) also displayed a 
significantly greater body weight at 12 months of age compared to age matched IGF-1-/C57 
(P<0.05) (see Figure 4.2A). 
 
Heart weights were increased in IGF-1+/mdx mice at 6 months of age by 20% (P<0.01), and 
by 33% at 12 months (P<0.001) compared to age matched IGF-1-/mdx  mice. Similarly IGF-
1+/C57 mice showed a 17% increase in heart weight at 6 months (P<0.05), and a 21% 
increase at 12 months (P<0.001) compared to age matched IGF-1-/C57 (see Figure 4.2B). 
 
IGF-1+/mdx mice demonstrated a greater heart weight/body weight (HW/BW) ratio at 6 
months of age (P<0.05) and 12 months of age (P<0.01) when compared to age matched IGF-
1-/mdx mice. In comparison IGF-1+/C57 mice showed no significant difference in HW/BW 
at 6 and 12 months of age when compared to age matched IGF-1-/C57 control mice (see 
Figure 4.3A). 
 
When heart weight was normalised to tibial length (HW/TL) IGF-1+/ mdx mice demonstrated 
a 21% increase at 6 months of age (P< 0.01) and a 26%  increase at 12 months of age (P< 
0.001) compared to age matched IGF-1+/ mdx. This trend was also evident in IGF-1+/C57 
mice with an increase of 17% at 6 months of age (P<0.01) and 21% at 12 months of age 
(P<0.01) compared to age matched IGF-1-/C57 (see Figure 4.3B). 
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Figure 4.2 Body weight and heart weight of mdx and C57 mice negative and positive for the 
IGF-1 transgene at 6 and 12 months of age. Body weight (gms) (A); heart weight (mg). Body 
weight is significantly increased in both IGF-1+/mdx and IGF-1+/C57 mice at 12 months of 
ge. Heart weight is significantly increased in IGF-1+/mdx and IGF-1+/C57 mice at both ages. 
(* P<0.05, **P<0.01, ***P<0.001) 
 
A. 
B. 
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Figure 4.3 Morphometric data from mdx and C57 mice negative and positive for the IGF-1 
transgene at 6 and 12 months of age. Heart weight normalised to body weight (mg/gm) (A), 
and heart weight normalised to tibial length (mg/mm) (B). Heart weight/body weight was 
increased only in IGF-1+/mdx mice at both age groups, however heart weight/tibial length 
was increased in both mdx and IGF-1+/C57 at both age groups. (* P<0.05, **P<0.01, 
***P<0.001) 
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4.2.3 Cardiac function 
Ex vivo cardiac experiments demonstrated a significant improvement in systolic function for 
IGF-1+/mdx at 12 months of age compared to 6 months (P<0.05), and an equivalent 
improvement compared to age matched IGF-1+/C57 mice (P<0.05) (see figure 4.4). 
The rate of contraction (+dP/dt) also increased significantly in 12 month old IGF-1+/mdx 
mice compared to 6 months (P<0.05) (see figure 4.5A).  
 
There were no significant difference in values between all groups of mice for the rate of 
relaxation (-dP/dt) (see figure 4.5B). 
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Figure 4.4 Cardiac function of mdx and C57 mice negative and positive for the IGF-1 
transgene at 6 and 12 months of age. Left ventricular developed pressure (mmHg) from 
isolated hearts Langendorff perfused hearts. Cardiac function improved significantly in IGF-
1+/mdx mice at 12 months of age compared to IGF-1+/mdx mice at 6 months and compared 
to age matched control IGF-1+/C57 mice. (* P<0.05, **P<0.01, ***P<0.001) 
 
  
123 
 
Rate of developed pressure
+
d
P
/d
t 
(m
m
H
g
/s
e
c)
0
2000
4000
6000
8000
10000
12000
6 12
Mouse age (months)
*
IGF-1-/mdx
IGF-1+/mdx
IGF-1-/C57
IGF-1+/C57
 
 
Rate of relaxation
-d
P
/d
t 
(m
m
H
g
/s
e
c)
-6000
-5000
-4000
-3000
-2000
-1000
0
6 12
Mouse age (months)
 
               
 
Figure 4.5 Rate of developed pressure and rate of relaxation for mdx and C57 hearts negative 
and positive for the IGF-1 transgene at 6 and 12 months of age. Contraction measured as rate 
of pressure development (+dP/dt) mmHg/sec (A), and rate of relaxation (-dP/dt) mmHg/sec 
(B). The rate of contraction increased significantly in IGF-1+/mdx mice at 12 months of age 
compared to IGF-1+/mdx at 6 months of age. (* P<0.05, **P<0.01, ***P<0.001) 
A. 
B. 
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4.2.4 Ventricular fibrosis 
Ventricular fibrosis, measured by picrosirius red staining and expressed as % collagen, was 
significantly higher for mdx mice compared to C57 mice at 6 and 12 months of age (P<0.01 
and P<0.001 respectively) (see Figure 4.6 and representative photomicrographs shown in 
Figure 4.7). 
 
At 6 months of age IGF-1+/mdx mice displayed levels of fibrosis comparable to age matched 
mdx mice, however by 12 months of age IGF-1+/mdx mice displayed levels of fibrosis that 
was significantly less than age matched control mdx (P<0.001) and 6 month old IGF-1+/ mdx 
(P<0.001). The percentage collagen exhibited by 12 month old IGF-1+/mdx decreased to 
values not significantly different to age matched IGF-1+/C57 (see Figure 4.6 and 
representative photomicrographs shown in Figure 4.7). 
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Figure 4.6 Ventricular fibrosis expressed as % collagen of mdx and C57 mice negative and 
positive for the IGF-1 transgene at 6 and 12 months of age.  
Percentage collagen was significant higher for IGF-1+/mdx at 6 months, but decreased in 
IGF-1+/mdx at 12 months to levels not significantly different to age matched IGF-1+/C57. 
(* P<0.05, **P<0.01, ***P<0.001) 
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Figure 4.7 Representative photomicrographs of ventricular sections of IGF-1-/mdx, IGF-
1+/mdx, IGF-1-/C57 and IGF-1+/C57 at 6 and 12 months of age (picrosirius red stained). 
Magnification x40. IGF-1 -/mdx hearts display significantly greater fibrosis than IGF-1-/C57 
hearts at both age groups. By 12 months of age IGF-1+/mdx hearts display significantly less 
fibrosis than IGF-1-/mdx  and the level of fibrosis is reduced to be not significantly different 
than age matched IGF-1+/C57. 
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4.2.5 Gene expression of TGF-β, procollagen, and fibronectin 
TGF-β 
Gene expression of TGF-β, as calculated by RT-PCR and expressed relative to β-actin, 
increased in IGF-1+/mdx mice compared to mdx mice at 12 months (P<0.001). There was no 
significant difference in TGF-β mRNA levels when comparing IGF-1+/mdx mice and IGF-
1+/C57 mice, or between IGF-1-/mdx mice and IGF-1-/C57 at 6 and 12 months of age (see 
figure 4.8). 
 
Procollagen 
Levels of procollagen mRNA, as calculated by RT-PCR and expressed relative to β-actin, 
were higher in mdx and IGF-1+/mdx mice at 6 months compared to age matched control 
(P<0.01 and P<0.05 respectively). This trend was also apparent when comparing IGF-1-/mdx 
to IGF-1+/mdx mice at 12 months of age (P<0.01 and P<0.001 respectively) (see figure 
4.9A). By 12 months of age, however there was no significant difference in the level of 
procollagen gene expression between IGF-1-/mdx and IGF-1+/mdx mice relative to age 
matched controls (see figure 4.9A). 
 
Fibronectin 
Gene expression of fibronectin, as calculated by RT-PCR and expressed relative to β-actin, 
was greater in IGF-1-/mdx mice at 6 months of age compared to IGF-1+/mdx and IGF-1-/C57 
mice at the same age (both P<0.05). Fibronectin mRNA levels decreased in IGF-1+/mdx 
mice at 12 months compared to IGF-1+/mdx mice at 6 months (P<0.01) to levels not 
significantly different to that of age matched IGF-1+/C57 mice (see figure 4.9B). There was a 
trend towards decreased fibronectin gene expression in IGF-1-/mdx at 12 months also. Larger 
error bars prevented this difference from reaching significance (see figure 4.9B). 
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Figure 4.8 Cardiac gene expression of TGF-β mRNA as determined by quantitative real time 
PCR relative to β-actin for mdx and C57 mice positive and negative for the IGF-1 transgene 
at 6 and 12 months of age. TGF-β mRNA levels were significantly higher for IGF-1+/mdx 
mice at 12 months of age compared to age matched IGF-1-/mdx mice.  
(* P<0.05, **P<0.01, ***P<0.001) 
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Figure 4.9 Cardiac gene expression for procollagen and fibronectin determined by 
quantitative real time PCR relative to β-actin for mdx and C57 mice positive and negative for 
the IGF-1 transgene at 6 and 12 months of age. mRNA levels of procollagen and fibronectin 
declined in an age dependant manner in the mdx transgenic mice. mRNA levels of 
procollagen were significantly higher in IGF-1+/mdx mice and IGF-1-/mdx mice at 6 months 
of age compared to age matched IGF-1+/C57 and IGF-1-/C57respectively and mRNA levels 
of fibronectin were significantly higher in IGF-1-/mdx mice at 6 months compared to age 
matched IGF-1+/mdx and IGF-1-/C57. (* P<0.05, **P<0.01, ***P<0.001) 
B. 
A. 
 
  
130 
 
4.3 DISCUSSION 
4.3.1 Cardiac hypertrophy 
IGF-1 has been shown to mediate cardiac hypertrophy in murine species (Duerr et al. 1995; 
Ito et al. 1993; Santini et al. 2007; Welch, S. et al. 2002). Transgenic IGF-1 overexpression 
increased heart weight in both mdx mice and C57, however the effect was more pronounced 
in the dystrophic heart. This suggests an enhanced growth promoting effect of IGF-1 in 
dystrophic muscle compared to normal muscle, reflected also in heart weight normalised to 
body weight with only IGF-1/mdx mice exhibiting a significant increase. This correlates to 
studies looking at overexpression of IGF-1 in the skeletal muscles of mdx and normal mice 
which found an increased growth promoting effect of IGF-1 on dystrophic muscle (Barton et 
al. 2002; Shavlakadze et al. 2004). 
 
IGF-1 appears to mediate a more dramatic effect on heart weight in the older animal, with 
ventricular weights greater at 12 months in both transgenic strains compared to 6 months of 
age. This effect is also observed in the diaphragms of transgenic mdx mice overexpressing 
IGF-1 in skeletal muscle (Barton et al. 2002) and in the hearts of transgenic mice 
overexpressing IGF-1B in cardiac muscle (Reiss et al. 1996).  
 
In order to further assess cardiac hypertrophy, heart weight was normalised to tibial length. In 
murine models, tibial length changes minimally after maturity and correlates better than body 
weight so it is useful for assessing changes in cardiomyocyte size with age (Yin et al. 1982). 
Cardiac hypertrophy was observed in mdx and C57 overexpressing IGF-1 at both ages 
examined, however the greatest increase was seen in the dystrophic heart at 12 months of 
age. 
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The growth promoting effects of IGF-1 are also dependent upon the mode of administration 
and the dose. Short term administration of IGF-1 has been shown not to increase heart weight 
(Ren 2002). IGF-1 administered by osmotic pump to normal rats resulted in a greater left 
ventricle weight normalised to tibial length with increased dose (2.2mg/kg/day and 
3mg/kg/day) (Duerr et al. 1995). In comparison, the transgenic model used in this current 
study provides chronic increased levels of IGF-1. This provides a more consistent model than 
intermittently administered exogenous sources and enables a valid comparison of the effects 
of IGF-1 with increasing age. 
 
Cardiac growth may be due to an increase in cardiomyocyte size and/or cellular proliferation. 
Studies have indicated that IGF-1 mediated increases in heart weight are due to increased 
cardiomyocyte size (hypertrophy), rather than number (hyperplasia) (Duerr et al. 1995; Ito et 
al. 1993; Santini et al. 2007). Although other studies have reported increased cardiomyocyte 
number in transgenic mice overexpressing IGF-1, a different isoform of IGF-1 was used 
(IGF-1B) (Reiss et al. 1996; Welch, S. et al. 2002). The degree to which hypertrophy occurs 
as opposed to hyperplasia may be dependent upon the age of the animal and the specific 
muscle. IGF-1 overexpressed in skeletal muscles of mdx mice exhibited more hyperplasia in 
the extensor digitorum longus at 3 months of age mice than at 14 months where the increased 
muscle size was due to hypertrophy. This was in contradiction to the diaphragm which 
displayed hyperplasia and hypertrophy at 3 months, followed by only hyperplasia at 14 
months of age (Barton et al. 2002).  
 
Cardiac hypertrophy observed in transgenic mice that overexpressed IGF-1 exclusively in the 
heart has been shown to be related to higher levels of atrial natriuetic peptide (ANP) at early 
ages, while other cardiac hypertrophy markers such as brain natriuretic peptide (BNP), α-
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skeletal actin, β-myosin heavy chain and glutamate transporter were not affected (Santini et 
al. 2007).  
 
4.3.2 Cardiac Function 
In order to determine if the observed cardiac hypertrophy conferred a physiological change as 
opposed to a pathological one, functional experiments were performed on isolated mouse 
hearts. This showed that IGF-1 overexpression improved cardiac function in 12 month old 
mdx by 20% compared to aged matched controls. This increase was 22% greater than IGF-
1/mdx hearts at 6 months of age, and was accompanied by a 30% increased rate of 
contraction. The improvement in cardiac function suggests the observed hypertrophy is a 
physiologic change. While IGF-1 has been shown in other models to improve cardiac 
function (Cittadini et al. 1998; Duerr et al. 1995; Santini et al. 2007; Serose et al. 2005), this 
current study is the first to report improvement in cardiac function with IGF-1 overexpression 
in the dystrophic heart.  
 
The improved function at 12 months of age correlated with a dramatic reduction in levels of 
ventricular fibrosis. Even though IGF-I has been shown to stimulate fibroblasts (Petley et al. 
1999) it has been shown to reduce fibrosis in skeletal muscles of mdx mice (Barton et al. 
2002), in the injured heart (Santini et al. 2007) and the delta-sarcoglycan deficient heart 
(Serose et al. 2005).  
 
IGF-1 appears to be capable of resolving the inflammatory response and thereby attenuating 
fibrosis. After myocardial infarction, transgenic overexpression of IGF-1 has been shown to 
decrease levels of proinflammatory cytokine IL-6 that promotes fibrosis while levels of anti-
inflammatory cytokines IL-4 and IL-10 were increased (Santini et al. 2007).  
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An age related impact of IGF-1 is demonstrated by 12 month transgenic IGF-1+/ mdx mice 
with reduced ventricular fibrosis and improved cardiac function as compared to younger 
mice. One possible explanation is that IGF-1 overexpression in the mdx mouse heart may not 
be able to resolve fibrosis at 6 months of age due to increased circulating levels of TNF-α. 
TNFα is an early and potent proinflammatory cytokine that stimulates the inflammatory 
response.
 
Elevated TNF-α increases catabolism within skeletal muscle and can interfere with 
IGF-1 signalling (Grounds & Torrisi 2004). TNF-α strongly inhibits IGF-1 gene and protein 
expression of muscle cells (Fernandez-Celemin et al. 2002; Frost, Lang & Gelato 1997). As 
TNF-α levels have been shown to be upregulated in the active stage of DMD (Porreca et al. 
1999) and mdx mice (Porter et al. 2003) perhaps at 6 months of age TNF-α levels in the heart 
are high enough to inhibit IGF-1 signalling and thereby block its ability to resolve the 
inflammatory process. Future therapeutic strategies involving increasing levels of IGF-1 may 
prove more effective if combined with reducing TNF-α activity (Shavlakadze et al. 2004).   
 
The mechanisms involved in the increased contractile performance mediated by IGF-1 are 
unclear and beyond the scope of this current study. Concomitant with its anabolic and 
antiapoptotic effects, IGF-1 enhanced calcium responsiveness of cardiomyocytes and 
intracellular Ca
2+
 replenishing capacity (Ren 2002), and this mechanism may be involved 
with improved systolic function. 
             
4.3.3 TGF-β 
Despite fibrosis decreasing at 12 months of age, this was not accompanied by a decrease in 
TGF-β levels. Values were not different between strains of mice, with only a slight increase 
in IGF-1/mdx at 12 months compared to mdx at the same age. Another study found that 
increased TGF-β levels were not part of the cardiac inflammatory response after cardiotoxin 
injury and myocardial infarction, but rather increased levels of interleukins 6 and 1β (Santini 
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et al. 2007). This highlights a selective involvement of certain cytokines in the cardiac 
inflammatory response (Santini et al. 2007).   
 
4.3.4 Procollagen and fibronectin 
Collagen and fibronectin are secreted by fibroblasts which are key mediators of the fibrotic 
response as reviewed by Tomasek (Tomasek et al. 2002). This current data showed decreased 
procollagen and fibronectin mRNA levels in IGF-1+/mdx mice at 12 months of age which 
was accompanied with decreased fibrosis. Mdx fibroblasts have been shown to synthesize 
more fibronectin than normal fibroblasts and incubating mdx fibroblasts in IGF-1 decreased 
fibronectin levels (Mezzano et al. 2007). From current results it is possible that this same 
effect exists at an organ level, not just in cell culture. 
 
Fibrosis is a function of both synthesis and degradation of the ECM. The lack of clear 
temporal correlation observed in this study, between TGF-β, procollagen and fibronectin with 
fibrosis highlights the complex pathways involved and it is likely that other signalling 
molecules are involved. MMPs may participate in fibrosis and remodelling of the ECM via 
direct digestion of the ECM, regulation of matrikines and/or release of growth factors such as 
IGF-1 from the ECM (Taipale & Keski-Oja 1997). Elevated myocardial IGF-1 mRNA has 
been shown to have a positive correlation with MMPs 11 and 14 and TIMPS 1 to 4 therefore 
suggesting a link between IGF-1 expression in transgenic animals and alterations in ECM 
metabolism (Barton et al. 2005).  
 
 
 
 
  
135 
 
4.4 SHORTCOMINGS OF THE STUDY 
The next phase of research involving this IGF-1+/mdx mouse model would be to further 
examine the molecular pathways involved in cardiac fibrosis. In particular, analysis of TNF-α 
would be valuable to ascertain if it prevented IGF-1 mediated reduction in fibrosis at 6 
months of age. Other cytokines of interest would be proinflammatory IL-6 and anti-
inflammatory IL-4 and 10 as these have been implicated in the resolution of the inflammatory 
response of the heart (Santini et al. 2007).  Also of importance would be cardiac levels of 
MMPs and TIMPs to determine their involvement in the balance between collagen deposition 
and degradation in the dystrophic heart.  
 
Only two age groups were examined in this current study. More frequent sampling is required 
to elucidate a signaling profile of the cytokines involved in fibrosis. Future research could 
also examine younger and older age groups. It would be valuable to study this model at 
younger ages to observe the effects on IGF-1 on initiation of fibrotic pathways and at 15 
months of age where marked reduction in cardiac function has been observed (Van Erp, Irwin 
& Hoey 2006).  
 
Future studies to further elucidate the mechanism behind improved cardiac function mediated 
by IGF-1 would benefit from single cell experiments such as cell shortening, rate of cell 
shortening and intracellular calcium levels, to determine changes at a cellular level.  
 
Transgenic mdx mice overexpressing IGF-1 in skeletal muscle have been generated and 
histological and functional experiments have found improvements in skeletal muscle 
pathology (Barton et al. 2002). To date the cardiac involvement of these mice has not been 
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assessed to see if improvements in skeletal pathology results in an improvement of the 
cardiac phenotype. 
 
4.5 CONCLUSION 
The major findings of this study indicate that IGF-1 mediates cardiac growth, and by 12 
months of age imparts a positive inotropic effect on the dystrophic heart which is 
accompanied with a marked reduction in ventricular fibrosis.  
 
 The observed cardiac growth appeared different from
 
both normal growth of the immature 
heart, in which no changes
 
in left ventricular function are usually observed, and from 
pathological growth
 
which is
 
associated with decreased contractile performance (Scheuer & 
Buttrick 1987).  
 
Efficient repair of the IGF-1/mdx heart induced by IGF-1 may prevent the formation of an 
environment into which fibroblasts migrate thereby reducing fibrosis as observed in this 
study and in mdx skeletal muscle (Barton et al. 2002).  
 
This study provides further evidence that TGF-β is not the principle driver in the progression 
of fibrosis in dystrophic cardiomyopathy as also suggested by others (Gosselin et al. 2004; 
Van Erp, Irwin & Hoey 2006). Indeed inflammation after myocardial infarction and 
cardiotoxin injury found levels of TGF-β not to be affected (Santini et al. 2007). The 
evidence suggests that the progressive fibrosis characteristic of dystrophic muscle may be a 
result of reduced degradation of collagen as opposed to active synthesis and this is further 
supported by the decreased mRNA levels of fibronectin and procollagen observed in this 
study. Indeed IGF-1 has been linked to ECM remodelling through its positive correlation 
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with MMPs 11 and 14 and TIMPs 1 and 2 which are involved in ECM metabolism (Barton et 
al. 2005). 
 
The ability of IGF-1 overexpression to improve function and attenuate fibrosis in the 
dystrophic heart warrant further investigation of this growth hormone as a potential therapy 
to ameliorate the dystrophic phenotype. While IGF-1 therapy would not address the primary 
deficit associated with DMD, it may be beneficial in protecting the heart from the secondary 
symptoms of dystrophin deficiency. It is also acknowledged that it is difficult to translate the 
transgenic model to the clinical setting and delivery of IGF-1 to the patient’s heart is an issue. 
AAV vectors offer a possible technique to deliver IGF-1 to a specific muscle and avoid side 
effects on other tissues. IGF-1Ea has been successfully injected into the skeletal muscles of 
mdx mice using AAV vectors, on its own (Barton 2006b) and in conjunction with 
microdystrophin (Abmayr et al. 2005).  
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CHAPTER 5 EFFECT OF MYOD AND DYSTROPHIN KNOCKOUT ON CARDIAC 
STRUCTURE AND FUNCTION 
5.1 INTRODUCTION 
The mdx mouse exhibits a milder phenotype than DMD. This may be due to upregulation of 
utrophin (Deconinck et al. 1997), or increased muscle regeneration (Anderson, Bressler & 
Ovalle 1988). Other mouse models that have been suggested as alternatives to the mdx mouse 
for studies into dystrophin deficient cardiomyopathy include the dystrophin/utrophin double 
knockout mouse (Deconinck et al. 1997), and the MyoD and dystrophin double knockout 
mouse (mdx:MyoD(-/-)) (Megeney et al. 1999).  
 
Dystrophin /utrophin knockout mice exhibit a more severe progressive muscular dystrophy 
than mdx mice that results in premature death, however utrophin /mdx mice failed to develop 
cardiomyopathy (Deconinck et al. 1997). This could be due to the shorter life span of only 20 
weeks of these mice which does not allow time for cardiomyopathy to develop.  
 
It has been argued that the mdx:MyoD(-/-) mouse displays a phenotype more closely aligned 
to that observed in DMD, and in particular a more severe cardiomyopathy (Duan 2006). 
mdx:MyoD(-/-) mice are characterised by a marked kyphosis, a waddling gait characterised 
by weight bearing on the tarsal joints, and an increased skeletal myopathy leading to 
premature death  (Megeney et al. 1996). The marked skeletal myopathic phenotype appears 
to be due to a reduction in skeletal muscle regeneration as a result of reduced activity of 
satellite cells (Megeney et al. 1996).  
 
Myogenic transcription factor, MyoD is directly involved in satellite cell activation (Rudnicki 
et al. 1992). Knocking out the MyoD gene in the mdx mouse would determine if enhanced 
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muscle regeneration contributed to the milder phenotype of the mdx mouse. Indeed  
mdx:MyoD(-/-) mice have been shown to have reduced muscle hypertrophy and significantly 
reduced regeneration in skeletal muscles, however some regenerative potential did persist 
(Megeney et al. 1996). MyoD therefore appears to be required for efficient regeneration at the 
level of satellite cell formation, survival or function. MyoD may also be indirectly required 
by myofibres for the expression of growth factors essential for activating satellite cells 
(Megeney et al. 1996).     
 
Controversy exists as to whether cardiomyopathy associated with DMD is a secondary 
phenomenon due to skeletal muscle pathology or is a result of dystrophin deficiency alone. A 
study of 9 DMD patients found that the severity of skeletal muscle pathology was associated 
with the extent of cardiac dysfunction (Hunsaker et al. 1982). X-linked dilated 
cardiomyopathy (XLDC) challenges this idea. Dystrophin is present in skeletal muscle, but 
absent from the heart of these patients. Lack of cardiac dystrophin alone is sufficient to cause 
severe cardiomyopathy (Muntoni et al. 1995). In support of this, a study involving γ-
sarcoglycan mice inserted with a transgene to rescue γ-sarcoglycan only in skeletal muscle, 
found no beneficial effects on the heart (Zhu et al. 2002).  
 
The mdx: MyoD(-/-) mouse model has the potential to distinguish if dystrophic 
cardiomyopathy is primarily due to dystrophin deficiency, or a secondary phenomenon 
associated with skeletal muscle pathology. As MyoD is expressed only in skeletal muscle, not 
in the heart, changes in cardiac involvement in the mdx:MyoD(-/-) mouse compared to the 
mdx mouse would be due to the increased level of skeletal muscle damage.  
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Mdx:MyoD(-/-) mice exhibit cardiac hypertrophy by 5 months of age predominantly in the 
left ventricle (Megeney et al. 1999). Ventricular fibrosis increased with age compared to mdx 
hearts, and was also localised to the left ventricle (Megeney et al. 1999). This escalation in 
the cardiac involvement of the model compared to age matched mdx mice is due to increased 
skeletal myopathy suggesting that dystrophin deficiency in cardiomyocytes is not the sole 
cause behind DMD cardiomyopathy. Further to this, the mdx:MyoD(-/-) mouse heart may 
reflect the progressive dilated cardiomyopathy observed in DMD more closely than the mdx 
mouse (Duan 2006). 
 
To date cardiac functional data has not been assessed for the mdx:MyoD(-/-) mouse. If the 
cardiomyopathy of mdx:MyoD(-/-) mice more closely resembles DMD patients it would be 
an extremely useful model to assess potential therapies for dystrophic cardiomyopathy. This 
current study aims to examine ex vivo cardiac function of the mdx:MyoD(-/-) mouse to 
determine any changes in systolic and diastolic function. This will add to the body of 
knowledge along with the observed morphological changes and activation of protein kinases 
observed in other studies (Megeney et al. 1999).  
 
Additional objectives of the current study were to determine levels of fibrosis and gene 
expression of TGF-β, procollagen and fibronectin which are implicated in profibrotic 
pathways in this transgenic model. Increased fibrosis is a feature of both mdx and DMD 
cardiomyopathy, however post mortem studies of DMD suggest that it is more extensive in 
human hearts and localised to the left ventricle (Frankel & Rosser 1976). A previous study 
showed that 5 month old mdx:MyoD(-/-) mice exhibit increased fibrosis compared to mdx 
which was localised to the left ventricle (Megeney et al. 1999). This current study examined 
the level of cardiac fibrosis of the mdx:MyoD(-/-) model at 3 months of age and determined 
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the levels of gene expression of TGF-β, procollagen, and fibronectin in an attempt to 
elucidate fibrotic molecular pathways, with particular reference to this transcription factor. 
This age group was chosen as the study aimed to examine levels of cardiac hypertrophy 
similar to those observed in the IGF-1 transgenic mdx mice experiments. 
 
5.2 RESULTS 
5.2.1 Generation of mdx:MyoD(-/-) mice 
Male mice with the MyoD promoter, exon 1 and half of intron 1 deleted and replaced by a 
VGKneo cassette, were crossed with female mdx and C57 mice. Genotyping, as outlined in 
Chapter 2, resulted in three groups of mice: mdx:MyoD(-/-), C57:MyoD(-/-) and mdx. 
 
5.2.2 Morphology 
There was no significant difference in body weight, heart weight, heart weight normalised to 
body weight (HW/BW) or heart weight normalised to tibial length (HW/TL) between mdx, 
mdx:MyoD(-/-), C57:MyoD(-/-) mice (Figures 5.1 and 5.2).  
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Figure 5.1 Body weight and heart weight from mdx, mdx:MyoD(-/-) and C57:MyoD(-/-) 
mice at 3 months of age. Body weight (gms) (A.), and heart weight (mg) (B.). There was no 
significant difference in body weight or heart weight between the different strains of mice.  
(* P<0.05, **P<0.01, ***P<0.001) 
 
A. 
B. 
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Figure 5.2 Morphological data from mdx, mdx:MyoD(-/-) and C57:MyoD(-/-) mice at 3 
months of age. Heart weight / body weight (mg/gm) (A.), heart weight / tibial length 
(mg/mm) (B.). There was no significant difference in heart weight normalised to body weight 
or tibial length between the different strains of mice. (* P<0.05, **P<0.01, ***P<0.001) 
 
A. 
B. 
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5.2.3 Cardiac function 
An improvement in cardiac function (mmHg), rate of contractility (mmHg/second), rate of 
relaxation (mmHg/second), was observed in mdx:MyoD(-/-), mice compared to mdx mice 
(P<0.05, P<0.001, P<0.05 respectively) as shown Figure 5.3 and 5.4. There was no 
significant difference in functional data between mdx:MyoD(-/-), and C57:MyoD(-/-) (Figure 
5.3 and 5.4).  
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Figure 5.3 Cardiac function of mdx, mdx:MyoD(-/-) and C57:MyoD(-/-) mice at 3 months of 
age. Left ventricular developed pressure (mmHg) from isolated hearts Langendorff perfused 
hearts. There was a significant increase in left ventricular developed pressure in  
mdx:MyoD(-/-) hearts compared to mdx. (* P<0.05, **P<0.01, ***P<0.001) 
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Figure 5.4 Rate of developed pressure and rate of relaxation of mdx, mdx:MyoD(-/-) and 
C57:MyoD(-/-) hearts at 3 months of age. Contraction measured as rate of pressure 
development (+dP/dt) mmHg/sec (A), and rate of relaxation (-dP/dt) mmHg/sec (B). Both the 
rate of contraction and rate of relaxation significantly increased in mdx:MyoD(-/-) hearts 
compared to mdx. (* P<0.05, **P<0.01, ***P<0.001) 
 
A. 
B. 
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5.2.4 Ventricular Fibrosis 
Mdx:MyoD(-/-) mice exhibited a significant increase in ventricular fibrosis (expressed as % 
collagen) compared to mdx and C57:MyoD(-/-) mice (P<0.05 and P<0.001). Mdx mice also 
displayed more fibrosis than C57:MyoD(-/-) mice (P<0.001). (see Figure 5.5 and 
representative photomicrographs Figure 5.6) 
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Figure 5.5 Ventricular fibrosis expressed as % collagen of mdx, mdx:MyoD(-/-) and 
C57:MyoD(-/-) mice at 3 months of age. Percentage collagen was significantly higher for 
mdx:MyoD(-/-) hearts compared to mdx and C57:MyoD(-/-) and mdx hearts displayed 
significantly more fibrosis than C57:MyoD(-/-). (* P<0.05, **P<0.01, ***P<0.001) 
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Figure 5.6 Representative photomicrographs of ventricular sections of C57:MyoD(-/-), mdx 
and mdx:MyoD(-/-) at 3 months of age (picrosirius red staining). Magnification x40. Removal 
of the MyoD gene from mdx mice results in significantly increased cardiac fibrosis compared 
to mdx and C57:MyoD(-/-) hearts. 
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5.2.5 Cardiac gene expression of TGF-β, procollagen and fibronectin 
There was no difference in gene expression of TGF-β and procollagen between mdx, 
mdx:MyoD(-/-) and C57:MyoD(-/-) mice as determined by RT-PCR analysis relative to β-
actin (see Figure 5.7 and 5.8A).   
  
A significant increase in mRNA levels of fibronectin in mdx:MyoD(-/-) compared to 
C57:MyoD(-/-) mice (P<0.05) and in mdx compared to C57:MyoD(-/-) (P<0.05) was 
observed, however there was no significant difference between mdx and mdx:MyoD(-/-) (see 
Figure 5.8B). This paralleled the change in fibrosis (see fig 5.5) 
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Figure 5.7 Cardiac gene expression levels of TGF-β mRNA as determined by quantitative 
real time PCR relative to β-actin for mdx, mdx:MyoD(-/-) and C57:MyoD(-/-) mice at 3 
months of age. There was no significant difference in levels of TGF-β mRNA between all 
strains of mice. (* P<0.05, **P<0.01, ***P<0.001) 
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Figure 5.8 Cardiac gene expression of procollagen (A.) and fibronectin (B.) as determined by 
quantitative real time PCR relative to β-actin of mdx, mdx:MyoD(-/-) and C57:MyoD(-/-) 
mice at 3 months of age. There was no significant difference in procollagen mRNA levels, 
however levels of fibronectin mRNA was increased for both mdx and mdx:MyoD(-/-) hearts 
compared to C57:MyoD(-/-).(* P<0.05, **P<0.01, ***P<0.001) 
 
 
A. 
B. 
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5.3 DISCUSSION 
At 3 months of age mdx:MyoD(-/-) mice do not exhibit  cardiac hypertrophy as was expected, 
however it has been reported at 5 months of age with areas, predominantly in the left 
ventricle, showing an increase in cardiomyocyte size (Megeney et al. 1999). This may reflect 
progressive changes from a normal heart weight at 3 months to sporadic cellular hypertrophy 
by 5 months (Megeney et al. 1999).  
 
Unexpectedly an increase in cardiac function, systolic and diastolic function was observed in 
mdx:MyoD(-/- ) mice at 3 months of age compared to mdx mice. This surprising result 
warrants further investigation as previous data at 5 months of age, suggest that the 
mdx:MyoD(-/-) model displays a more severe cardiomyopathy than the mdx mouse. 
The increased cardiac function occurred in the face of a significant increase in ventricular 
fibrosis in mdx:MyoD(-/-) mice compared to mdx mice and C57:MyoD
-/- 
 mice. This paradox 
may be an early compensatory mechanism of the heart as it is working harder due to the 
increased skeletal pathology placing an extra work load on the heart. Further, it has been 
shown in other studies that the changes in cardiac function are not always contingent upon 
levels of fibrosis (Cohn et al. 2007; Van Erp, Irwin & Hoey 2006). Cardiac hypertrophy did 
not accompany this increased cardiac function, however other studies have reported 
hypertrophy at 5 months of age (Megeney et al. 1999). 
 
Ventricular fibrosis was determined by sampling two sections from the left ventricle, two 
sections from the right ventricle and one from the interventricular septum. Although it was 
not quantified, fibrosis appeared to be predominant in the left ventricle (data not shown). This 
was also a feature of mdx:MyoD(-/-) mice at 5 months of age, suggesting an accelerated left 
ventricle involvement in the development of cardiomyopathy in these mice (Megeney et al. 
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1999). On the other hand, mdx mice exhibit fibrosis in both left and right ventricles (Quinlan 
et al. 2004). The pattern of fibrosis exhibited by mdx:MyoD(-/-) mice more closely resembles 
DMD patients where autopsy studies found fibrosis to be more severe in the left ventricle 
with a sparing of the right ventricle (Frankel & Rosser 1976). Further to this, 
echocardiography studies of DMD patients showed myocardial degeneration localised 
initially to the left ventricular posterior wall, lateral wall and apex, and eventually the 
ventricular septum and left ventricular anterior wall (Sasaki et al. 1998). In contrast, 
ultrasound studies on the mdx mouse showed diffuse, rather than regional cardiac dyskinesia 
(Quinlan et al. 2004). The extent and localisation of cardiac fibrosis in the mdx:MyoD(-/-) 
model warrants further investigation, particularly in older animals. 
 
The observed increased fibrosis did not correlate with gene expression levels of TGF-β 
inmdx:MyoD(-/-) mice which were not significantly different to mdx or C57:MyoD(-/-) mice. 
This finding is in accordance with results from the previous age study, in which higher levels 
of fibrosis observed in mdx mice at 6 and 12 months of age did not correlate to increased 
TGF-β levels. Levels of TGF-β may perhaps increase before 3 months initiating pro-fibrotic 
pathways. In support of this hypothesis, TGF-β has been shown to be increased early in the 
mdx diaphragm at 6 and 9 weeks, but not at 12 weeks (Gosselin et al. 2004).  
 
Procollagen mRNA levels also did not correlate to fibrosis, with no significant difference in 
expression observed for mdx:MyoD(-/-) mice compared to mdx and C57:MyoD(-/-)  mice.  
Fibronectin gene expression, however, was significantly increased in mdx:MyoD(-/-) and mdx 
mice compared to C57:MyoD(-/-) mice which paralleled with the observed increase in 
collagen deposition. This highlights the dynamic nature of the ECM and suggests that 
fibronectin may be a better marker for active collagen synthesis than procollagen. 
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The main findings of this study are that mdx:MyoD(-/-) mice display an increased cardiac 
pathology with higher levels of fibrosis than mdx at 3 months of age. As MyoD is only 
expressed in skeletal muscle, the increased cardiac involvement of mdx:MyoD(-/-) mice may 
reflect cardiomyopathy secondary to increased skeletal muscle damage. These results have 
important implications for potential cardiac therapies for DMD patients as they imply that 
perhaps treating just the heart will not be sufficient to alleviate the cardiac phenotype.  
 
The observed increased cardiac fibrosis of mdx:MyoD mice compared to mdx and 
C57:MyoD(-/-) also supports the hypothesis that increased regeneration may play a role in 
the milder phenotype of the mdx mouse compared to DMD patients. 
 
This study and others provide further support for the lack of correlation between TGF-β and 
progression of fibrosis with other signalling molecules thought to be involved (Gosselin et al. 
2004; Van Erp, Irwin & Hoey 2006). Cardiac fibronectin mRNA levels paralleled increases 
in ventricular fibrosis implying that this gene may be a useful indicator of collagen synthesis.  
 
5.4 SHORTCOMINGS OF THE STUDY 
Due to time constraints on this study, only one age group was examined. Future research of 
the mdx:MyoD(-/-) model needs to address different ages as mdx mice exhibit a progressive 
cardiomyopathy. This study was the first to assess cardiac function of the model. One 
unexpected finding of the study was the increase in cardiac function in the mdx:MyoD(-/-) 
compared to the mdx mouse. Future research would benefit from older age groups to 
determine if this was a compensatory mechanism. Echocardiography would also provide 
valuable information regarding the cardiac hypertrophy observed at 5 months.                                                     
This study focused on three genes involved in collagen synthesis associated with fibrosis. As 
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the rate of collagen degradation also plays a pivotal role in collagen accumulation, future 
research would benefit from an examination of genes involved in collagen degradation such 
as MMPs and TIMPs.  
 
In conclusion, the findings of increased cardiac involvement of the mdx/MyoD(-/-) transgenic 
mouse observed in this study and others, warrant its further characterisation as a model for 
DMD cardiomyopathy (Megeney et al. 1996; Megeney et al. 1999). 
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
Duchenne muscular dystrophy is a debilitating neuromuscular disease that affects 1 in 3500 
newborn boys. The disease is characterised by a progressive muscular weakness leading to 
most boys being wheelchair bound by the age of 11. Most patients die in early adulthood due 
to respiratory and cardiac failure. The last decade has seen improvements in ventilatory 
assistance which has prolonged the life span significantly. This in turn has resulted in an 
increased presentation of cardiac manifestations highlighting cardiomyopathy as a major 
contributor to mortality.  
 
There is currently no treatment to cure DMD. While gene therapy offers a potential cure, this 
technology is still years away. An urgent need exists for therapies to alleviate the devastating 
consequences of the disease including cardiac failure, inflammation and fibrosis. 
 
6.1 STUDY 1 Aging and inflammatory gene expression 
The mdx mouse is the most commonly used animal model in DMD research. The degree of 
cardiac involvement in the model appears to be progressive. Cardiac hypertrophy and 
increased levels of fibrosis were observed at the youngest age examined, 3 months and by 6 
months of age decreased systolic and diastolic function is evident supporting the initial 
hypothesis that the mdx mouse reflects dystrophin deficient cardiomyopathy. 
 
Increased cardiac fibrosis is characteristic of the dystrophic heart and does not necessarily 
correlate with cardiac function. The fibrotic pathways involved are complex and 
multifactorial. While increased levels of TGF-β mRNA were observed at 3 months of age, 
they did not persist with age. This suggests that TGF-β may be involved in the initiation of 
profibrotic pathways activating collagen synthesis, but perhaps the fibrosis observed later in 
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the mdx mouse life span is a result of decreased collagen degradation. This hypothesis is 
supported by the literature which demonstrates a role for altered ECM metabolism mediated 
in part by MMPs and their inhibitors TIMPs (Li, McTiernan & Feldman 2000). 
 
Little data exists regarding cardiac levels of genes involved in remodelling the ECM in the 
mdx mouse, and this study is the first to our knowledge to provide data on fibronectin and 
procollagen mRNA levels in this model. Expression levels of both of these genes decreased 
by 12 months of age which may further reflect a shift away from active collagen synthesis 
toward a decline in its degradation sustaining high levels of fibrosis as shown 
diagrammatically in figure 6.2. 
 
6.2 STUDY 2 IGF-1 ameliorates fibrosis and improves function in mdx hearts at 12 
months of age 
Evidence from previously reported studies supports the hypothesis that IGF-1 overexpression 
is capable of ameliorating the fibrosis characteristic of skeletal dystrophic muscle (Barton et 
al. 2002) and improving cardiac function in various animal models of cardiac disease 
(Cittadini et al. 1996; Duerr et al. 1995; Kajstura et al. 2001; Santini et al. 2007; Serose et al. 
2005). To examine the effects of IGF-1 on the dystrophic heart, this current study involved 
the generation of a novel transgenic mouse model that overexpressed cardiac restricted IGF-1 
isoform Ea in the mdx mouse. Two age groups, 6 and 12 months, were utilised to observe any 
differences in the effect of IGF-1 overexpression with age of the animal. 
 
IGF-1 induced cardiac growth at all ages examined. This hypertrophy was accompanied by 
improved left ventricular systolic function and increased rate of contraction in the dystrophic 
heart at 12 months. This demonstrates the involvement of IGF-1 in cardiac hypertrophy, with 
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functional benefits to mdx mice midway through their lifespan and therefore supports the 
initial hypothesis the study was based on. 
 
IGF-1 overexpression ameliorated fibrosis and improved cardiac function at 12 months of age 
in the mdx mouse as illustrated in figure 6.1. The marked reduction in fibrosis at 12 months 
of age did not correlate with elevated TGF-β levels, once again supporting the hypothesis that 
this cytokine is not the main driver in the progression of fibrosis (Fig 6.2). This agrees with 
evidence from the literature suggesting TGF-β does not play a role in the cardiac 
inflammatory response after cardio toxin injury and myocardial infarction (Santini et al. 
2007). 
 
IGF-1 decreases fibronectin in cell culture (Mezzano et al. 2007), and in the whole heart by 
12 months of age as shown in this current study. The reduction of fibronectin mRNA 
expression correlated with a reduction in procollagen mRNA and reduced fibrosis (Fig 6.2). 
 
6.3 STUDY 3 Cardiac involvement in the mdx/MyoD(-/-) mouse model 
Skeletal muscle regeneration involves activation of satellite cells. Myogenic regulator, MyoD 
plays an important role in satellite cell function as it is required for myogenic precursor cells 
to enter the proliferative phase prior to muscle differentiation (Megeney et al. 1996). It is 
expressed only in skeletal muscle.  
 
 Cardiac pathology in mdx mice at 3 months of age was exacerbated by removal of MyoD 
from the germline. The mdx/MyoD(-/-) double knock out mouse exhibited increased cardiac 
fibrosis which appeared secondary to the increased skeletal muscle myopathy observed by 
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others. This suggests that skeletal muscle damage may play a role in the degree of 
cardiomyopathy observed with dystrophin deficiency.  
 
To further examine the effects of skeletal muscle pathology on the heart, it would be valuable 
to perform histological and functional experiments on the hearts of mdx mice that 
overexpress IGF-1 in skeletal muscle only, excluding the heart. These mice display reduced 
fibrosis and increased force generation in skeletal muscles (Barton et al. 2002). To date 
cardiac functional experiments have not been performed on this mouse model. Any cardiac 
improvements in this model would be attributable to decreased skeletal muscle pathology. 
 
Surprisingly, cardiac function of the mdx:MyoD(-/-) mouse was found to increase and this 
could be regarded as an early compensatory mechanism resulting from the extra work load 
placed on the heart by the increased skeletal muscle pathology. Future research addressing 
cardiac function in older age groups is required to determine the duration of this 
phenomenon.  
 
Mdx mice display a milder phenotype than DMD and this may be due in part to increased 
regeneration. The increased cardiac pathology exhibited by the mdx:MyoD(-/-) mice 
compared to mdx and C57:MyoD(-/-) lends support to this hypothesis (Fig 6.1). 
 
The mdx:MyoD(-/-) model further highlighted the lack of correlation between levels of 
ventricular fibrosis and TGF-β mRNA levels, further supporting the notion of the lack of 
involvement of TGF-β in the progression of fibrosis in dystrophic hearts. Procollagen mRNA 
levels also did not correlate with higher levels of fibrosis exhibited by mdx:MyoD(-/-), 
however fibronectin levels did. The IGF-1 study also found a correlation between fibronectin 
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levels and fibrosis, with decreased fibrosis of IGF-1+/mdx hearts at 12 months of age 
accompanied with decreased fibronectin mRNA levels. This suggests that fibronectin may be 
a better marker of active collagen synthesis than procollagen (Fig 6.2). 
 
The increased cardiac fibrosis of the mdx:MyoD(-/-) compared to the mdx mouse supports the 
hypothesis that it may reflect DMD cardiomyopathy more closely, however the improvement 
in cardiac function calls for further characterisation of the model.  
 
All three studies in this dissertation highlighted the complex pathways involved in the 
initiation and progression of fibrotic pathways in the dystrophic heart. Future research into 
the molecular pathways of fibrosis needs to address cardiac levels of MMPs and TIMPs due 
to the important roles they play in the balance between ECM deposition and degradation. 
Expression of other cytokines such as proinflammatory IL- 6 and anti-inflammatory IL-4 and 
10, are also of interest as these have been implicated in the inflammatory response of the 
heart.  
 
While an attempt has been made in each study to examine suitable age groups, there exists a 
need to include younger and older age groups. Younger ages could provide a more detailed 
view of the initiation of fibrotic pathways, while the older age groups enable experiments to 
be performed on symptomatic cardiomyopathy.  
 
Further research in each of the three studies would also benefit from additional cardiac in 
vivo analysis using echocardiography to provide data on cardiac output and ejection fraction 
and Millar catheter experiments to provide blood pressure and volume. 
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Figure 6.1 Flow chart combining IGF-1 and MyoD contributions to pathophysiology of 
dystrophic deficient muscle. Dystrophin deficiency in cardiomyocytes results in a loss of the 
DGC at the sarcolemma, increasing its permeability. This leads to an influx of calcium, 
activating calcium proteases.  
1.IGF-1 may increase cardiac contractility by increasing cardiomyocyte calcium sensitivity. 
The inflammatory response is activated resulting in necrosis.  
2.IGF-1 may limit fibrosis by inhibiting necrosis, resolving the inflammatory response and/or 
attenuating the renin-angiotensin system.  
3.IGF-1 induces proliferation and differentiation of satellite cells enhancing regeneration. 
Removal of myogenic regulator MyoD from the germline of mdx mice reduces the efficiency 
of regeneration, increasing fibrosis.  
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Figure 6.2 Diagrammatical representation of the balance between collagen synthesis and 
collagen degradation in the hearts of mdx, IGF-1+/mdx and mdx:MyoD(-/-) mice at 3, 6 and 
12 months of age.  
At 3 months of age increased mRNA levels of TGF-β in mdx mice and elevated mRNA 
levels of fibronectin (FN) in mdx:MyoD(-/-) suggesting active collagen synthesis contributing 
to high levels of fibrosis observed in both strains. 
At 6 months of age mdx and IGF-1+/mdx mice both exhibit increased fibrosis that correlates 
with increased mRNA levels of FN and procollagen.  
By 12 months of age ventricular fibrosis is elevated in the mdx mouse, but this no longer 
correlates with cardiac mRNA levels of these TGF-β, FN or procollagen suggesting a shift 
toward decreased collagen degradation maintaining high levels of fibrosis.  
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6.4 CONCLUSION 
While gene therapy theoretically offers the best chance of a cure for DMD patients its 
implementation is still years away. In the interim, treatment strategies are aimed at alleviating 
the symptoms of DMD and focus on promoting muscle regeneration, hypertrophy or 
relieving fibrosis.  
 
This current study provides evidence for the first time that IGF-1 overexpression can mediate 
cardiac hypertrophy in the dystrophic heart. Importantly this overexpression was associated 
with improved cardiac function and rates of contraction. One striking finding of this study 
was the ability of IGF-1 to significantly reduce ventricular fibrosis by 12 months of age. 
Cardiac fibrosis severely impacts on the life expectancy of DMD patients causing left 
ventricular dysfunction and arrhythmias, and eventually systolic dysfunction may lead to 
heart failure and sudden death (Finsterer & Stollberger 2003). While the difficulties of 
transferring findings from this transgenic model to the clinical situation are acknowledged, 
the results of this study implicate IGF-1 as a potential therapy that may enhance muscle mass, 
reduce ventricular fibrosis and improve function in the dystrophic heart. The complex 
interplay of factors involved in fibrotic pathways was further highlighted by this series of 
experiments and more research is required to further elucidate the exact molecular pathways.  
 
Finally, there exists a need for animal models that more accurately reflects the 
cardiomyopathy associated with DMD. The mdx:MyoD(-/-) mouse characterised in this study 
offers potential as a model of cardiac fibrosis. However the unexpected findings of functional 
improvement in the face of fibrosis means that further research is required including in vivo 
studies (echocardiography or Millar catheter experiments) and the use of mice of different 
ages. 
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 In summary the findings from this study may contribute to the knowledge of IGF-1 as a 
potential cardiac therapy, the prospect of an alternative mouse model for DMD 
cardiomyopathy, and further elucidation of cytokines, protein and growth factor involvement 
in fibrotic pathways in the dystrophic heart. 
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